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I. Introduction 
 
1.1.    Mineralo- and glucocorticoids 
 
1.1.1. Physiology of mineralocorticoids and regulation by the renin-angiotensin- 
          aldosterone system 
 
The most important circulating mineralocorticoid, aldosterone, is secreted by the zona 
glomerulosa of the adrenal gland (100-150µg/day). A cytochrome P450 enzyme, CYP11B2 
(aldosterone synthase, see 1.1.3.) catalyzes this synthesis by converting deoxycorticosterone 
to corticosterone and subsequently to aldosterone (Kawamoto et al., 1992). Aldosterone plays 
a major role in the regulation of the salt and water household of the body. By binding to the 
epithelial mineralocorticoid receptors in the renal cortical collecting tubules, sodium 
resorption and potassium excretion are promoted. Water is retented at the same time leading 
to volume expansion. This is an osmotic effect directly related to increased sodium resorption. 
The effects of aldosterone are primarily mediated by augmented expression of Na+/K+ 
ATPase pumps on the basolateral membrane of epithelial cells, and probably non-genomic 
effects leading to increased apical permeability for Na+ and increased luminal H+ permeability 
(Ngarmukos et al., 2001). Similar effects can also be seen in the gut, the salivary and sweat 
glands. Besides the classical adrenal biosynthetic pathway, extra-adrenal sites of aldosterone 
production have been identified in brain (Gomez-Sanchez et al., 1997a), blood vessels 
(Hatakeyama et al., 1994) and in heart (Silvestre et al., 1998). 
The adrenal aldosterone synthesis is regulated by the renin-angiotensin-aldosterone system 
(RAAS) (Stewart, 2002). This compensatory mechanism is activated when small changes in 
sodium or potassium balance or a decrease in blood pressure occur (Figure 1). Renin, a 
proteolytic enzyme, is released by the juxtaglomerular apparatus in the kidney and cleaves a 
dipeptide from the hepatic glucoprotein angiotensinogen, thereby forming the decapeptide 
angiotensin I. In turn, angiotensin I is converted to the octapeptide angiotensin II by the 
angiotensin-converting enzyme (ACE), which is localized in the vascular endothelium. 
Angiotensin II is a potent vasoconstrictor and can thus elevate blood pressure but it also 
stimulates the zona glomerulosa of the adrenal gland to synthesize and secrete aldosterone, 
which leads to sodium retention and potassium loss. Angiotensin II has also an important 
inhibitory effect on the secretion of renin that constitutes a negative feedback mechanism. 
Aldosterone secretion is also regulated by the plasma potassium concentration and to a much 
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lesser extent by ACTH. Hyperkalemia leads to direct stimulation of the zona glomerulosa 
cells whilst hypokalemia inhibits the aldosterone synthesis (Stewart, 2002). 
 
Figure 1. The renin-angiotensin-aldosterone system (adapted from Aktories et al., 2005) 
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The mineralocorticoid receptors have similar affinity for both aldosterone and the 
 
nd permits aldosterone to bind to and activate the mineralocorticoid receptor (Ngarmukos et 
creased activity of 11β-HSD2, cortisol 
ccumulates and binds to the mineralocorticoid receptor, which leads to hypertension and 
hypokalemia. Such conditions include inhibition of 11β-HSD2 following liquorice ingestion, 
but also inherited impairment of 11β-HSD2 due to mutations in its HSD11B2 gene (Stewart, 
2003). 
glucocorticoid cortisol. Despite the fact that glucocorticoids are present at much higher 
concentrations in plasma, the mineralocorticoid receptors, however, clearly have specificity 
for aldosterone. Mineralocorticoid-responsive tissues, like kidney, colon and salivary gland, 
contain high concentrations of the enzyme 11β-hydroxysteroid dehydrogenase Type 2 (11β-
HSD2), which converts cortisol to the inactive metabolite cortisone. As cortisone has a much 
lower affinity for the mineralocorticoid receptors, 11β-HSD2 inactivates the glucocorticoid
a
al., 2001). In conditions associated with a de
a
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1.1.2. Physiology of glucocorticoids and regulation of the glucocorticoid household 
 
The most important glucocorticoid, cortisol, is synthesized and secreted by the zona 
fasciculata of the adrenal gland. A cytochrome P450 enzyme, CYP11B1 (11β-hydroxylase, 
see 1.1.3.) catalyzes this synthesis by converting deoxycorticosol to cortisol (Kawamoto et 
al., 1992). The glucocorticoids act by binding to Type II glucocorticoid receptors in many cell 
types, like liver, muscle, adipose tissue and bone. Glucocorticoids have actions on glucose, 
protein and bone metabolism and possess anti-inflammatory and immunosuppressant actions. 
 
Figure 2. The hypothalamic-pituitary-adrenal axis 
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Glucocorticoids stimulate several processes that collectively serve to increase and maintain 
normal glucose concentrations in the blood. These include an increase in liver 
gluconeogenesis and an increase in amino acid degradation. In adipose tissue, cortisol 
stimulates lipolysis, resulting in the release of free fatty acids and glycerol. Glucocorticoids 
also regulate growth and development, p
-
articularly in fetal tissues. The presence of high 
oncentrations of circulating glucocorticoids for long periods can lead to muscle wasting, 
 (Shupnik et al., 1998). Cortisol 
ynthesis and secretion are regulated by the pituitary hormone adrenocorticotropic hormone 
TH concentration is increased in response to physical and 
nvironmental stresses. When the concentration of free cortisol in the blood is low, the 
hypothalamic-pituitary-adrenal axis is activated (Figure 2). The hypothalamic peptide 
c
inhibition of bone formation and delayed wound healing
s
ACTH. Physiologically, AC
e
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corticotropin-releasing hormone (CRH) acts on the pituitary to stimulate ACTH release. In 
turn, ACTH stimulates the zona fasciculata of the adrenal gland to produce cortisol. The 
hypothalamic-pituitary-adrenal axis loop is completed through cortisol-negative feedback: 
cortisol acts directly at the pituitary to decrease ACTH secretion and at the hypothalamus to 
suppress CRH release (Raff et al., 2003). 
 
1.1.3. Biosynthesis of the mineralo- and glucocorticoids 
 
Cytochrome P450 enzymes. 
roduced in multi-step pathways that involve the 
articipation of five cytochrome P450 enzymes. The name cytochrome P450 (CYP) derives 
from the fact that these enzymes have a hem  group and an unusual spectrum (Omura et al., 
 of the active site. The substrate will occupy the sixth 
 
The adrenal steroid hormones are p
p
e
1964). The reduced form of the heme, when complexed with carbon monoxide, absorbs light 
strongly at 450 nm. The reason why cytochrome P450 absorbs in this range is the unusual 
ligand to the heme iron. Four ligands of the iron are provided by the pyrrole nitrogens of the 
porphyrine (Figure 3), the fifth coordination position is occupied by a thiolate group from a 
cysteine at the heme binding region
coordination position. 
 
Figure 3. The protoporphyrine of P450 
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animals, plants, fungi and bacteria. At the moment more than 2500 cytochrome P450 
sequences are known (http://drnelson.utmem.edu/CytochromeP450.html). P450s in humans 
are either drug metabolizing enzymes or steroidogenic enzymes, e.g. enzymes involved in the 
biosynthesis of steroidal hormones.  
 
The CYP enzymes are expressed ubiquitously in different life forms: they have been found in 
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The general molecular mechanism is activation and cleavage of molecular dioxygen. During 
the catalytic cycle a single oxygen is inserted into the substrate while the other oxygen atom 
leaves the reaction forming a water molecule, according Eq.1. This reaction requires the 
addition of two electrons (reduction) to the heme, delivered by a specific electron transfer 
system.  
The Class-1-CYP-enzymes CYP11B1 (11β-hydroxylase) and CYP11B2 (aldosterone 
synthase), which are involved in the gluco- and mineralocorticoid synthesis, are membrane 
bound mitochondrial enzyme systems. Two soluble components, the flavoprotein 
adrenodoxin-reductase and the iron-sulphur protein adrenodoxin catalyze the electron transfer 
from NADPH to the P450 enzyme (Bureik et al., 2002a) (Figure 4). 
 
Figure 4. The electron transport pathway of Class-1-P450s (Bureik et al., 2002a) 
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Heme
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[2Fe-2S] e-e-
N DPH
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2H O
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Eq.1 NADPH + H+ + O2 + R-H                 NADP+ + H2O + R-OH
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The P450 enzymes catalyze many types of reaction, including hydroxylations, epoxidations, 
sulfoxidations, N-oxidations, dealkylations and deaminations. The mechanism of 
hydroxylation is described in Figure 5. The binding of the substrate (R-H) to the sixth 
coordination position of the heme-iron (Fe3+) triggers an electron transfer from the reductase 
protein, which causes the reduction of heme-iron. The reduced heme-iron (Fe2+) is then able 
to coordinate molecular oxygen. Transfer of a second electron leads to the cleavage of the O-
O bond, release of water and finally the transfer of one oxygen to the substrate (Meunier et 
al., 2004). 
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Figure 5. Reaction cycle of the heme-iron of CYP enzymes 
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Biosynthesis of the corticoids. 
 
The biosynthesis of the mineralo- and glucocorticoids is shown in Scheme 1. In case of the 
mineralocorticoids, the P450 enzyme cholesterol desmolase (CYP11A1, scc: side chain 
cleavage enzyme) hydroxylates and cleaves the side chain of cholesterol, the biosynthetic 
source of all steroidal hormones, to yield pregnenolone. This steroid is then transferred from 
the mitochondria to the smooth endoplasmatic reticulum, where 3β-hydroxy-steroid 
hydrogenase (3β-HSD) converts it into progesterone, followed by hydroxylation in position 
21 by 21-hydroxylase (CYP21) to form 11-deoxycorticosterone (DOC). In the zona 
glomerulosa of the adrenal gland where the mineralocorticoid biosynthesis takes place, DOC 
is 11β-hydroxylated by aldosterone synthase (CYP11B2) to yield corticosterone. CYP11B2, 
zyme of the mineralocorticoid 
 corticosterone in 18-position to form 18-
hydroxycorticosterone. Finally, a second 18-hydroxylation and water release, catalyzed again 
by CYP11B2, results into the mineralocorticoid aldosterone. 
The biosynthesis of the glucocorticoids starts also from cholesterol, which is converted into 
pregnenolone and subsequently, transformed into progesterone by 3β-HSD. This steroid is 
hydroxylated at position 17 by 17α-hydroxylase (CYP17) into 17α-hydroxyprogesterone and 
further hydroxylated at position 21 by CYP21 to form 11-deoxycortisol. In the zona 
fasciculata of the adrenal gland, 11-deoxycortisol is hydroxylated in position 11β by 11β-
hydroxylase (CYP11B1), located inside the mitochondria, to yield the glucocorticoid cortisol. 
In contrast to CYP11B2, which can hydroxylate its substrate in 11β- and 18-position, 
CYP11B1, the key enzyme of the glucocorticoid synthesis, can only insert a hydroxyl group 
in 11β-position (Kawamoto et al., 1992). 
located in the inner membrane of the mitochondria is the key en
synthesis. In a next step, CYP11B2 hydroxylates
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Scheme 1. The biosynthesis of corticoids 
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CYP11B1 and CYP11B2, the key enzymes of the corticoid biosynthesis. 
 
Steroid 11β-hydroxylase (CYP11B1) is the key enzyme of the glucocorticoid biosynthesis. In 
the zona fasciculata of the adrenal gland, it catalyzes the 11β-hydroxylation of deoxycortisol 
 water household and thus the regulation of the blood pressure. 
es have the 11β-hydroxylase and the 18-
o different enzymes, as explained above. In 
eing used as template, have been 
eveloped to gain insight in the 3D-structure of the active site of these enzymes (Belkina et 
l., 2001; Ulmschneider et al., 2005a; Voets et al., 2005). 
into cortisol. Cortisol is the main glucocorticoid in the human and regulates energy 
mobilization and, thus, the stress response. 
Aldosterone synthase (CYP11B2) is the key enzyme of the mineralocorticoid biosynthesis. 
This P450 enzyme catalyzes in the zona glomerulosa of the adrenal gland the conversion from 
11-deoxycorticosterone to corticosterone by 11β-hydroxylation, and two hydroxylations in 18 
position to give the most potent mineralocorticoid aldosterone. An intermediate of these last 
steps is 18-hydroxycorticosterone. As mentioned before, aldosterone is involved in the 
regulation of the salt and
CYP11B1 and CYP11B2 are both mitochondrial P450 enzymes bound to the inner 
mitochondrial membrane. 
The genes encoding CYP11B1 and CYP11B2 are tandemly arranged on chromosome 8, 
approximately 45 kB apart from each other. They are about 94% identical at gene level 
(Taymans et al., 1998). Despite this high homology, these enzymes show clearly different 
catalytic properties. Both CYP11B1 and CYP11B2 hydroxylate deoxycortisol and 
deoxycorticosterone in 11 position. However, CYP11B1 is a pure 11β-hydroxylase and can 
not hydroxylate in position 18. CYP11B2 do
hydroxylase activity for the aldosterone synthesis, and is also capable of hydroxylating 
cortisol in position 18 (Kawamoto et al., 1992). 
An interesting feature is the interspecies differences of these enzymes. In human, rat and 
mouse the corticoid synthesis is carried out by tw
bovine, porcine and frog, however, the gluco-and mineralocorticoid synthesis is catalyzed by 
a single enzyme CYP11B (Bureik et al., 2002a).  
The 3D-structures of CYP11B1 and CYP11B2 are unknown, since the membrane anchor 
prevents the proteins from crystallizing. Alternatively, homology modelling methods in which 
the known structures of bacterial or human P450s are b
d
a
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1.2.    Pathophysiology of the renin-angiotensin-aldosterone system 
0 year olds to over 10 per cent in those aged 80. There is a poor prognosis with 30 per cent 
nt mortality after five years (Sani, 2004). 
 
igure 6. Pathophysiological action of aldosterone 
 
1.2.1. Congestive heart failure 
 
Congestive heart failure is described as any condition in which the heart is unable to 
adequately pump blood throughout the body. These conditions cause symptoms as shortness 
of breath, fatigue, weakness and swelling (oedema) of the legs. The most common cause is 
coronary artery disease and hypertension. In the United States, each year 400.000 new cases 
are being diagnosed. The prevalence of the disease increases with age from 1-2 per cent in 50-
6
mortality within one year, increasing to 60-70 per ce
F
 
 
Congestive heart failure is considered to be a neurohormonal imbalance. Chronic activation of 
neurohormonal pathways such as the renin-angiotensin-aldosterone system leads to elevated 
plasma aldosterone levels, which correlate with mortality in chronic heart failure (Sani, 2004). 
The renin-angiotensin-aldosterone system is pathologically activated in patients with 
congestive heart failure to compensate for myocardial cell dysfunction and to normalise the 
output and function of the heart (Figure 6). Aldosterone and angiotensin II induce sodium and 
water retention and increased blood pressure, which lead to a further reduction of the cardiac 
 9
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output. The renal perfusion is again reduced and this leads to the further release of renin 
(“circulus vitiosus”). This prolonged activation of the RAAS exerts adverse effects on the 
heart dysfunction and leads to the progression of heart failure disease (Brilla, 2000a).  
 activates mineralocorticoid receptors present 
la, 2000b). In 
is way, either effector hormone of RAAS, aldosterone and angiotensin II, induces the 
esides the classical adrenal biosynthetic pathway, extra-adrenal sites of aldosterone 
l expression of CYP11B2, the key enzyme 
 
 
1.2.2. Myocardial fibrosis 
 
A second important effect of the pathophysiological activation of the RAAS is the stimulation 
of cardiac fibroblasts. Aldosterone binds to and
in cardiomyocytes and fibroblasts in the heart. This leads to fibroblast growth and 
proliferation and an increased production of collagen type I and type III (Khan et al., 2004). 
Collagen is synthesized in the fibroblasts as procollagen, which contains polypeptide 
extensions at its amino- and carboxy-terminal end. These peptides are removed from the 
procollagen by procollagen-specific proteinases, allowing the rigid collagen to integrate into 
the growing fibrils. The production and deposition of collagens in the cardiac fibroblasts leads 
to myocardial fibrosis (Lijnen et al., 2000). The heart becomes stiffer and less elastic, which 
results in the deterioration of the heart function. 
The collagen synthesis is stimulated by various growth factors, e.g. endothelin 1 (ET-1) and 
transforming growth factor (TGF)-β1. Aldosterone increases the expression of ET-1 in cardiac 
fibroblasts. Moreover, angiotensin II decreases the activity of the matrix metalloproteinase 
MMP 1 which is the key enzyme of the interstitial collagen degradation (Bril
th
collagen synthesis also in an autocrine manner. 
B
production have been identified in the heart (Silvestre et al., 1998). In addition to the effects 
of aldosterone release after RAAS activation, this cardial biosynthesis of aldosterone can have 
pathophysiological importance too. The myocardia
of aldosterone synthesis, is increased in patients with heart failure or after myocardial 
infarction. This increase is associated with increased myocardial fibrosis (Satoh et al., 2002). 
In healthy humans however, only a very small amount of CYP11B2 expression was detected. 
In rats, it is described that aldosterone, produced locally in the myocardium, triggers 
myocardial fibrosis as well (Weber et al., 1990). So, in addition to the indirect effects of 
aldosterone on the failing heart from sodium retention, hypervolemia and hypertension, 
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aldosterone exerts also direct effects on the heart. The myocardial aldosterone system is 
regulated by the same stimuli as the adrenal system, e.g. K+ and angiotensin II. 
 
1.2.3. Therapy options for congestive heart failure and myocardial fibrosis 
 
Long-term activation of the RAAS has detrimental effects on the cardiovascular system of 
congestive heart failure patients. Treatments that interfere or block the RAAS may improve 
the output of the heart and relieve the symptoms.  
The major clinically useful site of enzyme inhibition is the angiotensin-converting enzyme 
CE), which promotes blood pressure elevation by converting angiotensin I to the 
 for 
e heart to pump blood throughout the body. Angiotensin receptor blockers, on the other 
ronolactone, in 
(A
vasoconstrictor angiotensin II (AT-II). ACE Inhibitors dilate the arteries, making it easier
th
hand, block the angiotensin II receptors and show similar action as the ACE inhibitors. 
Although ACE inhibitors reduce the AT-II activity, usual doses of these inhibitors do not 
completely block the production of aldosterone. In fact, increased levels of aldosterone may 
be seen after several months of therapy (Struthers, 1996). This phenomenon is called 
“aldosterone escape”. It shows that some aldosterone production is independent of ACEs and 
can occur at extra-adrenal sites, such as for instance in the heart. 
Beta-blockers have been shown to block renin release and conversion of prerenin to renin. 
They also relax the heart and reduce the vigor of its contractions. Other drugs for the 
treatment of heart failure are diuretics, which cause the kidneys to excrete excess amounts of 
salt and water in the urine, and digoxin, which increases the contractility of the heart. 
However, these drugs are not able to remove myocardial fibrosis, which plays an important 
role in the malfunction of the myocardium and the further progression of the heart disease. 
 
1.2.4. Clinical studies with aldosterone receptor antagonists: RALES and EPHESUS 
 
Due to the high mortality rate of heart failure patients and the knowledge about the 
aldosterone-induced changes of the heart, new therapy options were investigated. In 1999, 
results of the Randomized Aldactone Evaluation Study (RALES) showed the importance of 
the treatment with the aldosterone receptor antagonist, spironolactone (Aldactone®). In a 
double-blind study, patients with severe heart failure were treated with spi
addition to standard treatment including ACE inhibitors, diuretics and digoxin. Previous 
results showed that these therapeutics were not able to inhibit the aldosterone synthesis 
 11
  INTRODUCTION 
 
completely (Aldosterone escape, see 1.2.3.). When spironolactone was added additionally 
(25mg/day), mortality among patients was reduced by 30%, hospitalization by 35%. Due to 
these results, the trial was discontinued in order to treat the placebo group with the effective 
spironolactone (Pitt et al., 1999). Additionally, other studies show that spironolactone can 
oppose the promotion of cardiac fibrosis by aldosterone (Brilla et al.,1993, Zannad et al., 
2000) The spironolactone treatment reduced circulating levels of procollagen Type I and III 
peptides (Macfayden et al.,1997). The antagonist, however, showed progestational and 
ntiandrogenic side effects, like gynecomastia and impotence in men and hirsutism and 
drogen and 
rogesterone receptors. Moreover, a correlation between the use of spironolactone and 
hyperkalemia-associated mortality was observed: Juurlink demonstrated that after publication 
of the RALES study, the rate of prescriptions of spironolactone and hyperkalemia-associated 
mortality increased by a factor of 5 and 3, respectively (Juurlink et al., 2004). 
Eplerenone (Inspra®), a selective aldosterone receptor antagonist, has been used in the 
EPHESUS study (Eplerenone Post-acute myocardial infarction Heart failure Efficacy and 
Survival study). Eplerenone has a higher degree of selectivity for the aldosterone receptor and 
a low binding affinity for progesterone, androgen and glucocorticoid receptors. Patients 
ceived either placebo or eplerenone (43mg/day) within two weeks of a myocardial 
farction. The study showed a decrease of sudden death by 21% and a 23% reduction in 
a
menstruational disturbances in women, because of its high affinity for the an
p
re
in
hospitalization. Due to eplerenone’s higher level of selectivity, the EPHESUS study showed 
no increased side effects, although there was an increased incidence of hyperkalemia (Pitt et 
al., 2003). 
 
Figure 7. The aldosterone antagonists used in the RALES and EPHESUS studies 
 
O
O
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O
O
O
O
O
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 12
  INTRODUCTION 
 
1.2.5. New therapy for the treatment of congestive heart failure and myocardial fibrosis. 
 
The results of the RALES and EPHESUS studies show the importance of the aldosterone 
receptor antagonists. Blockade of aldosterone receptors substantially reduces the risk of both 
 new therapeutic option for the treatment of congestive heart failure and myocardial fibrosis 
nthesis, preferably by inhibition of the key 
nzyme CYP11B2. It should be clinically advantageous to reduce aldosterone formation 
ected and interfering 
ne step later at the receptor level. Non steroidal inhibitors are to be preferred because they 
P11B2 inhibitors 
morbidity and death among patients with severe heart failure. The treatment with 
spironolactone, however, was accompanied with severe side effects because of its poor 
selectivity for the aldosterone receptor. Eplerenone turned out to be more selective, but the 
hyperkalemia-associated mortality, described for spironolactone, can be expected to occur as 
well. Another crucial point is that treatment with aldosterone antagonists does not reduce the 
high aldosterone levels in the blood. 
A
could be the blockade of the aldosterone biosy
e
rather than leaving the pathologically elevated aldosterone levels unaff
o
are expected to have fewer side effects on the endocrine system than the steroidal antagonists. 
It is crucial that the CYP11B2 inhibitors do not affect 11β-hydroxylase (CYP11B1), the key 
enzyme of the glucocorticoid synthesis. To find inhibitors with selectivity towards CYP11B2 
is challenging, as CYP11B1 and CYP11B2 have a sequence homology of more than 93% 
(Taymans et al., 1998). 
The CYP11B2 inhibitors could also be an interesting and promising tool for treatment of post-
myocardial infarction patients. After a myocardial infarction, the myocardial aldosterone 
production is increased and this leads to the formation of fibrotic scar tissue, which impairs 
the heart function. As aldosterone antagonists were able to prevent myocardial fibrosis after 
myocardial infarction by blocking the cardiac aldosterone action (Silvestre et al., 1999), 
selective CYP11B2 inhibitors could also play an important role here. 
 
1.3.    Evaluation of new CYP11B2 inhibitors 
 
1.3.1. Screening system for the identification of CY
 
Adequate test systems are necessary to evaluate new compounds as possible aldosterone 
synthase inhibitors and to determine the selectivity of these new CYP11B2 inhibitors. In the 
past, our working group used mitochondria from bovine adrenal cortex (Hartmann et al., 
1995) and tissue preparations of rat adrenal glands (Wächter et al., 1996). This latter method 
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used ACTH stimulated rat adrenal fragments in potassium containing buffer (Häusler et al., 
1989). However, interspecies differences exist between human CYP11B2 and bovine 
CYP11B. As explained before, bovine CYP11B catalyzes the synthesis of both gluco- and 
mineralocorticoids and is therefore not the appropriate target enzyme to test possible 
CYP11B2 inhibitors. On the other hand, rat CYP11B2 has more resemblance to the human 
enzyme but the homology between rat CYP11B2 and human CYP11B2 (69.6%) is even less 
than the homology between the human and the bovine enzyme (74.3%). Thus, only the 
humane enzyme can be used for the testing of possible CYP11B2 inhibitors since the use of 
enzymes of other species can not predict the inhibitory activity towards human CYP11B2 and 
the selectivity towards CYP11B2. Therefore, the evaluation of inhibitors requires test systems 
using the human enzymes CYP11B2 and CYP11B1. 
Two cell lines derived from V79 chinese hamster cells were established to express human 
CYP11B1 and CYP11B2. They were called V79MZh11B1 and V79MZh11B2, respectively 
zymes 
 to evaluate the selectivity of the inhibitor. 
ecently, our working group demonstrated the functional expression of human CYP11B2 in 
, which is capable of transferring 
(Denner et al., 1995a). V79 cells have been proven to be suitable mammalian cells for stable 
expression of microsomal cytochrome P450 of human origin. Most importantly, these cells 
lack any endogenous cytochrome P450 activity (Denner et al., 1995b). Because of the time-
consuming handling of the cells and the high costs, these cell lines cannot be used for high-
throughput screening. However, comparing the inhibitor’s effect on two different en
using identical conditions is an appropriate strategy
R
the fission yeast S. Pombe (Ehmer et al., 2002). The integration of human CYP11B2-cDNA 
into the chromosomal DNA of Schizosaccheromyces pombe led to a stable recombinant yeast 
line PE1. Although Class-1-CYP-enzymes depend for their activity on an electron transport 
chain that consists of the two proteins Adx and AdR, coexpression of these proteins is not 
needed for efficient substrate conversion by fission yeast cells. The explanation for this 
phenomenon is the presence of the yeast specific protein etp1
electrons on mammalian cytochromes P450 (Bureik et al., 2002b). Using this expression 
system, an assay could be established for the rapid, cheap and effective screening of potential 
CYP11B2 inhibitors. 
Potent and selective inhibitors could be detected using the above described screening 
procedures: in a first step, candidate compounds are tested in the fission yeast system; then, 
the selectivity of the most potent compounds is evaluated in V79MZh11B2 and 
V79MZh11B1. While recombinant fission yeast provides a low-cost system, V79 cells 
constitute a mammalian system that is closer in the physiology to human adrenal cells. 
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1.3.2. Inhibitors of the aldosterone biosynthesis 
Only few inhibitors of aldosterone biosynthesis are known at the moment. Mespirenone, a 
erivative of the aldosterone receptor antagonist spironolactone, proved to be a potent and 
renal mineralocorticoid synthesis (Weindel et al., 
991). The production of aldosterone was inhibited about 40% at a concentration of 100 µM 
ers et al., 1990). 
 1994, Soll described some non steroidal inhibitors of the aldosterone biosynthesis (Soll et 
ctivity of guanabenz-related 
amidinohydrazones were evaluated in rat adrenal glomerulosa cells. The most potent 
compound (Figure 8) exhibited an IC50 value of 16 nM.  
 
Figure 8. Steroidal and non steroidal inhibitors of the aldosterone biosynthesis 
 
d
quite specific steroidal inhibitor of the ad
1
in rat adrenal glands. Thus, in addition to its antagonistic effects on the receptor level, 
mespirenone is also able to inhibit the aldosterone synthesis. 
The aromatase inhibitor fadrozole (CGS 16949A), which is in use for the treatment of breast 
cancer, is able to reduce aldosterone and corticosterone levels in vitro using rat adrenal gland 
fragments. It inhibits the aldosterone biosynthesis 100 times more than the corticosterone 
synthesis (Häusler et al., 1989). In vivo, however, the corticoid biosynthesis is only inhibited 
at doses ten times higher than used in the breast cancer treatment (Dem
In
al., 1994). The aldosterone biosynthesis inhibitory a
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1.3.3. Inhibitors of aldosterone synthase 
 
Until now, only a few steroidal inhibitors of aldosterone synthase are described in the 
he 18-methyl substituted derivatives of progesterone, 18-vinylprogesterone (18-literature. T
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VP) and 18-ethynylprogesterone (18-EP) were developed to bind covalently to the heme 
roup of the P450 enzyme CYP11B2 (Defaye et al., 1996). These “suicide” inhibitors have a 
steroidal structure, based on the natural substrate of the enzyme. They are able to inhibit the 
 aldosterone. However, these compounds have not been 
sted towards the human CYP11B2. 
igure 9. Steroidal CYP11B2 inhibitors (Defaye et al., 1996) 
g
18-hydroxylation of corticosterone to
te
 
F
 
O
O
O
O
18-VP 18-EP  
 
For the discovery and structural optimization of non steroidal CYP11B2 inhibitors, our in 
 current work. 
house library of compounds, which have been synthesized as potential inhibitors of P450 
enzymes like CYP19, CYP17 and CYP5, was screened for inhibition of aldosterone synthase. 
This search resulted in several hits. Among them were the E-and Z-isomers of the 
unsubstituted (imidazolylmethylene)tetrahydronaphthalene and -indane (Figure 10). This 
class of compounds A was further investigated but turned out to show little or no selectivity 
(Ulmschneider et al., 2005a). Recently, our working group found that exchange of the 
imidazole ring by a pyridyl moiety increased potency and especially selectivity 
(Ulmschneider et al., 2005b). These (pyridylmethylene)tetrahydronaphthalenes and -indanes 
B proved to be potent and selective CYP11B2 inhibitors. The imidazole compounds A are the 
lead structures, from which we started in the
 
Figure 10. Non steroidal CYP11B2 inhibitors 
 
N
n 
N
H
n 
N
R Rn = 0,1
A
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B
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II. Aim and working strategy 
 
2.1. Aim of this work 
 
Chronic elevations in plasma aldosterone levels play an important role in the development 
nd progression of congestive heart failure and myocardial fibrosis. The treatment of these 
cardiovascular diseases with aldosterone antagonists resulted in a reduction of mortality in 
heart failure patients, but was also accompanied by severe side effects.  
A new pharmacological approach for the treatment of congestive heart failure and myocardial 
fibrosis was recently suggested by our working group, i.e. inhibition of aldosterone 
biosynthesis with non steroidal, selective CYP11B2 inhibitors (Ehmer et al., 2002; Hartmann 
et al., 2003). By reducing the aldosterone secretion, these inhibitors could prevent or diminish 
fibrotic remodelling of the failing heart and facilitate its action due to their diuretic effects.  
The structure of the active site of the target enzyme is not yet elucidated, so a “key-lock” 
design of inhibitors is not possible. Unlike other P450 enzymes there are almost no CYP11B2 
inhibitors known. Until now, only our working group described non steroidal CYP11B2 
inhibitors, which are used i  work as lead compo Ulmschneider et al., 2005a; 
Ulmschneider et al., 2005b). It is known that the concept of heme iron complexing 
compounds is appropriate to discover highly potent and selective inhibitors. These 
compounds interact with the substrate binding site in the apoprotein moiety and complex the 
heme iron which is located in the active site. This complexation mechanism does not only 
increase binding affinity of the in ts oxygen activation of the heme 
which is required for the catalytic process. 
By modifying the lead structure, we wa potency and selectivity and explore the 
active site of the CYP11B2 enzyme. Thus, the aim of this work was to develop  vivo highly 
ctive and selective non steroidal CYP11B2 inhibitors, which can be used as a novel 
a
n this und (
hibitors, but also preven
nt to enhance 
in
a
treatment of congestive heart failure and myocardial fibrosis. 
 
2.2. Working strategy 
 
The working strategy used in this work is depicted in Figure 11. Starting point is the design of 
potential inhibitors, followed by the synthesis of the compounds and the evaluation of 
biological activity and probing selectivity in vitro and in vivo. 
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Figure 11. Rational drug design, synthesis and evaluation of potential drugs 
 
Design of compounds 
Synthesis 
In vitro assay CYP11B2 (fission yeast): activity 
In vitro assay CYP11B2 and CYP11B1  
(V79 cells): Activity and selectivity 
In vitro assay CYP17 and CYP19: 
Activity and selectivity 
In vivo assay in rats 
Further preclinical trials 
Clinical trials 
 
 
 
Our compounds have been designed and synthesized based on the lead structures found by 
screening the in-house compound library. Changing the core of our lead compound, whilst 
considering the fact that CYP inhibitors should contain a heme iron complexing functional 
group, led to new classes of compounds. 
450 enzymes (CYP 17, 17α-hydroxylase-C17,20-lyase and CYP19, 
romatase) to check further selectivity. In a last step only highly active and selective 
in vivo to determine their ability to reduce aldosterone 
After synthesis, the potencies have to be evaluated in vitro towards human CYP11B2 using a 
human CYP11B2 expressing fission yeast system. When the compounds show good 
inhibitory activity they will be tested towards human CYP11B2 and CYP11B1 in V79 cells to 
obtain more information on activity and selectivity. The compounds will also be evaluated 
towards other related P
a
CYP11B2 inhibitors will be tested 
levels in the body. 
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2.3. Inhibitors of CYP11B2 
 
Figure 12. General structures 
 
 
N
NH
NHNH2
n 
N
NH
NHNH2
R R'
R
R = H, OMe, OCH2-3-Pyr
n = 0,1
R = H, OMe, OCH2-3-Pyr
R' = H, OMe  
 
First, we have synthesized amidinohydrazones to test whether the aminoguanidine moiety is a 
good alternative for nitrogen containing heterocycles to obtain strong complexation with the 
heme group of the CYP enzyme (see 3.1.).  
 
 
Figure 13. General structures 
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Het =
 
y modifying the lead compound, we found a new class of compounds, the heteroaryl 
such as 
les, 3- and 4-pyridines and 5-pyrimidines, were synthesized to investigate 
hich nitrogen containing heterocycle is most appropriate to coordinate with the heme iron 
 
 
 
B
substituted naphthalenes. Different azole and pyridine substituted naphthalenes, 
imidazoles, oxazo
w
(see 3.2.). 
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Figure 14. General structures 
 
N
R
Y
X N
N
X,Y = CH, NR = H, Br, Cl, CN, OH,       OMe, OEt, OPr, OBn
       COOMe, CONHR  
 
ve, we evaluated the role of the core and of 
the substituents in a series of 3-pyridine substituted naphthalenes. The influence of the chain 
ngth, the size and the position of the substituents on the naphthalene core was investigated 
Additionally to the comparative study outlined abo
le
(see 3.3.). Molecular dynamics studies were performed to explain interesting structure-
activity relationships. 
 
Figure 15. General structures 
 
n 
Het
R
N
R'
N
R"
R',R'' = H, Me, Et
R = H, OMe
Het = 1-Im, 3-Pyr, 4-Py
n = 0,1
r
 
The inhibitors described in chapter 3.4. were derived from the highly active 3-pyridine 
substituted naphthalenes. Instead of aromatic naphthalenes, we synthesized 3-pyridine 
substituted 3,4-dihydronaphthalenes, indenes and styryls. Additionally, docking studies 
revealed the importance of hydrophobic interactions between the inhibitors and the binding 
pocket of aldosterone synthase. 
 
hapter 3.5. focused on the in vivo experiments of active and selective CYP11B2 inhibitors in 
pharmacokinetic properties of active compounds were investigated in vitro 
nd in vivo. Metabolic stability assays and Caco-2 cell permeation studies were performed on 
3-pyridine substituted (dihydro)naphthalenes and indenes. 
 
C
rats. In addition, 
a
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III. Results 
 
3.1.    Synthesis and biological evaluation of amidinohydrazones as inhibitors of  
        CYP11B2 
3.1.1. Introduction 
 
A number of non steroidal inhibitors of the aldosterone synthesis have been described (Soll et 
al., 1994). These com unds are no zole substanc carrying an a
This class of compounds is based on the α2-adrenergic receptor agonist guanabenz I, which is 
able to inhibit the synthetic pathway of aldosterone at high concentrations. The inhibitors 
were evaluated in an isolated rat adrenal glomerulosa cell preparation in which the 
aldosterone biosynthesis was stimul II. The m pound II 
inhibited the aldosterone formation with an IC50 of 16 nM. It was, however, not investigated if 
these compounds are specific CYP11B2 inhibitors.  
 
 Inhibitors of aldosterone biosynthesis 
 
  
 
po n-a es midinohydrazone group. 
ated by angiotensin ost potent com
Figure 16.
NH
Cl Cl
N
NH NH2
N
O
NH
NHNH2
O
N
         I
Guanabenz
II
 
nctional group, mostly a nitrogen containing 
eterocycle, capable of forming a coordinate bond with the heme iron of the enzyme. In order 
to investigate whether amidinohydrazone derivatives are CYP11B2 inhibitors and whether the 
od a ernative for the nitrogen containing heterocycle, we prepared a 
 
. In 
 we describe the syntheses of compounds 1-13 as well as their evaluation as 
 human CYP11B2. 
 
As explained before, P450 inhibitors contain a fu
h
non-azole moiety is a go lt
series of amidinohydrazones (Figure 17). A combination of the core of our lead structure III
Ulmschneider et al., 2005a) and the amidinohydrazone moiety yielded compounds 1-8,12-(
13. The benzophenone derivatives 9-11 were synthesized to mimic the active compound II
the following
inhibitors of
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Figure 17. General structures 
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3.1.2. Synthesis 
 
The amidinohydrazone compounds were prepared from the appropriate ketones, by 
condensation with aminoguanidine nitrate in methanol in the presence of sulfuric acid 
(method 1).  
 
Scheme 2a. Synthesis of amidinohydrazones 1-8 
n R
N
R'
N
H
NH2
NH
salt
n R
O
R'
.
1-8a 1-8
method 1
 
 R R’ n 
1 H H 0 
2 H H 1 
3 OCH3 H 0 
4 OCH3 H 1 
5 H OCH3 1 
6 
N
7 
CH2O
 
H 0 
N
CH2O
 
H 1 
8 H 
N
CH2O
 
1 
 
a : method 1: aminoguanidine nitrate, H2SO4, methanol, 50°C, 3 h - overnight. 
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Compounds 1-5 were synthesized from commercially available ketones 1-5a. The pyridinyl 
compounds 6-8 were prepared from the corresponding methoxy substituted precursors 3-5a. 
Demethylation with AlCl3 in toluene gave the hydroxylated compounds 6-8b (method 2). 
ubsequent reaction with picolyl chloride and K2CO3 as base gave the pyridinyl ketones 6-8a 
trate to give the desired pyridine 
ompounds 6-8 (Scheme 3).  
 
Scheme 3a. Synthesis of 3-pyridyl ketones 6-8a 
S
(method 3), which reacted with aminoguanidine ni
c
 
n R
O
R'
n R
O
R'
n R
O
R'method 2 method 3
 
  
  
  3a R=OCH3, R’=H, n=0  6b R=OH, R’=H, n=0  6a R=OCH2-3-Pyr, R’=H, n=0 
  4a R=OCH3, R’=H, n=1  7b R=OH, R’=H, n=1  7a R=OCH2-3-Pyr, R’=H, n=1 
ometry of the hydrazone 
unction was determined with Nuclear Overhauser Effect experiments. Only the isomer with 
the guanidine function anti to the aromatic ring could be detected. This anti-configuration, 
which is in analogy with results foun  by ay diffraction of the 6-
methoxytetralone derivative 4 (Pitzele et al., 1988), mi e related to steric hindrance. 
 
The benzophenone derivatives 9-11 were prepared from (3-methoxyphenyl) phenyl-
methanone 9a (Negash et al., 1997) and bis(3-methoxyphenyl)methanone 10a (Riechers et 
al., 1996). The pyridine analogue 11a was synthesized, starting from the methoxy compound 
9a. Demethylation with BBr ave the hydroxylat mpound 11b (method 4), which 
reacted with picolyl chloride and K2CO3 to give the pyridine compound 11a (method 3). 
Condensation of the benzophenones 9-11a with aminoguanidine nitrate (method 1) or sulfate 
(method 5) yielded the wanted compounds 9-11 as a ure of isomers (ratio1:1). The two 
isomers have very close Rf val and could not be sep d using column chromatography. 
 
    5a R=H, R’=OCH3, n=1  8b R=H, R’=OH, n=1  8a R=H, R’=OCH2-3-Pyr, n=1 
 
a : method 2: AlCl3, toluene, reflux, 2 h; method 3: picolyl chloride hydrochloride, K2CO3, DMF, 
   100°C, 3 h. 
 
 
The compounds 1-8 were characterized using proton NMR and the ge
f
d  single-cristal X-r
ght b
3 g ed co
mixt
ues arate
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Scheme 4a. Synthesis of the diphenylmethylene compounds 9-11 
 
O
R R'
N
R R'
NH
NHNH2
method 1
 9a    R=H, R'=OCH3
10a   R=R'=OCH3
11a   R=H, R'=OCH -3-Pyr.
11b   R
2
=H, R'=OH
 9    R=H, R'=OCH3
10   R=R'=OCH3, HNO3-salt
11   R=H, R'=OCH2-3-Pyr.
method 4
or method 5
3method
 
 
 
a : method 1: aminoguanidine nitrate, H2SO4, methanol, 50°C, 3 h - overnight; method 3: picolyl 
    chloride hydrochloride, K2CO3, DMF, 100°C, 3 h; method 4: BBr3, CH2Cl2, -78°C, overnight; 
    method 5: aminoguanidine hemisulfate, H2SO4, methanol, reflux, 24 h. 
 
 
 
The tricyclic amidinohydrazone compound 12 and semicarbazone 13 were prepared from the 
condensation of 9H-fluorenone 12a with aminoguanidine nitrate and semicarbazide 
hydrochloride, respectively (method 1 or method 6). 
 
Scheme 5a. Synthesis of the tricyclic compounds 12-13 
 
O N
NH
XNH2
method 1
12  X=NH, H2SO
13  X=O, HCl sa
12a
or method 6
a : meth ine nitrate, H2SO4 C, 3 h - overnight;  
    meth e hydrochloride, N 2 T, overnight. 
 
 
 
4 salt
lt  
 
od 1: aminoguanid
od 6: semicarbazid
, methanol, 50°
aOAc, H O, R
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3.1.3. Biological results and discussion 
0 nM. 
he percent inhibition values are presented in Table 1. 
 
The inhibitory activity of compounds 1-13 and fadrozole as a reference was determined in 
vitro using CYP11B2 expressing fission yeast. The fission yeast was incubated with [14C]-
deoxycorticosterone as substrate in the presence of the inhibitor at a concentration of 50
T
 
Table 1. Inhibition of human CYP11B2 by amidinohydrazones 1-13 
 
 % inhibitiona
Compound 
 human CYP11B2b
1 n.i. 
2 n.i. 
 n.i. 
5 1.0 
6 10.9 
7 10.6 
fadrozole 68 
3 1.3 
4
8 3.2 
9 2.8 
10 3.1 
11 n.i. 
12 n.i. 
13 n.i. 
 
a Mean value of four determinations, standard deviat
b
ion less 
than 10%.  S. pombe expressing human CYP11B2; 
substrate: deoxycorticosterone, 100 nM; inhibitor, 500 nM. 
n.i. = no inhibition. 
 
The amidinohydrazones did not show any inhibitory effects towards human CYP11B2, except 
for the pyridine compounds 6 and 7. These two compounds showed a 10% inhibition of the 
target enzyme CYP11B2. 
These results might be due to the fact that the amidinohydrazone compounds are not able to 
reach the active site of the target enzyme in the yeast cell. The expression of CYP11B2 in 
yeast can cause in some cells the formation of inclusion bodies between the inner and the 
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outer membrane of the mitochondria (Bureik et al., 2002b), making it more difficult for the 
compounds to enter the cells. To investigate this theory, we used human cells in a further 
experiment. Similarly to the assay described by Soll (Soll et al., 1994) using rat zona 
glomerulosa primary cells, the pyridine compound 11 was tested for its effect towards the 
adrenocortical tumor cell line NCI-H295R (Gazdar et al., 1990; Rainey et al., 1994). This cell 
ne is derived from an invasive human adrenocortical tumour and is able to produce all the 
ineralocorticoids, glucocorticoids and adrenal androgens. The 
teroid concentrations were measured after exposition of the cells to the selected compound. 
Compound 11, which is very similar to the m t active compound described by Soll et al., 
ad no effect on the formation of aldosterone, cortisol or the androgens, androstenedione and 
HEA (Table 2).  
able 2. Effect of compound 11 on the formation of selected steroids in the adrenocortical  
li
adrenocortical steroids, e.g. m
s
os
h
D
 
T
    tumor cell line NCI-H295R 
 
Steroid secretion Compound 11 Control 
Aldosterone (pg/ml) 1364.4 ± 165.8 1360.5 ± 157.2 
Cortisol (ng/ml) 38.43 ± 2.64 38.56 ± 1.14 
Androstenedione (ng/ml) 3.06 ± 0.38 3.49 ± 0.33 
DHEA (ng/ml) 11.31 ± 0.62 10.36 ± 0.44 
 
An explanation for this inactivity could be the fact that the amidinohydrazones are strong 
bases. Under physiological conditions, the compounds are protonated and may not be able to 
permeate the cell membrane. Experiments using cell free homogenate were not performed, 
because we are only interested in potential inhibitors that can pass the cell membranes. 
 
We can conclude that our amidinohydrazone compounds are not able to penetrate cells and/or 
to inhibit CYP11B2 intracellularly. Neither do they show an effect on human steroidogenic 
CYP enzymes within the cell. The amidinohydrazone moiety is not a good alternative for the 
azole group, which is an important structural feature of CYP inhibitors. Its aromatic nitrogen 
is able to complex the heme iron of the CYP enzyme and its pKb-value is more or less in the 
range of physiological pH. This enables the compound to permeate cell membranes as a base. 
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3.2.    Synthesis and biological evaluation of heteroaryl substituted naphthalenes as 
          inhibitors of CYP11B2. 
 
3.2.1. Introduction 
 
We recently reported that amidinohydrazones are not able to inhibit CYP11B2 (Voets et al., 
2004, see 3.1.). These compounds were not able to penetrate cells because of their 
unfavorable pKb-values and/or to inhibit CYP11B2 intracellularly. In search of a new 
approach, we returned to the azole substituted lead structure III. We changed the core 
structure of III by moving its exocyclic double bond into the ring. In this way we found a new 
lass of compounds, the heteroaryl substituted naphthalenes IV (Figure 18).  
 From lead structure III to a new class of inhibitors IV 
 
c
 
Figure 18.
HetHet
RR
N
NH
III IV  
 
ifferent azole and pyridine substituted naphthalenes, such as 1- and 5-imidazoles, 5-
 
f our 
evaluation of these 
D
oxazoles, 3- and 4-pyridines and 5-pyrimidines, were synthesized to investigate which
nitrogen containing heterocycle is most appropriate to coordinate with the heme iron o
target enzyme. This section contains the syntheses and the biological 
heteroaryl substituted compounds 14-23 (Figure 19). 
 
Figure 19. General structures 
 
A
N
N
N
R
Het
O
14-16 21-2317-20  
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3.2.2. Synthesis 
-Naphthalen-2-yl-1H-imidazole 14 was prepared by reacting 2-bromo-1-(2-
aphthyl)ethanone 14a with formamide at high temperatures (method 8) (Bredereck et al., 
1953). The bromocompound 14a was synthesized through bromination of 2-acetonaphthone 
14b with tetrabutylammonium tribromide (method 7). The reaction of tosylmethylisocyanide 
(tosmic) with N-methylimine 15a or the aldehyde 16a yielded the N-methylimidazole 15 or 
the oxazole 16, respectively (method 9). 
 
Scheme 6a. Synthesis of azole substituted naphthalenes 14-16 
 
 
 
5
n
O
Br
A
H
A
N
O
14a
15a  A = NMe
16a  A = O
14  A = NH
15  A = NMe
16  A = O
method 8
method 9
14b
method 7
 
 
a : method 7: tetrabutylammonium tribromide, CH2Cl2/methanol, RT, 1 h; method 8: formamide, 
185°C, 2 h; method 9: tosmic, K2CO3, RT, overnight. 
 
The reaction of the naphthylboronic acid 17-19a with imidazole in the presence of a copper 
salt yielded the 1-imidazole substituted naphthalenes 17-19 (method 11-12) (Lam et al., 1998; 
Lan et al., 2004). The boronic acids 17a and 19a were commercially available. 2-Methoxy-3-
naphthylboronic acid 18a was prepared by treating 2-methoxynapthalene 18b with nBuLi and 
B(OCH3)3 (method 10). The 1-imidazole substituted quinoline 20 was prepared by coupling 
3-bromoquinoline 20a with imidazole in the presence of CuO (method 13) (Kauffmann et al., 
982).  1
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Scheme 7a. Synthesis of 1-imidazole substituted naphthalenes 17-20 
 
Y
N
N
R
B(OH)2
R
N
Br
OMe
R = H
R = 3-OMe
R =
method 11
20
 6-OMe
17a
18a
19a
a
method 13
17-20
method 12
method 10
18b
 
 
 
a : m d 10: 1 BuL , -20 °C T, 2 h  B(OCH3  °C, 1 h, RT night ) HC , 
ethod 11: im azole, Cu c)2, CH 2, RT, 48 h; method 12: im
 general method for introducing a pyridyl or pyrimidyl group on the naphthalene ring is the 
d-catalyzed cross-coupling of bromonaphthalenes with suitable pyri(mi)dyl containing 
etho ) n i, THF  – R 2) ) , -603 , over  3 l, RT
    20 min; m id (OA 2Cl idazole, CuI, methanol, 
    reflux, 3 h; method 13: imidazole, CuO, K2CO3, nitrobenzene, reflux, 24 h. 
 
 
A
P
nucleophilic coupling partners. In this case we used the Suzuki coupling.  
The first step of the synthesis of the wanted compounds 21-23 was the preparation of the 
heteroarylboronic acids 24-26. nButyllithium was added to a mixture of bromopyri(mi)dine 
24-26a and triisopropyl borate, followed by an acid quench (method 15) (Li et al., 2002). The 
next step was the Suzuki coupling of the 2-bromo-6-methoxynaphthalene 21a with the 
heteroarylboronic acids 24-26 in the presence of potassium carbonate and 
tetrakis(triphenylphosphine)palladium as a catalyst (method 14) (Miyaura et al., 1995).  
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Scheme 8a. Synthesis of pyri(mi)dine substituted naphthalenes 21-23 
 
 
Het
O
Het B(OH)2
Br
O
N
Y
BrN Br
+
21  Het = 3-Pyr
22  Het = 4-Pyr
23  Het = 5-Pyrim
24-26
method 14
method 15
24a  Y = C
26a  Y = N
21a
H25a
 
a : me  14: NaCO h3)4, DME, 80°C, overnight; m  15: 1) B(O nBuLi, toluene/ 
   THF, -70°C, 0.5 20°C - R
 
or the determination of the inhibitory activity of compounds 14-23 and fadrozole as a 
ference, CYP11B2 expressing fission yeast was used. The fission yeast was incubated with 
tion, extraction and analytics were 
sed as described for the yeast assay. The IC50 values at a concentration of 500 nM are also 
resented in Tables 3 and 4. 
 
 
thod 3, Pd(PP ethod iPr)3, 
h 2) HCl, - T. 
 
3.2.3. Biological evaluation 
 
F
re
inhibitor and [14C]-deoxycorticosterone as substrate. The product formation was monitored by 
HPTLC using a phosphoimager. The percent inhibition values are shown in Tables 3 and 4. 
The compounds, showing more than 60% inhibition in S. Pombe, as well as a few other 
compounds with less activity, were tested om V79 MZh cells expressing either CYP11B1 or 
CYP11B2 (Ehmer et al., 2002) to get information about activity and selectivity in mammalian 
cells. The same substrate and similar conditions for incuba
u
p
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Table 3. Inhibition of human adrenal CYP11B1 and CYP11B2 by azole substituted  
 
   compounds 14-20 
Y
N
N
RA
N
14-16 17-20  
 
  % inhibitiona  -value (nM)c   IC50  
Compound A R CYP11B2b  V79 11B1
d 
CYP11B1 
V79 11B2e 
CYP11B2 
ectivity 
ctorf
 Sel
fa
1 NH  41  296  0.7 4 207 
1 NMe 28  n.d.  - 
1 O 11  12 66 
1  H 80   38 35 
1  3-OMe 87  19 
1  6-OMe  218 4 
2  Y=N   604 10 
f   68  1  10 
5  n.d. 
6  805  
7 1317  
8 81  4 
9 49 849  
0 17 6338  
adrozole 10 
a our terminat , standa  deviation less th . b S. pombe xpressing hu P11B2; 
orticosterone, 0 nM; i ibitor, 500 nM. an value of ur determina , standard 
s seen in Table 3, the azole substituted naphthalenes 14-16 and 19-20 exhibited moderate to 
nge between 218 and 604 nM. The IC50 
 Mean value of f
substrate: deoxyc
de ions
 10
rd
nh
an 10%
 
 e
fo
man CY
tionsc Me
deviation less than 20%. n.d. = not determined. d Hamster fibroblasts expressing human CYP11B1; substrate: 
deoxycorticosterone, 100 nM. e Hamster fibroblasts expressing human CYP11B2; substrate: deoxycorticosterone, 
100 nM. f IC50 CYP11B1/ IC50 CYP11B2. 
 
 
A
low potency in the yeast assay (11-49%). Only the unsubstituted and 3-methoxy substituted 1-
imidazolyl naphthalenes 17 and 18 showed a pronounced inhibitory activity (80-87%) higher 
than the reference fadrozole (68%). These compounds 17 and 18 were also very active 
towards CYP11B2 in V79 cells with IC50 values of 38 nM and 19 nM, respectively. The 
compounds 14, 19 and 20, which showed moderate to low activity in the yeast assay, 
exhibited higher IC50 values in the V79 assay in the ra
values were thus in good accordance with the values of the yeast assay. The only exception 
was the oxazolyl compound 16, which was very potent in the mammalian cell assay (IC50 = 
12 nM) and showed almost no activity in the yeast assay (11% inhibition). This oxazole 
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substituted compound 16 turned out to be the most selective inhibitor of this series with a 
selectivity factor of 66. This means that 16 is 66 times more potent towards CYP11B2 than 
CYP11B1 and is much more selective than the reference fadrozole (selectivity factor = 10). 
The other azole substituted naphthalenes 17-20 displayed a variety of moderate to low 
electivity factors ranging from 4 to 35. Interestingly, the 5-imidazolyl compound 14 
xhibited a selectivity factor of 0.7.  
able 4. Inhibition of human adrenal CYP11B1 and CYP11B2 by pyri(mi)dine substituted  
s
e
 
T
   compounds 21-23 
 
Het
O
21-23   
 
  % inhibitiona  IC50-value (nM)c   
Compound Het CYP11B2b  V79 11B1
d 
CYP11B1 
V79 11B2e 
CYP11B2 
 Selectivity 
factorf
21 3-Pyr 91  1577 6  263 
22 4-Pyr n.i.  n.d. n.d.  - 
23 5-Pyrim 29  n.d. n.d.  - 
fadrozole  68  10 1   
a Mean value of four determinations, standard deviation less than 10%. b S. pombe expressing human CYP11B2;
substrate: deoxycorticosterone, 100 nM; inhibitor, 500 nM. n.i. = no inhibition 
 
 
 
 moderate or no inhibition at all. 
c Mean value of four 
determinations, standard deviation less than 20%. n.d. = not determined. d Hamster fibroblasts expressing human
CYP11B1; substrate: deoxycorticosterone, 100 nM. e Hamster fibroblasts expressing human CYP11B2; substrate:
deoxycorticosterone, 100 nM. f IC50 CYP11B1/ IC50 CYP11B2. 
 
 
When we compare the pyri(mi)dine substituted compounds, we notice the high activity of the 
3-pyridine substituted compound 21 (Table 4). In the yeast assay, compound 21 inhibited the 
target enzyme CYP11B2 with 91%. In the V79 cell assay, it has a very low IC50 value of 6 
nM. Additionally, the 3-pyridine substituted compound is surprisingly selective with a 
selectivity factor of 263. The 4-pyridine and 5-pyrimidine substituted compound 22 and 23, 
on the other hand, showed
 
 
 32
  RESULTS  
For the compounds which displayed activity towards CYP11B2, the selectivity towards other 
steroidogenic CYP enzymes, the estrogens producing CYP19 (aromatase) and the androgens 
forming CYP17 (17α-hydroxylase-C17,20-lyase), was investigated (Table 5).  
 
Table 5. Inhibition of human CYP19 and human CYP17 by heteroaryl substituted  
   compounds 14-23 
 
A
N
N
N
R
Het
O
14-16 21-2317-20
 
 
   
IC50-value (nM)a   
% inhibitionc
[IC50-value (nM)] 
Compound A R Het human CYP19b  human CYP17d
14 NH   n.d.  n.d. 
15 NMe   n.d.  n.d. 
16 O   n.d.  n.d. 
17  H  2821  13 
18  3-OMe  129  4 
19  6-OMe  n.d.  n.d. 
20  Y=N  n.d.  n.d. 
21   3-Pyr. 586         72 [667] 
22   4-Pyr. n.d.  n.d. 
23   5-Pyrim. n.d.  n.d. 
fadrozole    30  5 
ketoconazole    n.d.  40 
a Mean value of four determinations, standard deviation less than 20%. n.d. = not determined b human placental 
CYP19; 1mg/ml of protein; substrate: androstenedione, 500 nM. c Mean value of four determinations, standard 
deviation less than 10%. n.d. = not determined. d E.coli expressing human CYP17; 5 mg/ml; substrate: 
progesterone, 2.5 µM; inhibitor, 2.5 µM.  
 
 
The IC50 values of the compounds for CYP19 were determined in vitro using human placental 
microsomes and [1β-3H]androstenedione as substrate as described by Thompson and Siterii 
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(Thompson and Siterii, 1974) using our modification (Hartmann and Batzl, 1986). The 
bitory activity with IC50 values of 2821 nM and 
86 nM. Only compound 18 had an IC50 value of 129 nM, which is still much higher than the 
rence fadrozole (IC50 = 30 nM). 
he percent inhibition values of the compounds towards CYP17 were determined in vitro 
The 6-methoxy compound 21 
howed a higher activity towards CYP17 with an IC50 value of 667 nM. 
3.2.4. Discussion and conclusion 
 
The (imidazolylmethylene)tetrahydronaphthalenes and –indanes described by our working 
group (Ulmschneider et al., 2005a), proved to be potent and moderate selective CYP11B2 
inhibitors. With the aim of further increasing activity and most of all selectiv y towards 
ldosterone synthase, we modified the lead compound III (Figure 18). Instead of exocyclic 
ouble bond bearing (imidazolylmethylene)tetrahydronaphthalenes and indanes, we 
es of heteroaryl substituted naphthalenes 14-23.  
t heteroaryl substituted 
CYP11B2, however, was quite low (selectivity factor = 35 
nd 4).  
compounds 17 and 21 exhibited very low inhi
5
IC50 value of the refe
T
using progesterone as substrate an the 50.000g sediment of E.coli recombinantly expressing 
human CYP17 (Hutschenreuter et al., 2004). The 1-imidazole substituted compounds 17 and 
18 exhibited a weaker (4-13%) inhibition as the reference ketoconazole (40%) at a 
concentration of 2.5 µM. This is not a strong inhibition taking into consideration that potent 
CYP17 inhibitors are much more active than ketoconazole (IC50 ketoconazole = 4.5 µM; IC50 
SA40 = 36 nM; factor = 125) (Hutschenreuter et al., 2004). 
s
 
 
it
a
d
synthesized a seri
 
An important requirement for strong CYP inhibitors is a nitrogen containing heterocycle 
which can complex with the heme iron of the target enzyme. This complexation mechanism 
does not only increase binding affinity of the inhibitors, but also prevents oxygen activation 
of the heme which is required for the catalytic process. Differen
naphthalenes were synthesized and tested for their potency towards CYP11B2. The 3-pyridine 
substituted compound 21 turned out to be very active and highly selective with an IC50 value 
of 6 nM and a selectivity factor of 263. The replacement of this group by other heterocyclic 
moieties, like 4-pyridine, 5-pyrimidine, 1- and 5-imidazole and 5-oxazole, resulted in a 
decrease or loss of activity. Only the 1-imidazole substituted compounds 17 and 18 were very 
active. Their selectivity towards 
a
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An explanation for the difference in binding affinities (potency) between the 3-pyridine and 
-pyridine compounds 21 and 22 has been postulated before (Ulmschneider et al., 2005b). For 
an optimal orbital overlap of the pyridyl nitrogen and the heme iron, the pyridyl moiety 
hould be located perpendicular with respect to the plane of the heme group. In case of the 4-
yridine compounds, the distorsion of this geometry weakens the interaction and results in 
low inhibitory activities. 
Another interesting point is that the 5-imidazolyl compound 14  a selectivit of 0.7. 
It is 1.5 times active to s CYP1 ards CY 1B2. Th tion 
that it might b ble to f selectiv  CYP1  as well. These inhibitors 
could be used for the treatme f Cus nd th etabo  
are diseases related to increase rtisol
e can conclude from this present chapter that the 3-pyridyl moiety is ideal with respect to 
yl 
ectivity towards CYP11B2. 
herefore, 6-methoxy-3-pyridyl naphthalene 21 will be used as a new lead compound in the 
llowing chapters. 
4
s
p
 has y factor 
more ward 1B1 than tow P1 is is an indica
e possi ind e inhibitors of 1B1
nt o hing's syndrome a e m lic syndrome, which
d co  levels.  
 
W
activity and selectivity. Additionally, the 3-pyridine substituted naphthalene affected the sex 
hormone producing enzymes CYP17 and CYP19 only marginally. The other heteroar
substituted compounds displayed lower activity and/or sel
T
fo
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3.3.   Synthesis and biological evaluation of 3-pyridine substituted naphthalenes and  
         quinolines as inhibitors of CYP11B2. 
 
3.3.1. Introduction 
 
By comparing the inhibitory activities of different heteroaryl substituted naphthalenes, we 
found that the 3-pyridine substituted naphthalene is a promising new lead for the development 
of novel aldosterone synthase inhibitors (see 3.3.). In order to investigate this 3-pyridine 
compound in detail, a series of different substituents was introduced on different positions of 
the naphthalene ring. Additionally, some 3-pyridine substituted quino(xa)lines 46-48 were 
sted to evaluate the role of the naphthalene core (Figure 20).  te
 
Figure 20. General structures 
 
N
R
Y
X N
N
27-44 46-4845  
m carbonate 
nd tetrakis(triphenylphosphine)palladium as a catalyst (method 14). 
y treating the corresponding naphthols 33b,37-39b 
ethanesulfonic anhydride and dry pyridine at 0°C (method 16) (Mewshaw et 
, 2003). The naphthols 33b and 38b were commercially available. The 1,5-dichloro-6-
 
39b by treating 39c with N-
hlorosuccinimide (method 18). 
 
 
3.3.2. Synthesis 
 
The 3-pyridine substituted naphthalenes 27-28,30-39,41-42,45 were synthesized by the route 
shown in Scheme 9. The key step of this synthesis is the Suzuki cross-coupling of bromo- or 
triflate-naphthalenes with the 3-pyridylboronic acid 24 in the presence of sodiu
a
The triflates 33a,37-39a were prepared b
with trifluorom
al.
methoxy compound 37b was synthesized following a literature procedure (method 17)
(Mewshaw et al., 2003) and the 1-chloro-7-methoxy naphthol 
c
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Scheme 9a. Synthesis of 3-pyridyl compounds 27-28,30-39,41-42,45 
 
OTf
R
N
RB(OH)2
N
OH
R
Br
R
B(OH)2
N
OH
O
OHO
+
27-28,30-39,41-42,45
33a,37-39a
27-28a,30-32a,
34-36a,41-42a,45a
33b,37-39b
+
method 14
method 16
method 14
24
24
37c 39c
method 17 method 18
H 33 6-CN 38 7-OMe 
28 6-Br 34 5-Cl-6-OMe 39 1-Cl-7-OMe 
 41 6-COOMe 
31 6-OPr 36 5-(3-Pyr)-6-OMe 42 6-OMe-7-COOMe 
32 6-OBn 37 1,5-diCl-6-OMe 45 phenanthrene 
4, DME, 80°C, 2.5 h - overnight; method 16: trifluoromethanesulfonic  
 min, RT, overnight; method 17: N-chlorosuccinimide, ACN, 
  RT, overnight; method 18: N-chlorosuccinimide, ACN, reflux, 3 h. 
 
 
 
no R no R no R 
27 
30 6-OEt 35 5-Br-6-OMe
 
 
a : method 14: NaCO3, Pd(PPh3)
    anhydride, dry pyridine, 0 - 5°C, 30
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The bromonaphthalenes 30-32a were prepared by treating 6-bromo-2-naphthol 49 with 
potassium carbonate and an alkyl halogenide (method 19). The dihalogenated naphthalenes 
34-35a were synthesized by reacting 2-bromo-6-methoxynaphthalene 21a with N-bromo- or 
N-chlorosuccinimide (method 20). 
 
Scheme 10a. Synthesis of compounds 30-32a, 34-35a 
 
OH
Br
O
Br
R
Br
O
Br
O
X
49 30a R=Et
31a R=Pr
32a R=Bn 
21a 34a X=Cl
35a X=Br
method 19
method 20
 
    N-bro reflux, 3 h, RT, overnight. 
The synthesis of the ester 42a is shown in Scheme 11 (Murphy et al., 1990). Treatment of 3-
hydroxy-2-naphthoic acid 42d with bromine in glacial acetic acid gave the 4,7-dibromo 
compound 42c (method 21), which was then selectively debrominated at the 4-position with 
tin and glacial acetic acid to yield the bromo compound 42b (method 22). In a last step 42b 
was refluxed with Me2SO4 and K2CO3 to give the wanted ester 42a (method 23). 
Treatment of the 6-m thoxy su hthalene at –78°C gave the 
pou  (metho ross- -m p
acid  with 3-brom 24a yie d the 3-m po ethod 14). The 
conversion of the ester 41 to the amides 43 and 44 was performed in a one step reaction 
following a literature procedure (Jagdm et al., 1990). The methyl ester was treated with 
form thoxide in anhydrous DMF ( e 12). 
 
 
a : method 19: RX, K2CO3, DMF, reflux, 3 h; method 20: N-chlorosuccinimide or  
mosuccinimide, THF, 
 
 
e bstituted nap 21 with BBr3 
hydroxylated com nd 29 d 24). The c coupling of 2 ethoxy-3-na hthylboronic 
18a opyridine lde ethoxy com und 40 (m
ann 
amide and sodium me method 25) (Schem
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Scheme 11a. Synthesis of compound 42
 
a 
OH
O
OH
OH
O
OH
Br
Br
OH
O
OH
Br
O
Br
MeO
MeO
method 21
method 23
method 22
42a 42b
42c
42d
 
 
a : m  21: Br2, glacial acetic acid, 0°C - reflux, 2 h; met
   me  23: M e, re  h. 
 
Scheme 12a. Synthesis of compounds 29,40,43-44 
 
ethod hod 22: Sn, glacial acetic acid, reflux, 3 h; 
thod e2SO4, K2CO3, aceton flux, 4
N
MeOOC
N
RHN
O
O
N
OH
N
B(OH)2
O
N
ON
Br
method 24
21 29
method 14
+
4018a 24a
method 25
41 43 R=H
44 R=Me  
 
a : method 24: BBr3, CH2Cl2, -78°C, 30 min, RT, overnight; method 14: NaCO3, Pd(PPh3)4, DME,  
    80°C, 4 h; method 25: RNHCHO, NaOMe, dry DMF, 100°C, 1 h. 
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The first step in the synthesis of the quinoline and quinoxaline analogues 46-48 (Scheme 13) 
was the preparation of the brominated compounds 46-48a. The hydroxyl compounds 47-48b 
ere treated with POBr3 to yield compounds 47-48a (method 26) (Young et al., 1951). The 3-w
bromoquinoline 46a was commercially available. Subsequently, the bromo compounds were 
coupled with 3-pyridylboronic acid 24 to give the 3-pyridine substituted quino(xa)lines 46-48 
(method 14). 
 
Scheme 13a. Synthesis of compounds 46-48 
 
Y
X N
Y
X Br
Y
X OH
N
B(OH)2+
method 26
24
method 14
46-48
46-48a47b X=N, Y=CH
48b X,Y=N
 
 
a : method 26: POBr , 155°C, 4 h; method 14: NaCO , Pd(PPh ) , DME, 80°C, overnight. 
nes showed a pronounced inhibitory activity 
ilar to or higher than the reference fadrozole (68%). The 3-methoxy and 7-methoxy 
compounds  showed little or no activity at all (< 27%). Introduction of a 
ethoxy or ethoxy group in 6-position did not change potency (21 and 30), but larger 
3 3 3 4
 
3.3.3. Biological evaluation 
 
The inhibitory activities of the compounds 27-48 towards human CYP11B2 were determined 
using human CYP11B2 expressing fission yeast. After incubation with [14C]-
deoxycorticosterone as substrate in the presence of the inhibitor at a concentration of 500 nM, 
the product formation was monitored by HPTLC using a phosphoimager. The percent 
inhibition values are shown in Table 6. 
Most of the 3-pyridine substituted naphthale
sim
compounds 40 and 38 and the quinolines 46 and 47 had only moderate activity (≈ 40%), while 
43, 44, 45 and 48
m
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substituents like propoxy diminished inhibitory activity (31) or resulted in  of 
potency as shown for the benzyloxy compou tende cy e 
substituents in 5-position. The 5-chlorinated and 5-brom pounds 34 and 35 showed 
high inhibitory activities, but introducing a large 3-pyridyl substitue  in 36) 
diminished the potency drastically. The additional ring in the phenanthrene compound 45 was 
also too large as this com w potency (27%). The shift of the methoxy 
substituent from the 6- into the 7-position resulted in oderate inhibitor (38
introdu stituent in the 1-pos n of com ound 38 increased the 
activity significantly (39
 
Table 6. Inhibition of hum and CYP11B2 by 3-pyridine substituted  
pounds 27-48 
 
 complete loss
nd 32. The same n can be seen for th
inated com
nt the 5-position (
pound exhibited a lo
 a m ). However, 
cing an additional chloro sub itio p
). 
an adrenal CYP11B1 
   com
N
R
Y
X NN
27- 44 46- 8445
 
hibitiona 50-value (nM)c  
 
  % in IC  
Com R CYP11B2b V79 11B1
d 
11B1 
V79 11B2e 
CYP11B2 actorf
pound 
CYP
 Selectivity 
f
21 6-OMe 91 77 6 263 
92 26 28 208 
85 39 15 196 
6-O 88 71 23 116 
6-OEt 86 19 12  451 
6-OPr 36 d. - 
86 2517 13  192 
15  
27 H 58  
28 6-Br 29  
29 H 26  
30 54
31 n. n.d.  
32 6-OBn 3 n.d. n.d.  - 
33 6-CN 98 691 3  238 
34 5-Cl-6-OMe 
35 5-Br-6-OMe 68 4481 33  136 
36 5-(3-Pyr)-6-OMe 9 n.d. n.d.  - 
37 1,5-diCl-6-OMe 82 4898 28  174 
38 7-OMe 46 n.d. n.d.  - 
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  % inhibitiona IC50-value (nM)c   
Compound R CYP11B2b V79 11B1
d 
CYP11B1 
V79 11B2e 
CYP11B2 
 Selectivity 
factorf
39 1-Cl-7-OMe 85 2724 29  94 
40 3-OMe 30 n.d. n.d.  - 
41 6-COOMe 74 10505 72  145 
42 6-OMe-7-COOMe n.d. >10000 >10000  - 
d.  - 
48 X,Y=N 13 n.d. n.d.  - 
10 1  10 
43 CONH2 n.i. n.d. n.d.  - 
44 CONHMe n.i. n.d. n.d.  - 
45  27 7553 n.d.  - 
46 X=CH,Y=N 40 n.d. n.d.  - 
47 X=N,Y=CH 53 n.d. n.
fadrozole  68 
a M
sub
ean value of four determinations, standard deviation less than 10%. b S. pombe expressing human CYP11B2; 
strate: deoxycorticosterone, 100 nM; inhibitor, 500 nM. n.i. = no inhibition c Mean value of four 
 
tor of 10. The most selective compounds 33 and 30 were 238-fold and even 
51-fold more selective for CYP11B2.  
pe of 
costerone to corticosterone 
y CYP11B2 was measured at five substrate concentrations (50 nM – 2 µM) in the absence or 
presence of inhibitor at different concentrations (3 – 15 nM). Using the Lineweaver-Burk 
equation: 1/v = 1/Vmax + Km/Vmax [S], the plots at different inhibitor concentrations were 
determinations, standard deviation less than 20%. n.d. = not determined. d Hamster fibroblasts expressing human 
CYP11B1; substrate: deoxycorticosterone, 100 nM. e Hamster fibroblasts expressing human CYP11B2; substrate: 
deoxycorticosterone, 100 nM. f IC  CYP11B1/ IC  CYP11B2. 
 
50 50
The most potent compounds, showing more than 60% inhibition in S. pombe, were tested for 
activity and selectivity in V79 MZh cells expressing either CYP11B1 or CYP11B2. [14C]-
Deoxycorticosterone was used as substrate and the products were monitored as in the yeast 
assay. In Table 6 the IC50 values are presented. 
All the compounds exhibited very high activity towards CYP11B2 with IC50 values in the
range of 3 nM to 72 nM. The 6-cyano compound 33 was the most potent CYP11B2 inhibitor 
with an IC50 value of 3 nM. In addition, these active compounds were highly selective by 
showing only low inhibition of CYP11B1 (IC50 = 691-10505 nM). It was very surprising that 
all of them were much more selective than the reference fadrozole which displayed a 
selectivity fac
4
 
Using the CYP11B2 expressing V79 cells, the 6-cyano compound 33 was tested for its ty
CYP11B2 inhibition. The conversion of the substrate deoxycorti
b
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obtained as shown in Figure 21. Plotting 1/v against 1/[S] gives rise to an Y-intercept of 
1/Vmax. The intercept on the x-axis equals –1/Km and the slope of the line is Km/Vmax. The Km 
is defined as the substrate concentration which gives rise to a velocity equal to half of the 
maximal reaction velocity. As the inhibitor concentration increased, the Km increased giving 
rise to a value designated as Km,obs. The slope of the line and the X-intercept changed, while 
the Y-intercept was unaffected. This is the typical hallmark of competitive inhibition. The 
 the substrate to b ite. As th bitor bin he 
enzyme, it forms an enzyme-inhibitor comple not be co d
 
Figure 21. Lineweaver-Burk plots for the conversion of deoxycorticost
                  in the presence of different concentrations of compound 33  
inhibitor competes with ind in the active s e inhi
nverted to pro
ds to t
uct.  x which can
erone to corticosterone  
y = 12,017x + 0,0825
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The dissociation constant for inhibitor binding, Ki, could be determined using the equation Ki 
 [I] / K  / Km – 1, where [I] is the inhibitor concentration (nM) and K  is the K  value 
ue 
deoxyc also 
compet e IC50 
values i 50 m rusoff, 
1973). nd 30 and the dichloro compound 37 revealed Ki values of 
8 nM and 18 nM, respectively. 
 
 
= m,obs m,obs m
in presence of inhibitor. The 6-cyano compound 33 exhibited a Ki value of 1.9 nM (Km val
orticosterone = 185 nM). Assuming that the other inhibitors of this class are 
itive inhibitors, we can calculate the corresponding Ki values from the respectiv
using the equation of Cheng and Prusoff: K  = IC /1 + [S]/K  (Cheng and P
Thus, the 6-ethoxy compou
 43
  RESULTS  
Table 7. Inhibition of human CYP19 and human CYP17 by 3-pyridine substituted  
   compounds 27-48 
 
 
 
IC50-value (nM)a   
% inhibitionc
[IC50-value (nM)]c
Compound R human CYP19b  human CYP17d
27 H 5727  40 
28 6-Br >36000  46 
29 6-OH >36000  65 
30 6-OEt 6638  53 
31 6-OPr n.d.  n.d. 
32 6-OBn n.d.  n.d. 
33 6-CN >36000           73 [686] 
34 5-Cl-6-OMe 1805  32 
35 5-Br-6-OMe 9107  38 
36 5-(3-Pyr)-6-OMe n.d.  n.d. 
37 1,5-diCl-6-OMe 970           83 [233] 
38 7-OMe n.d.  n.d. 
39 1-Cl-7-OMe >36000          94 [27] 
40 3-OMe n.d.  n.d. 
41 6-COOMe 1252  12 
42 6-OMe-7-COOMe n.d.  n.d. 
43 CONH2 n.d.  n.d. 
X,Y=N n.d.  n.d. 
44 CONHMe n.d.  n.d. 
45  n.d.  n.d. 
46 X=CH,Y=N n.d.  n.d. 
47 X=N,Y=CH n.d.  n.d. 
48 
fadrozole  30  5 
ketoconazole  n.d.  40 
a Mean value of four determinations, standard deviation less than 20%. n.d. = not determined b human placenta
CYP19; 1mg/ml of protein; substrate: androstenedione, 500 nM. 
l 
 
 
c Mean value of four determinations, standard
deviation less than 10%. n.d. = not determined. d E.coli expressing human CYP17; 5 mg/ml; substrate:
progesterone, 2.5 µM; inhibitor, 2.5 µM.  
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Selectivity towards the steroidogenic CYP enzymes, CYP19 and CYP17, was also evaluated 
(Table 7). The IC50 values of the compounds for CYP19 were determined in vitro using 
human placental microsomes and [1β-3H]androstenedione as substrate. The compounds 
exhibited very low to no inhibitory activity with IC50 values in the range between 970 nM and 
ively. 
he most selective CYP11B2 inhibitor 30 was further tested toward two crucial human 
being responsible for 75% of the drug metabolism and 
YP2D6 for which a genetic polymorphism is described. No inhibitory effect could be 
 
CH3-group in the 3 or 6 position 
D structural models considerably (Kirton 
>36000 nM. The percent inhibition values of the compounds towards CYP17 were 
determined in vitro using progesterone as substrate and the 50.000g sediment of E.coli 
recombinantly expressing human CYP17. Most of the compounds showed a similar inhibition 
at a concentration of 2.5 µM as the reference ketoconazole (40%). The ester 41 displayed a 
weaker inhibition (12%). The 6-methoxy substituted naphthalene 33 showed a higher activity 
towards CYP17 (IC50 = 686 nM) and the chloro substituted compounds 37 and 39 exhibited 
IC50 values of 223 and 27 nM, respect
T
hepatic CYP enzymes, CYP3A4 
C
observed (CYP3A4, ketoconazole IC50 = 50 nM, 30 no inhibition at 50 nM; CYP2D6, 
quinidine IC50 = 20 nM, 30 no inhibition at 20 nM) (Voets et al., 2005). 
 
3.3.4. Docking and molecular dynamics studies 
 
Docking and molecular dynamics studies were performed by Dr. Iris Antes (Max Planck
Institut, Saarbrücken) to explain very interesting structure-activity relationships of three pairs 
of imidazole and pyridine compounds (Table 8).  
While in the case of the unsubstituted pyridyl and imidazolyl derivatives (27 and 17) both 
compounds were very potent inhibitors, introduction of a O
leads to a strong decrease of activity for one compound of the pairs. In case of the 3-methoxy 
compounds the pyridyl derivative lost activity dramatically whereas for the 6-methoxy 
compounds it was the imidazolyl compound which exhibited a strong drop of activity.  
Because there are no X-ray structures available for CYP11B2, due to its membrane bound 
nature, a 3D model was built using the X-ray structure of human CYP2C9 as template 
(Williams et al., 2003). The use of mammalian cytochrome P450 structures as templates has 
already shown to improve the quality of resulting 3
et al., 2002). 
 
 
 45
  RESULTS  
Table 8. IC50 values for CYP11B2 inhibition and Fe(heme)-N(inhibitor) distances after  
              docking and molecular dynamics of selected compounds. 
 
N
R
N
N
R
21,27,40 17-19  
 
IC50-value (nM)    Compound R V79 11B2 
CYP11B2 
 
Fe-N 
distance (Ǻ) 
after docking 
 
Fe-N 
distance (Ǻ) 
after MDa
27 H 28.4  2.48 2.63 
17 H 38.5  2.38 2.13 
21 6-OMe 6.2  2.27 2.48 
19 6-OMe 218.0 2.29 7.36 
40 3-OMe >500 2.52 10.58 
18 3-OMe 19.1 2.08 2.52 
a Time for MD simulations: 1ns 
 
f the presentations the final locations of the 
ulation are only shown if a large movement was observed (Figure 22(d) 
ases the final positions were almost identical to the starting positions. 
After docking of the inhibitors into the protein structure, molecular dynamics simulations 
were performed with the inhibitor-protein complexes. In Figure 22 (a-f) the starting and the 
final positions after 1ns of molecular dynamics of the compounds in the binding pocket are 
shown. In all pictures the starting structures of the locations of the important binding pocket 
residues are presented. To enhance the clarity o
residues after the sim
and 22(e)). In all other c
 
 
Figure 22 (See next page). Selected residues of the energy minimized structures of CYP11B2  
     complexed with the compounds 27 (a), 17 (b), 21 (c), 19 (d), 40 (e) and 18 (f).  
     For the inhibitors the starting (orange) and end (yellow) positions of the MD 
     simulations are shown. In (d) and (e) the end conformations of Met230 and  
     Leu227 are also given. 
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Regarding the loca  of the inhi ained close to the docked position 
except for compounds 19 an  (Figure 22(d) and 22(e)), t com  wh  ha n 
li o no tivi bin g ex nts  large mo ents  o : 
t the end of the simulations the compounds had moved away from the heme and the Fe-N 
 
were studied. One major difference was observed for compound 19 and 40 
simulation the 
 reorient themselves and subsequently 
e group. 
In addition it was observed, that the methoxy group of compound 18 fits perfectly into a 
hydrophobic groove formed by the amino acid residues of Thr318 (CH3 group), Arg490 
(CH2-CH2 chain), and Pro491 as shown on the right side of Figure 22(f). In case of compound 
40 the larger size of the pyridyl ring and especially the different geometry of the complex due 
to the binding of the nitrogen to the heme prohibits that the methoxy group fits in this pocket. 
Thus, the methoxy group is turned by nearly 180 degrees, leading to the above described 
unfavorable position of the inhibitor. 
 
3.3.5. Discussion and conclusion 
 
In this chapter, the 6-methoxy 3-pyridine substituted naphthalene 21, which is a very active 
and selective CYP11B2 inhibitor (see 3.2.), was used as the new lead compound. A series of 
different substituents was introduced on the 3-pyridine substituted naphthalene core to get 
more insight into this new class of compounds. The influence of the chain length, the size and 
the position of the substituents on the naphthalene core was investigated. In addition, some 
quino(xa)line compounds have been synthesized to evaluate the role of the naphthalene ring. 
The structure-activity relationships obtained revealed that the naphthalene core is more 
appropriate than the (iso)quinoline or quinoxaline moiety. The corresponding compounds
8 displayed low or no activity at all. Obviously, a nitrogen atom at this position is 
unfavourable for an optim nteraction with the active site.  
tion bitors, the ligands rem
d 40 he pounds ich d show
ttle t  ac ty in the din perime . In these cases vem  were bserved
a
contact was broken. 
To gain a deeper insight into these phenomena, the binding modes of the compounds in the
original positions 
in comparison to the other compounds. The requirement for a strong inhibitor binding is a Fe-
N interaction which is almost perpendicular with respect to the plane of the heme. In the case 
of compound 19 and 40 this leads to positions much closer to the I-helix (partially shown in 
Figure 22: Val316-Thr319) than observed for the other inhibitors. These positions are 
energetically obviously unfavourable because the hydrophilic/hydrophobic regions in the I-
helix are located close to the aromatic regions of the ligands. Thus, during the 
compounds, while minimizing unfavourable contacts,
lose contact with the hem
 46-
4
al i
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  RESULTS  
Substitution in the 6-position of the naphthalene core is appropriate to have high activity and 
selectivity. Only in case pace-fillin tituents, like propoxy or benzyloxy (31,32), the 
activity drops drastically. Further substitution in the 5-positi  not result in lower 
t was not too large as for compound 36. A loss in activity 
, showing a low activity towards CYP11B2, was probably too large to fit 
. The other steroidogenic CYP enzymes CYP17 and CYP19 
nd the drug-metabolizing enzymes CYP3A4 and CYP2D6 were not affected. Only the 1-
 be a potent CYP17 inhibitor.  
dditionally, the 6-cyano compound 33 was tested for its type of CYP11B2 inhibition and 
turned out to be a competitive inhibitor with a Ki value of 1.9 nM (Km value 
eoxycorticosterone = 185 nM). 
 
 the 
nt compounds 19 and 40 however, major rearrangements of the inhibitors in the 
omplex were observed leading to the breaking of their Fe-N interactions. A closer analysis of 
trates some predictive value. 
 summary, we have obtained a new class of non steroidal highly active and selective 
of s g subs
on did
potency, as long as this substituen
was observed when substituents are introduced in 3- or 7-position (38,40). The phenanthrene 
compound 45
adequately into the active site of the target enzyme. 
In this study, we demonstrated that 3-pyridine substituted naphthalenes showed in vitro a 
highly selective inhibition of CYP11B2 versus CYP11B1, despite the high homology between 
the two enzymes. These compounds showed even better selectivity profiles than the 
(pyridylmethylene)tetrahydronaphthalenes and –indanes (Ulmschneider et al., 2005b). The 
best 3-pyridyl compounds described in this work were more than 190-fold more selective for 
CYP11B2 (27,28,33,34). In the case of the 6-ethoxy compound 30 an exceptional 451-fold 
stronger inhibition was observed
a
chloro-7-methoxy compound 39 turned out to
A
d
The results of the molecular dynamics studies showed that for the highly potent compounds
17, 18, 21 and 27 the docked positions remained stable throughout the simulations. For
two less pote
c
the ligand interactions with the binding pocket revealed that in the case of 19 and 40 the 
formation of a close Fe-N interaction leads to unfavourable contacts between the ligands and 
the I-helix of the protein. As it is known that a strong Fe-N interaction is a prerequisite for 
strong inhibitor binding, it can be concluded that the reason for the little inhibitory potency of 
19 and 40 is mainly sterical. In addition, this study shows that the protein model of CYP11B2, 
which has been improved continuously (Ulmschneider et al., 2005a, Ulmschneider et al., 
2005b, Voets et al., 2005), demons
In
inhibitors of aldosterone synthase. The most active CYP11B2 inhibitor was the 6-cyano 
compound 33 (IC50 = 3 nM). The 6-ethoxy compound 30 turned out to be a very active and 
the most selective inhibitor (IC50 = 12 nM) showing a selectivity factor of 451 
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3.4.    Synthesis and biological evaluation of heteroaryl substituted dihydronaphthalenes  
          and indenes as inhibitors of CYP11B2. 
By modifying our lead compound, the (imidazolylmethylene)tetrahydronaphthalenes and 
indanes III, we found a new class of 3-pyridine substituted naphthalenes IV, which showed in 
vitro a highly selective inhibition of CYP11B2 versus CYP11B1, despite the high homology 
between the two enzymes (Voets et al., 2005, see 3.3.). We changed the core structure of III 
by moving its exocyclic double bond into the ring. The naphthalene compounds showed the 
best selectivity profiles of all the CYP11B2 inhibitors described until now in the literature.  
 
Figure 23. From lead structure III to a new class of inhibitors V 
 
 
3.4.1. Introduction 
 
Het
n 
N
NH
RR
n 
Het
R
IVIII V  
 
stead of introducing an unsaturated bridge into the ring, which yielded the aromatic 
aphthalene compounds, we now introduce a saturated bridge to mimic the aliphatic ring in 
the 
phthalenes and indenes V (Figure 23).  
In
n
the lead compound III. This modification leads to a new class of CYP11B2 inhibitors, 
heteroaryl substituted dihydrona
 
Figure 24. General structures 
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 this chapter, the synthesis of a series of dihydronaphthalenes and indenes (Figure 24) and 
 
In
their biological activity towards the human CYP enzymes CYP11B2, CYP11B1, CYP17 and
 50
  RESULTS  
CYP19 are described. Molecular modelling and docking studies using our homology 
e were performed to understand some interesting structure-
ctivity relationships. 
modelled CYP11B2 structur
a
 
3.4.2. Synthesis 
 
The pyridine substituted indenes and dihydronaphthalenes 50-51,53-55,59 were synthesized 
by the route shown in Scheme 14.  
 
Scheme 14a. Synthesis of compounds 50-51,53-55,59 
 
n 
O
Br
R"
R
n 
OH
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R"
R
n 
Br
R"
R
n 
Het
R"
R Het B(OH)2
n 
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R
  50-51
53-55,59
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   50-51b
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   50-51c
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method 7 method 27
method 14
24-25
  
5
 50-51d
3-54d,59d
+
method 28
 
 
no n ’ Het  no n  R’’ Het 
50 3-Pyr  54 1 7-OMe H Pyr 
51 3-Pyr  55 1 6-OMe H -Pyr 
53 6-O e 3-Pyr  59 1 H Me 3-Pyr 
 
a : method trabut mo  tribrom CH2Cl2/met  RT, 1 h; od 27 NaBH
    0°C – R  h; method 2 uene, reflux, 2 h; m  14: NaC (PPh )4, DME, 80°C, 
    2 h – 
R R’ R
0 H -  3-
1 H H 4
1 M  H 
 7: te ylam nium ide, hanol,  meth : 4, MeOH, 
T, 1 8: pTSA, tol ethod O , Pd3 3
overnight. 
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The α-bromoketones 50-51,53-54,59c, synthesized by reacting the corresponding ketones 50-
51,53-54,59d with tetrabutyl ammonium tribromide (method 7), were reduced with NaBH4 
(method 27). The resulting alcohols 50-51,53-54,59b were refluxed in toluene with a catalytic 
amount of pTSA to yield the dehydrated compounds 50-51,53-54,59a (method 28). The last 
step was the Suzuki cross-coupling with a pyridylboronic acid in the presence of sodium 
carbonate and tetrakis(triphenylphosphine)palladium as a catalyst (method 14). 
 
Scheme 15a. Synthesis of compounds 52,58,60 
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ethod H2, DMF, 0  h; m
   PPA, 110°C m H4, M  0 T, 1 SO4, 
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An alternative synthetic pathway was used for the synthesis of the 3-pyridine substituted 
compounds 52,58,60 (Scheme 15). The alkylation of 3-pyridylacetonitrile 66 with the 
to give the wanted indenes and 
cheme 16a. Synthesis of compounds 56-57 
brominated alkyl derivatives 52,58,60e produced the nitriles 52,58,60d (method 29). 
Hydrolysis with NaOH yielded the acids 52,58,60c (method 30), which were cyclized to the 
corresponding indanones and tetralones 52,58,60b by treatment with PPA (method 31). The 
reduction with NaBH4 to the alcohols 52,58,60a (method 27) was followed by the 
dehydration with sulfuric and acetic acid (method 32) 
dihydronaphthalenes 52,58,60.  
 
S
 
N
R'
N
R' OH
Br
O
N
N CN
NNCmethod 29
NHOOC
56 R' = Me
57 R' = Et
method 33
method 34
56-57a
56d
56c56b
+
6656e
method 31
method 30
 
 
a : me : NaN , DMF, 0-80°C, 6 h d 30: NaOH , EtOH, reflux, 48 h; od 31: 
    PPA, 110°C, 20 m R’M ene, reflux overnight; method 3 Cl, 
   100°C, 2 h. 
 
thod 29 H2 ; metho  in H2O meth
min; ethod 33: gX, tolu , 3 h, RT, 4: H
 53
  RESULTS  
The Grignard reaction of the tetralone  with an alky nesium halogenide od 33) 
and the following dehydration of the resulting alcohols 56-57a with HCl (method 34) yielded 
the 1-alkyl substituted dihydronaphthalenes 56-57 (Sch 16). The 3-pyridin stituted 
te  was prepared as described above. The a tion of 3-pyridylacetonitrile 66 
 56b l mag (meth
eme e sub
tralone 56b lkyla
with phenethyl bromide 56e produced the nitrile 56d (method 29). Hydrolysis with NaOH 
yielded the acid 56c (method 30), which was cyclized to the corresponding tetralone 56b by 
treatment with PPA (method 31). 
 
The synthesis of the 1-imidazole substituted indene and dihydronaphthalenes 61-63 is shown 
in Scheme 17. The α-bromoketones 50-51,53c were stirred with imidazole for 24 hours to 
give the imidazole 61-63b (method 35). The reduction with NaBH4 to the alcohols 61-63a 
(method 27) and the subsequent acid-catalyzed dehydration (method 32) yielded the 1-
imidazolyl compounds 61-63. 
 
Scheme 17a. Synthesis of compounds 61-63 
 
n 
O
Br
R
n 
N
OH N
R
n 
N
N
R
n 
N
O N
R
61
61-63a50- 61-63b
method 35 method 27
51c,53c
-63
method 32
 
n R 
0 H 
1 H 
3 1 6-OMe 
 
 
a idazol  DMF, RT, 2 ethod 27: Na eOH, 0°C  RT, 1 h; me  32:  
no 
61 
62 
6
 : method 35: im e, 4 h; m BH4, M  – thod
   CH3COOH, H2SO4, 100°C, 1 h. 
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  RESULTS  
The (E) and (Z)-3-styrylpyridine 64 and 65 were synthesized by a modified Wittig reaction 
(Scheme 18). The benzylalcohol 64b was transformed into the phosphonium salt 64a (method 
 in the presence of K2CO3 as a base and 
8-crown-6 as phase-transfer catalyst (method 37). The resulting E/Z mixture was separated 
36), which reacted with 3-pyridine carbaldehyde 67
1
by column chromatography. 
 
Scheme 18a. Synthesis of compounds 64-65 
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a : method 36: PPh3·HBr, toluene, reflux, 14 h; m thod 37: K2CO3, 18-crown-6, CH2Cl2, reflux, 14 h. 
 
3.4.3. Biological evaluation 
 
or the determination of the inhibitory activity towards human CYP11B2, CYP11B2 
wer activity 
an the 3,4-dihydronaphthalenes. The shift of the methoxy substituent from 6- into 7-position 
 
e
F
expressing fission yeast was incubated with [14C]-deoxycorticosterone as substrate and the 
inhibitor at a concentration of 500nM. The percent inhibition values are shown in Table 9. 
Most of the 3-pyridine substituted derivatives showed a higher inhibitory activity than the 
reference fadrozole (68%). Only the 7-methoxy compounds 54 exhibited a moderate activity 
(51%). The 1-imidazolyl compounds 61, 62 and 63 also displayed moderate activity (25-
54%). The 4-pyridine substituted naphthalene 15, on the other hand, had almost no activity 
(15%) at all. In general the 3-pyridine substituted indenes exhibited a slightly lo
th
of the 3,4-dihydronaphthalene core reduced activity resulting in a moderate inhibitor (54).  
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Table 9. Inhibition of human adrenal CYP11B1 and CYP11B2 by heteroaryl substituted  
   compounds 50-55 and 61-63 
 
n 
N
R
n 
N
N
R
50-55 61-63  
 
   % inhibitiona IC50-value (nM)c   
Compound n R CYP11B2b V79 11B1
d 
CYP11B1 
V79 11B2e 
CYP11B2 
 Selectivity 
factorf
50 0 H 90 2391 13  184 
51 1 H 95 1729 7  247 
52 0 5-OMe 66 5684 4  1421 
53 1 6-OMe 98 578 2 
54 1 7-OMe 51 n.d. n.d.
 275 
  - 
55 1 6-OMe 15 2529 2834  1 
334  2 
63 1 6-OMe 35 763 411  2 
fadrozole   68 10 1  10 
61 0 H 33 n.d. n.d.  - 
62 1 H 34 639 
a Mean value of four determinations, standard deviation less than 10%. b S. pombe expressing human CYP11B2; 
substrate: deoxycorticosterone, 100 nM; inhibitor, 500 nM. c Mean value of four determinations, standard 
deviation less than 20%. n.d. = not determined. d Hamster fibroblasts expressing human CYP11B1; substrate: 
deoxycorticosterone, 100 nM. e Hamster fibroblasts expressing human CYP11B2; substrate: deoxycorticosterone, 
100 nM. f IC50 CYP11B1/ IC50 CYP11B2. 
 
The most potent compounds, showing more than 60% inhibition in S. pombe, and a few less 
potent compounds were tested for activity and selectivity in V79 MZh cells expressing either 
CYP11B1 or CYP11B2. [14C]-Deoxycorticosterone was used as substrate and the products 
ere monitored as in the yeast assay. In Table 9 the IC50 values are presented. All the 
uted 
dene 52 had an exceptional selectivity factor of 1421. 
w
compounds with more than 60% inhibition in the yeast assay exhibited very high activity 
towards CYP11B2 with IC50 values in the range of 2 nM to 13 nM. They were also highly 
selective by showing only moderate inhibition of CYP11B1 (IC50 = 578-5684 nM). The most 
selective compounds 51 and 53 were over 240-fold more selective for CYP11B2 in contrast to 
the reference fadrozole which displayed a selectivity factor of 10. The 5-methoxy substit
in
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  RESULTS  
Selected compounds with less than 60% inhibition in the yeast assay (55, 62 and 63), also 
y at all in the CYP11B2 expressing V79 cells (IC50 values 
 the range between 334 nM to 2834 nM). 
showed only moderate or no activit
in
 
Table 10. Inhibition of human adrenal CYP11B1 and CYP11B2 by 3-pyridine substituted  
    compounds 56-60 and 64-65 
 
N
R'
N
R"
56-60 64-65  
 
   % inhibitiona  IC50-value (nM)c   
Compound R’ R” CYP11B2b  
V79 11B1d 
CYP11B1 
V79 11B2e 
CYP11B2 
 Selectivity 
factorf
56 Me H 94  1268 7  166 
57 Et H 81  2117 30  71 
58 H 3-Me 84  503 5  97 
59 H 4-Me 82  1291 13  99 
60 H 4-Et 20  1615 176  9 
64 E-isomer 25  n.d. n.d.  - 
65 Z-isomer 54  288 735  0.4 
fadrozole   68  10 1  10 
a Mean value of four determinations, standard deviation less than 10%. b S. pombe expressing human CYP11B2; 
substrate: deoxycorticosterone, 100 nM; inhibitor, 500 nM. c Mean value of four determinations, standard
deviation less than 20%. n.d. = not determined. 
 
: 
 
e activity (25-54% inhibition) (Table 10). 
n interesting finding is that the Z-isomer 65 exhibited little selectivity for CYP11B1 as 
d Hamster fibroblasts expressing human CYP11B1; substrate
deoxycorticosterone, 100 nM. e Hamster fibroblasts expressing human CYP11B2; substrate: deoxycorticosterone,
100 nM. f IC50 CYP11B1/ IC50 CYP11B2. 
 
Introduction of a methyl substituent in 1-, 3- or 4-position of the 3,4-dihydronaphthalene 
moiety did not change potency (56, 58, 59), but a larger ethyl substituent in 4-position 
resulted in a loss of activity (60). The 1-ethyl compound 57, however, still exhibited high 
activity in the yeast assay as well as in the V79 cells. The open styryl structures 64 and 65 
showed moderat
A
compared to CYP11B2 with a 2.5-fold lower IC50 for the 11β-hydroxylase. 
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For selected compounds 50-53, the Ki values were calculated using the equation of Cheng 
and Prusoff as described in 3.3.3. These CYP11B2 inhibitors revealed Ki values of 8.4, 4.6, 
2.6 and 1.3 nM, respectively (Km value deoxycorticosterone = 185 nM). 
 
Tests for selectivity towards other steroidogenic CYP enzymes (CYP19 and CYP17) were 
performed as well (Tables 11 and 12). The IC50 values of the compounds for CYP19 were 
determined in vitro using human placental microsomes and [1-3H]androstenedione as 
substrate. All the compounds showed very low or no inhibitory activity with IC50 values in 
the range between 814 and >36000 nM, thus being much less active than the reference 
fadrozole (IC50 = 30 nM), a rather specific aromatase inhibitor used for the treatment of 
breast cancer. 
 
Table 11. Inhibition of human CYP19 and human CYP17 by heteroaryl substituted  
    compounds 50-55 and 61-63 
 
  
 
 
IC50-value (nM)a  
% inhibitionc
IC50-value (nM)c
Compound n R Het human CYP19b human CYP17d
50 0 H 3-Pyr >36000 2 
51 1 H 3-Pyr 4073 37 
52 0 5-OMe 3-Pyr >36000 7 
53 1 6-OMe 3-Pyr 814 62 
54 1 7-OMe 3-Pyr n.d. n.d. 
55 1 6-OMe 4-Pyr n.d. n.d. 
61 0 H Im n.d. n.d. 
62 1 H Im n.d. n.d. 
63 1 6-OMe Im n.d. n.d. 
fadrozole    30 5 
ketoconazole    n.d. 40 
a Mean value of four determinations, standard deviation less than 20%. n.d. = not determined b human placental 
CYP19; 1mg/ml of protein; substrate: androstenedione, 500 nM. c Mean value of four determinations, standard 
deviation less than 10%. n.d. = not determined. d E.coli expressing human CYP17; 5 mg/ml; substrate: 
progesterone, 2.5 µM; inhibitor, 2.5 µM.  
 
The percent inhibition values of the compounds towards CYP17 were determined in vitro 
using progesterone as substrate and the 50.000g sediment of E.coli recombinantly expressing 
human CYP17. The indenes 50 and 52 and the 3- and 4-methyl 3,4-dihydronaphthalenes 58 
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and 59 displayed a weaker inhibition at a concentration of 2.5 µM as the reference 
etoconazole (40%), which is an antimycotic and an unspecific inhibitor of several CYPs. 
ilar or slightly higher inhibition (37-
2%). The most potent CYP17 inhibitor was the 1-methyl substituted compound 56 
k
The 3,4-dihydronaphthalenes 51, 53 and 57 showed a sim
6
exhibiting an IC50 value of 1085 nM. Thus, the tested compounds are all very weak CYP17 
inhibitors, having moderate to very low percent inhibition values. 
 
Table 12. Inhibition of human CYP19 and human CYP17 by 3-pyridine substituted  
   compounds 56-60 and 64-65 
 
 
  
IC50-value (nM)a   
% inhibitionc
IC50-value (nM)c
Compound R’ R” human CYP19b  human CYP17d
56 Me H 6045  69 [1085] 
57 Et H 1507  57 
58 H 3-Me  1787 27 
59 H 4-Me 3551  23 
60 H 4-Et n.d.  n.d. 
64 E-isomer n.d.  n.d. 
65 Z-isomer n.d.  n.d. 
fadrozole   30  5 
ketoconazole   n.d.  40 
a Mean value of four determinations, standard deviation less than 20%. n.d. = not determined b human placental 
 
 
apter 3.2., compound 17 was found to 
e a highly active inhibitor of CYP11B2. In this chapter, we observed that the corresponding 
ihydronaphthalene compound 61 shows a much lower activity. However, the 3-pyridine 
ihydronaphthalene 51 is again highly active.  
 
CYP19; 1mg/ml of protein; substrate: androstenedione, 500 nM. c Mean value of four determinations, standard
deviation less than 10%. n.d. = not determined. d E.coli expressing human CYP17; 5 mg/ml; substrate:
progesterone, 2.5 µM; inhibitor, 2.5 µM.  
 
3.4.4. Molecular modelling and docking studies 
 
Docking and protein modelling studies were performed by Dr. Iris Antes (Max Planck 
Institut, Saarbrücken) to explain some interesting structure-activity relationships of two 
imidazolyl and one pyridyl compound (Table 13). In Ch
b
d
d
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Table 13. IC50 values for CYP11B2 inhibition of selected compounds 
 
IC50-value (nM)    Compound Structure V79 11B2 
CYP11B2 
17 N
N
 
38.5 
51 N
 
6.9 
N61 
N
 
333.9 
 
To understand the differences in activity, the three compounds were docked into the 
YP11B2 model and molecular dynamics simulations of the docked complexes of C
compounds 51 and 61 were performed. During the 1ns simulations compound 61 moved away 
from the heme cofactor, whereas compound 51 stayed close to its docked position. In Chapter 
3.3., a correlation was found between the stability of the docked poses during molecular 
dynamics simulations and their IC50 values, which is confirmed here. Subsequently, our 
docking results were further analyzed in order to explain the different stabilities.  
 
Figure 25. Structure of the CYP11B2 binding pocket with the docked inhibitors 51 (a),  
       61 (b) and 17 (c).  
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In Figure 25(a-c), the best scoring docking poses for the three compounds and the amino acids 
of the binding pocket are shown. The ligand-protein interactions are indicated by green lines 
added to the pictures. Figure 25(b) shows the least active compound 61. Besides the Fe-N 
interaction with the heme group, it forms aromatic-hydrophobic interactions between its 
phenyl and imidazolyl ring and the binding pocket side chains (with Leu227/Phe231 and 
Leu382/Thr318, respectively). The corresponding highly active naphthalene compound 17, 
shown in Figure 25(c), forms strong phenyl-CH3 interactions with both aromatic rings of the 
naphthalene (with Leu382, Thr318, Leu227, and Phe231). The imidazole moiety is only 
forming the Fe-N interaction. In Figure 25(a), the docked complex of compound 51 is 
presented. This compound binds quite similar to compound 61. However, due to the larger 
size of the pyridine ring and the different geometry, the ligand interacts with other amino 
acids (with Val129 and Ala313 instead of Leu227, Phe231 and Leu382) of the binding pocket 
nd is thus placed differently in the pocket. Its Fe-N interaction is less distorted compared to a
compound 61. As a consequence, the IC50 value is strongly increased.  
 
Figure 26. Superimposition of the pyridine substituted compounds 51,53,56,58,59 (grey) and  
       the imidazole substituted compounds 61-63 (yellow). 
 
 
 
The differences in the orientation of the pyridyl and imidazolyl compounds in the binding 
pocket can be explained by superimposition of these two classes of compounds. From Figure 
26 it is clear that, when the lone pairs of the heterocyclic nitrogens are pointing in the same 
direction, the corresponding dihydronaphthalene cores are located with a different angle 
towards the plane of the heme, which in case of the pyridyl compound is more favorable. 
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3.4.5. Discussion and conclusion 
 
In this study, we describe the discovery of highly active and selective inhibitors of CYP11B2 
based on the modification of the lead structure III. Instead of 3-pyridine substituted 
aphthalenes, we synthesized 3-pyridine and 1-imidazole substituted 3,4-dihydronaphthalenes 
tion 
ata fo YP11B1 were compared. 
From the data presented in Tables 9 and 10 following structure-activity relationships could be 
educed. In order to obtain the necessary complexation with the heme iron, the 3-pyridyl 
 compounds were 
ery active. Small alkyl substituents in the 1, 3 and 4-position did not influence the high 
-position, however, seems to be limited in space as 
pound with a remarkable selectivity factor of 1421. This compound displays the highest 
electivity towards CYP11B2 described until now. Interestingly, compound 65 turned out to 
ct 
wards other steroidogenic CYP enzymes like CYP17 and CYP19 at very high 
concentrations. 
 
Comparing the docking poses of 17, 51, and 61, we made the following observations. Due to 
the loss of aromaticity in the second ring of the bicycle, the dihydronaphthalene compound 61 
can make fewer interactions in the core region than the naphthalene 17. To compensate this 
n
and indenes. To evaluate activity and selectivity of the synthesized compounds, inhibi
d r CYP11B2 and C
 
d
moiety was ideal with respect to activity and selectivity. The 1-imidazole substituted 
compounds were less active and replacement with a 4-pyridyl group resulted in almost no 
activity at all. The 3-pyridine substituted dihydronaphthalenes exhibited in general a slightly 
higher activity than the corresponding indanes. The styryl compounds, on the other hand, 
showed low activity. Whilst substitution in the 7-position of the dihydronaphthalene structure 
diminished activity, the unsubstituted and 6-methoxy dihydronaphthalene
v
activity of this class of compounds. The 4
an ethyl group in this position decreases the activity drastically.  
 
Most of the 3-pyridine substituted dihydronaphthalenes and indenes turned out to be very 
active and highly selective CYP11B2 inhibitors. The 6-methoxy substituted 
dihydronaphthalene 53 was the most active inhibitor with an IC50 value of 2 nM. The 5-
methoxy substituted indene 52 was a very potent (IC50 value = 4 nM) and the most selective 
com
s
be a slightly selective CYP11B1 inhibitor, being 2.5 times more active towards CYP11B1 
than CYP11B2. An important point to mention is that all the compounds show only effe
to
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weakening of the interactions, the compound forms additional aromatic/hydrophobic 
interactions via its imidazole ring. To obtain this interactions, the heterocycle shifts with 
respect to the Fe-atom of the heme-cofactor, weakening the Fe-N interaction. However, the 
requirement for a strong inhibitor binding is a Fe-N interaction, which is almost perpendicular 
with respect to the plane of the heme. This orientation leads to an optimal binding orbital 
geometry. Thus due to the distortion of this interaction, the imidazole compound ot as 
active as the others. Although the 3-pyridine dihydronaphthalene 51 has the same ligand-
protein interactions as 61, it is a strong inhibitor. Due to the size of the pyridyl ring, the ligand 
is docked differently and the distortion of the Fe-N interaction is much smaller than in 
compound 61. This docking study shows that there exists a specific “network” of hydrophobic 
interaction groups in the binding pocket, which has to be complemented by the inhibitor in a 
way that the geometry of the Fe-N interaction is retained. Only then strong binding is 
possible. This is very interesting, because such specific interactions normally consist of 
hydrogen bonds and the hydrophobic interactions are thought to play only a minor role for the 
exact positioning of the ligand. 
 
61 is n
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3.5.    In vivo experiments of CYP11B2 inhibitors
 
3.5.1. Concept of the in vivo experiments 
 
In the previous chapters, we described the discovery of in vitro highly active and selective 
inhibitors of CYP11B2. However, these compounds can only offer a new therapeutic option 
for the treatment of congestive heart failure and myocardial fibrosis if they show the same 
potency in vivo. The pharmacokinetic properties of a compound are crucial parameters for 
etermining its in vivo potency. The study of pharmacokinetics refers to the journey of the 
or the in vivo study, we used the animal model of Häusler et al., which is designed to test 
hibitors of the gluco- and mineralocorticoid biosynthesis. Adult male rats received a 
nd mineralocorticoid biosynthesis 
ver 18 h. The test compound was orally administered and after 2 h, the animals were 
decapitated and blood was collected. The plasma gluco- and mineralocorticoid levels were 
etermined using RIA (Häusler et al., 1989).  
t CYP11B2 inhibitors, some small 
odifications were made. The test compounds were administered intraperitoneally because 
 
d
drug from its point of entry to the site of action. Absorption, distribution, metabolism and 
elimination are the different phases of this process. Although a lot of in vitro models exist to 
predict these events, the use of an animal model is inevitable to obtain answers to a very 
important question in this project. Are the in vitro very active and highly selective compounds 
able to decrease the aldosterone levels in the blood? This would provide a proof of principle 
to the concept of the therapeutic treatment of cardiovascular diseases with CYP11B2 
inhibitors. Furthermore, it is important to evaluate the selectivity of these inhibitors in vivo. 
 
F
in
subcutaneous injection of ACTH, to stimulate the gluco- a
o
d
To investigate the in vivo action of our in vitro very poten
m
their bioavailability had not been investigated yet. To eliminate a stress reaction of the 
animals, decapitation was replaced by cervical dislocation. It is important that the test animals 
are free of stress, as stress stimulates the glucocorticoid biosynthesis. Because of their high 
activity and selectivity in vitro, it was decided to test the 6-methoxy substituted naphthalene 
21 and dihydronaphthalene 53 in this animal model. Fadrozole, for which the Häusler model 
had been optimized, was used as a reference substance. 
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3.5.2. The in vivo action of fadrozole 
 
In a first step, the in vivo action of the reference fadrozole in the modified animal model was 
investigated. ACTH-stimulation led to the elevation of both the corticosterone and 
aldosterone plasma concentration. Then, fadrozole was given in two different doses (4 and 0.4 
mg/kg). The results showed that fadrozole in a concentration of 4 mg/kg was able to reduce 
tion 
spectively), whereas no significant reduction of gluco- or mineralocorticoids was observed 
ood correlation with the data 
escribed by Häusler (Häusler et al., 1989) 
 
Figure 27. Action of fadrozole on the aldosterone and corticosterone plasma level 
the plasma aldosterone and corticosterone concentrations (64 and 52 % inhibi
re
at a lower dose of 0.4 mg/kg (Figure 27). These results were in g
d
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3.5.3. The in vivo action of CYP11B2 inhibitors 
 
The com 21 and  were sele rom the library of inhibitors, described in previous 
chapte in . They exhibited in vitro
with IC  values of 2 and 6 nM. Additionally, they were highly selective inhibitors with 
selectivity factors of of the selected com
calculated by comparing their IC50 values 50 value of fadrozole in the V79 
CYP11B2 in vitro assay. Fadrozole exhibited in this assay an IC50 value of 1 nM. As a dose of 
ron
53 cted fpounds 
 vivors, to be tested  very high activity towards CYP11B2 
50
263 and 275, respectively. The doses pounds were 
 with the IC
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4 mg of fadrozole s owed activ  in first in vivo test, a do kg of test 
compound pro 1 nM of its IC50 va e wa sed al test. s that for 
compound 53, which has an IC50 valu  of 2. , t ulated dose f o test is 4 
mg/kg × 2.1 = 8.4 mg. The action of the compounds is shown in Figure 2
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The in vitro active and selective inhibitors 21 and 53 showed in vivo a small reduction of the 
aldosterone plasma level (17.1 and 13.1% inhibition, respectively). The corticosterone level 
as not influenced by the test compounds. Although both of the compounds displayed some 
ved.  
3.5.4. Metabolic stability and metabolite identification 
 
In order to find out why the in vitro active CYP11B2 inhibitors showed only little activity in 
vivo, metabolic studies were performe cooperatio ith Ph  CR arbrücken. 
The reason the lo ctivi e inhibi  could ast m lism. The 
test compou  bear ring, h can be ily oxidized to the corresponding N-
oxide. Th would acc ce with he f at 
imidazolylm ylene] owed ivo activ e al  (Müller-
Vieira, 2005 Instead yl m they bear a metab re s imidazole 
ring  
w
selectivity, no statistically significant inhibition of aldosterone could be obser
 
d in n w armacelsus O, Sa
w in vivo afor ty of th tors  be their f etabo
nds a pyridine  whic eas
is  be in ordan  t inding th some 1-[4(5)-
 in veth indanes sh ity in th  same anim model
).  of a pyrid oiety olically mo table 
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The 6-meth  substi ound nd 53 w tested etabolic stability in 
rat liver mi somes e sub r fractio contai  dru tabolizing 
enzymes, e cytoch 0s, f onooxygenases, carboxylesterases and epoxide 
hydrolase. Therefore they are widely used as in vitro model system in order to investigate the 
rate to which a compound is metabolized by the hepatic enzymes. The test compounds were 
added to the liver microsomes and samples were taken at various time points. The remaining 
percentage parent  wa ermined by LC/MS. The assay showed that the 
naphthalene  has a f 93 utes, the drona 53 a half-life of 67 
minutes. This is an indication that these compounds are metabolically stable, knowing that the 
reference compounds verapamil an ne on lf-lif  a few s (Figure 
29).  
 
Figure 29. Metabolic s  21 (MV23) and 53 (MV45) after incubation in rat liver  
       m osome
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In addition, the possible major metabolites of the test compounds 
c
compounds. The metabolites were identified b
ti
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to predicted gains and losses in molecular mass of the parent compound. Once possible 
nd 21 (1) shows a product ion spectrum of m/z 236 and 
agment ions of m/z 221, 204 and 193. The fragmentation spectrum of (3) at retention time 
ts 
at 21 the corresponding naphthol 
29. 
Figure 30. UV (230 nm) and product ion MS/MS chromatograms of compound 21 (1) and its 
       metabolites (2a,b and 3) detected in rat liver microsomes incubated for 180 min 
 
metabolites are detected, they are subjected to further analysis by MS/MS. 
 
Metabolite identification of compound 21 
Possible major metabolites with the [M+H]+ at m/z 222 and 252 were detected in the full scan 
run (Figure 30) and proceeded for further MS/MS analysis (Figure 31). The MS/MS 
fragmentation of methoxy compou
fr
2.8 min shows for the parent ion at m/z 222 fragment ion of m/z 204 and 194 which sugges
 has undergone demethylation resulting in the formation of th
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The quasimolecular ions at m/z 252 for (2a) and (2b) and the fragment ions of m/z 220 and 
237 indicate that these two new signals at retention times 2.5 and 3.2 min bear an additional 
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 69
oxygen atom in their (6-methoxy-2-naphthyl)pyridine structure. This demonstrates that 
oxidation has occurred either hydroxylating the naphthalene ring or forming an N-oxide. 
 
Figure 31. MS/MS spectra of the [M+H]+ of 21 (1) (m/z 236) and the metabolites 2a,b (m/z  
        252) and 3 (m/z 222). The dash lines indicate possible sites of fragmentation 
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It was found that the m lic fate  dihydr alene 5 imilar to that of the 
n . Possibl s were detected in the full s  and p ed for 
f ys agm of the lite w M+H  224 
 
orresponding naphthol 68. Two other major metabolites 69a,b with the [M+H]+ at m/z 254 
 
etabo of the onaphth 3 is s
aphthalene 21 e metabolite can run roceed
urther MS/MS anal is. The fr entation  metabo ith the [ ]+ at m/z
suggests that 53 has undergone O-demethylation resulting in the formation of the
c
bear an additional oxygen atom in their dihydronaphthalene structure, indicating that 
oxidation occurred. The proposed metabolic pathway of compound 53 is illustrated in Scheme 
19. 
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Scheme 19. Proposed metabolic pathway of compound 53 
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 monolayers possessing functions similar to 
tinal enterocytes. The higher the measured transport in Caco-2 cells, the higher is the 
e 
ultiple dosing approach was developed for the test 
pounds (cassette dosing). The feasibility of the application of compound mixtures was 
pounds were only tested as a mixture because no inherent interactions were expected. 
Four reference compounds were used in each assay for validation of the transpor
o 2 cells. B ac ds ked  ( -6 )  
< ), app /sec) highly 0-6 cm  10) pe   
 
 
3.5.5. Permeability screening usin
 
Another crucial parameter for in vivo potency is oral absorption. The prediction of peroral 
drug absorption in vivo was performed by Christiane Scherer (Universität des Saarlandes) 
using a generally accepted in vitro model, Caco-2 monolayers (Yee, 1997). Caco-2 cells are 
derived from human adenocarcinoma colon cells and spontaneously differentiate when grown 
on porous polycarbonate membranes to form
intes
expected peroral absorption. 
The in vivo test compounds 21 and 53 and other selected compounds (17,27-30,33-
35,37,39,41,50-52,56-59) (structures in Table 14) which showed high activity and selectivity 
were screened for peroral drug absorption using Caco-2 monolayers. In order to increase th
throughput of the Caco-2 assay, a m
com
tested for 21, 27, 37 and 53 in comparison to the permeability of single dosing. The rest of the 
com
t properties 
10  cm/secf the Caco- y this appro h, compoun can be mar  as low (Papp
(10-6 cm < 10) or  (Papp (1 /sec) > rmeable. 1 medium (1 < P
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T o-2 cell pe ion in a ple dosing approach 
 
able 14. Cac rmeat  multi
n 
N
R
N
R'
R"
N
R
N
N
50-53 56-5921,27-30,33-35,     37,39,41
17
 
Compound R n R’ R” Papp (10-6 cm/sec)a,b
17     14.7 ± 0.6 
21 6-OMe    7.9 ±0.6 
29 6-OH    17.4 ± 1.0 
30 6-OEt    3.6 ±0.9 
33 6-CN    10.8 ± 0.4 
34 5-Cl-6-OMe    1.5 ± 0.1 
35 5-Br-6-OMe    1.0 ± 0.3 
37 1,5-diCl-6-OMe    2.5 ± 0 3 
39 1-Cl-7-OMe    0.5 ± 0.05 
41 6-COOMe    0 
50 H 0   6.6 ± 0.5 
51 H 1   14.6 ± 0.6 
52 5-OMe 0   12.5 ± 0.2 
53 6-OMe 1   13.5 ± 0.6 
56   Me H 3.4 ± 0.1 
57   Et H 21.6 ± 1.6 
58   H 3-Me 14.7 ± 0.6 
59   H 4-Me 16.3 ± 3.0 
atenolol     0.1 ± 0.03 
ketoprofene     25.7 ± 0.5 
testosterone     9.4 ±0.2 
erythromycin     < LOD 
27 H    2.9 ± 0.7 
28 6-Br    1.2 ± 0.1 
a Permeability of research compounds was ranked according to reference compounds: atenolol, ketoprofene, 
testosterone and erythromycin; LOD = limit of detection; b Mean value of three determinations. 
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Most of the tested compounds were medium to highly permeable. Only the halogenated 
naphthalenes (28,34,35,37,39) had a lower permeability. The 6-hydroxy naphthalene 29 and 
the 4-ethyl dihydronaphthalene 57 turned out to be most permeable compounds with Papp 
values of 17.4 and 21.6 10-16 cm/sec, respectively. The ester 41, on the other hand, was not 
permeable at all (Table 14).  
 
3.5.6. Lipophilicity and solubility 
 
The logP values of the compounds 14-23, 27-48 and 50-65 were calculated to obtain more 
information about lipophilicity, which is related to absorption and bioavailability (Table 15). 
The significance of logP is captured by the Rule-of-5, which states that a molecule will be 
poorly absorbed if its logP value exceeds 5 (Lipinski et al., 1997). All the inhibitors had logP 
values in the range between 1.7 and 5.0. Only the benzyloxy compound 32 and the ethyl 
substituted dihydronaphthalenes 57 and 60 exhibited a less favourable logP of 5.5.  
 
Table 15. LogP and solubility values of compounds 14-23, 27-48 and 50-65 
 
Compound logPa
 
Solubilitya,b 
(mol/l) 
Compound logPa
 
Solubilitya,b 
(mol/l) 
14 2.69 ± 0.51 2.9 e-4 30 4.34 ± 0.26 3.7 e-5
15 3.11 ± 0.25 3.3 e-4 31 4.87 ± 0.26 1.7 e-5
16 3.72 ± 0.33 1.4 e-4 32 5.46 ± 0.27 4.4 e-6
17 3.21 ± 0.57 2.8 e-4 33 3.33 ± 0.29 1.6 e-4
18 3.13 ± 0.81 9.7 e-5 34 4.35 ± 0.36 7.6 e-6
19 3.13 ± 0.81 2.2 e-4 35 4.38 ± 0.37 3.9 e-5
20 1.85 ± 0.81 2.0 e-3 36 4.00 ± 0.38 4.5 e-5
21 3.81 ± 0.26 7.9 e-5 37 4.71 ± 0.42 7.2 e-6
22 3.74 ± 0.26 7.9 e-5 38 3.81 ± 0.26 7.9 e-5
23 2.77 ± 0.30 1.6 e-4 39 4.28 ± 0.28 1.4 e-5
27 3.89 ± 0.24 2.0 e-4 40 3.56 ± 0.26 3.2 e-4
28 4.66 ± 0.34 1.3 e-6 41 3.87 ± 0.26 7.1 e-5
29 3.15 ± 0.25 2.3 e-4 42 3.71 ± 0.37 4.5 e-5
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Compound logPa Solubilitya,b 
(mol/l) 
Compound logPa
 
Solubilitya,b 
(mol/l) 
43 2.41 ± 0  1.8 e.27 -4 55 4.11 ± 0.34 1.1 e-4
44 2.53 ± 0.34 2.9 e-4 56 5.00 ± 0.33 1.0 e-4
45 5.05 ± 0.24 1.0 e-5 57 5.53 ± 0.33 4.5 e-5
46 2.41 ± 0.26 9.3 e-4 58 4.91 ± 0.33 1.3 e-4
47 2.58 ± 0.26 6.0 e-4 59 4.91 ± 0.33 9.5 e-5
48 1.68 ± 0.28 1.5 e-3 60 5.44 ± 0.33 4.1 e-5
50 4.05 ± 0.30 6.7 e-4 61 2.95 ± 0.57 4.7 e-4
51 4.41 ± 0.33 2.3 e-4 62 3.41 ± 0.57 2.5 e-4
52 3.99 ± 0.32 2.0 e-4 63 3.36 ± 0.58 2.2 e-4
53 4.36 ± 0.34 7.1 e-5 64 3.34 ± 0.27 3.4 e-3
54 4.39 ± 0.35 6.8 e-5 65 3.34 ± 0.27 3.4 e-3
a T values were ob  th b Web CD/L  
ACD/Aqu lubility 8.0 .4. 
 
Another ture of can  drugs i solubility e compo  water. The 
solubility largely dictates the route of drug administration a ite often fate of drug 
candidate lity can li ivo bi ility an
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3.5.7.    In vivo pharmacokinetic evaluation 
 
3.5.7.1. Pharmacokinetic profiles of compounds 21 and 53. 
 
It is the major purpose of in vivo pharmacokinetic studies to determine the relationship 
between dose and plasma concentration in order to obtain important information on drug 
absorption and elimination. Since the in vitro models (see 3.5.4. and 3.5.5.) were not able to 
explain the low in vivo potency of our CYP11B2 inhibitors 21 and 53, the pharmacokinetic 
properties of these compounds were investiga
P
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Figure 32. Mean plasma profiles of 21 (MV23), 51 (MV18), 53 (MV45), SU11A and TS3  
       after po cassette dosing in 4 adult male rats (5 mg/kg)  
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The pharmacokinetic profiles of 21 and 53, together with 51, SU11A and TS3, were 
determined after a peroral (po) dosing to adult male rats in a single cassette (N = 5). Blood 
samples were collected at different time points from the jugular vein. A HPLC-MS/MS 
method was established for quantification of the test compounds in rat plasma. The 
(pyridylmethylene)indanes SU11A and TS3 were described earlier in our working group as 
potent CYP11B2 inhibitors (Ulmschneider et al., 2005b). In vivo, SU11A and TS3 showed a 
reduction of the aldosterone plasma level of 15 and 25 %, respectively. The mean profiles of 
A TS3 
the plasma levels (ng/ml) of the compounds after po administration at the dose of 5mg/kg are 
presented in Figure 32. The pharmacokinetic parameters are shown in Table 16. 
 
Table 16: Pharmacokinetic parameters of the test compounds after oral dosing 
 
Parameter 
51 21 53 SU11
(5mg/kg) (5mg/kg) (5mg/kg) (5mg/kg) (5mg/kg) 
Cmax  obs. (ng/ml) 3940.9 222.4 43.0 5562.1 5644.3 
tmax obs. (h) 1 1 2 1 1 
t ½ β (h) 3.00 5.42 15.40 2.58 2.60 
Cl int (l/kg/h) 0.17 3.24 6.76 0.148 0.131 
AUCo-∞ (ng/mlxh) 29188.5 1543.5 739.5 33879.7 38191.6 
Cmax obs.: maximal concentration measured in the plasma; t max : time point with the maximal plasma concentration 
measured; t1/2 β: terminal half-life; Clint: intrinsic hepatic clearance; AUCo-∞ : area under the curve; Eh: hepatic extraction ratio 
 
After po dosing, different Cmax values in the range from 43 to 5644 ng/ml were measured. The 
lowest Cmax was found for the 6-methoxy dihydronaphthalene compound 53 followed by 21 
and 51. The highest Cmax (5644 ng/ml) was measured for TS3. After Cmax was reached, 
plasma levels of the 5 tested compounds were cleared with different rates (0.17 to 6.76 l/kg/h) 
resulting in different plasma terminal half-life values from 2.6 to 15.4 h. TS3 is the compound 
n in the body after po application. With regard to the area under the curve value, 
stability of 21 and 53 in liver microsomes (see 3.5.4.), we conclude that the low disposition is 
with the highest AUC (38192 ng×h/ml), followed by SU11A, 51, 21 and 53. 
 
Since the five compounds were given at the same dose, it is possible to compare their 
dispositio
which indicates the total amount of compound absorbed, we can conclude that compounds 
TS3, SU11A and 51 are much more absorbed in the body than 21 and 53. These latter 
compounds exhibit low compound disposition, which is in good correlation with their low 
maximal plasma concentration measured in this study. Keeping in mind the high metabolic 
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mainly due to lower absorption and not to rapid elimination of the compounds from the 
plasma. The low absorption of the 6-methoxy substituted compounds 21 and 53 could be the 
reason for the low activities exhibited in the in vivo experiment (see 3.4.3.).  
 
3.5.7.2. Pharmacokinetic evaluation in search of suitable in vivo candidates 
 
In order to find more suitable candidates for in vivo testing, the pharmacokinetic properties of 
other CYP11B2 inhibitors were investigated using the po cassette dosing approach. Test 
compounds with more favourable pharmacokinetic properties are expected to display better in 
vivo activity. Inhibitors, which displayed a selectivity factor > 100 in vitro and which were 
medium to highly permeable in the Caco-2 experiments, were administered perorally in rats in 
cassettes of 5 compounds at the time.  
 
Pharmacokinetic evaluation of compounds 27, 29, 30, 50 and fadrozole 
The naphthalene compounds 27, 29 and 30, the indene 50 and fadrozole were 
administered in a single cassette. After measurement of plasma drug levels (Figure 33) 
and calculation of the pharmacokinetic parameters, described in Table 17, the following 
observations could be made. 
 
Table 17. Pharmacokinetic parameters of the compounds 27, 29, 30, 50 and fadrozole 
 
Parameter 
Fadrozole 
(5mg/kg) 
27 
(5mg/kg) 
29 
(5mg/kg) 
30 
(5mg/kg) 
50 
(5mg/kg) 
Cmax  obs. (ng/ml) 486.90 373.80 13.20 10.90 339.00 
tmax obs. (h) 1.00 1.00 1.00 1.00 1.00 
t ½ β (h) 4.06 10.65 40.43 5.89 7.10 
Cl int (l/kg/h) 1.76 4.24 37.41 166.06 5.20 
AUCo-∞ (ng/mlxh) 133.70 30.10 961.30 2838.60 1179.00 
 
The compounds 29 and 30 show very low disposition in the body after po application. Their 
AUC values vary from 134 to only 30 ng/ml×h. In accordance, the Cmax values range from 13 
to 11 mg/kg. Compound 50 and 27 showed similar maximal plasma concentrations (339 and 
374 ng/ml, respectively) and presented higher AUC values. The plasma levels were cleared 
with different rates resulting in different half-life values (4.06-40.4 h). 
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Figure 33. Mean plasma profiles of 27 (MV22), 29 (MV28), 30 (MV39), 50 (MV26), and 
fadrozole after po cassette dosing in 3 adult male rats at the dose of 5 mg/kg 
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Pharmacokinetic evaluation of compounds 28, 56, SU1A, SU20A and fadrozole 
 a third cassette dosing, a mixture of 28, 56, SU1A and SU20A was administered peroral to In
male adult rats. In this case, very low plasma drug levels could be detected for all the 
compounds. The different Cmax values ranged from 7.6 to 138.1 ng/ml. The lowest Cmax was 
measured for the 1-methyl substituted dihydronaphthalene 56. Due to their low Cmax values, 
the test compounds also presented low AUC (31.9-220.7 ng/ml×h) (Table 18).  
 
Table 18. Pharmacokinetic parameters of compounds 28, 56, SU1A and SU20A 
 
NN
Br
N
Cl
N
N
F
5628 SU1A SU20A  
 
Parameter 
28 
(5mg/kg) 
56 
(5mg/kg) 
SU1A 
(5mg/kg) 
SU20A 
(5mg/kg) 
Cmax  obs. (ng/ml) 39.10 7.60 54.30 138.10 
tmax obs. (h) 1.00 1.00 2.00 1.00 
t ½ β (h) 5.99 6.83 3.96 1.61 
Cl int (l/kg/h) 22.66 156.51 17.02 8.11 
AUCo-∞ (ng/mlxh) 220.70 31.90 293.8 616.20 
 
 
Pharmacokinetic evaluation of compounds 37, 51, 52, 59 and fadrozole 
In a last cassette dosing, the pharmacokinetic parameters of the inhibitors 37, 51, 52, 59 and 
fadrozole were evaluated (Table 19). The lowest Cmax was found for 37 followed by 52 and 
59. Compound 51 and fadrozole showed similar maximal plasma concentrations. Fadrozole 
was the compound with the highest AUC (3575 ng/ml×h), followed by 51. Compound 52 
showed the lowest absorption in the body with an AUC value of only 69.4 ng/ml×h. The 
results found for fadrozole are in good correlation with the results of a previous cassette 
dosing. The plasma concentrations of 51, however, are much lower than the plasma levels 
measured in the first cassette dosing (see 3.5.7.1.). 
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Table 19. Pharmacokinetic parameters of compounds 37, 51, 52, 59 and fadrozole. 
 
N
R
N
Br
Cl
Cl
N
N
CN
O N
51 R = H
59 R = Me
37fadrozole 52
 
 
Parameters 
Fadrozole 
(5mg/kg) 
51 
(5mg/kg) 
37 
(5mg/kg) 
59 
(5mg/kg) 
52 
(5mg/kg) 
Cmax  obs. (ng/ml) 453.90 440.40 19.00 161.20 22.80 
tmax obs. (h) 1.00 1.00 1.00 1.00 1.00 
t ½ β (h) 2.24 4.85 67.79 5.25 1.26 
Cl int (l/kg/h) 1.40 2.24 13.92 5.14 72.05 
AUCo-∞ (ng/mlxh) 3575.10 2235.60 359.20 972.1 69.40 
 
 
3.5.8. Discussion and conclusion 
 
For testing the in vivo potency of our in vitro very active and highly selective CYP11B2 
inhibitors, we used the rat model of Häusler et al. with slight modifications. After stimulation 
of the gluco- and mineralocorticoid biosynthesis with ACTH, the test compounds were 
administered intraperitoneally. Two hours later, the rats were sacrificed and the aldosterone 
and corticosterone serum levels were determined by RIA and compared with untreated 
 level was not influenced by 
controls. 
The 6-methoxy substituted naphthalene 21 and dihydronaphthalene 53 were selected to be 
tested in vivo together with the reference compound fadrozole. The results showed that both 
of the in vitro highly active compounds were not able to decrease the serum aldosterone levels 
significantly. They showed in vivo only an inhibition of 17.1 and 13.1%, respectively. 
However, it might be possible to obtain a statistically significant inhibition by increasing the 
doses of the test compounds. Although the corticosterone serum
the compounds and thus some selectivity was noticeable, the in vivo results were 
disappointing. With IC50 values of 2 and 6 nM in the in vitro assay, the in vivo potency should 
have been much higher. In order to find out why the in vitro active CYP11B2 inhibitors 
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showed only little activity in vivo, some pharmacokinetic properties of the test compounds 
were investigated.  
Metabolic stability studies provided information on the extent to which these compounds are 
metabolized. By using rat liver microsomes, the half-lifes of the test compounds were 
determined. With half-lifes of 67 and 93 minutes, the compounds showed to be metabolically 
stable. The fast metabolism of test compounds has negative influence on the in vivo activity. 
The results of the metabolic stability assay, however, showed that a fast hepatic metabolism 
of the test compounds is probably not the reason for the low in vivo activity. Additionally, 
possible metabolites of the test compounds were characterized by LC-MS/MS. One of the 
major metabolites of the 6-methoxy substituted naphthalene compound 21 was the 
hydroxylated naphthalene compound 29, which exhibited high activity in the CYP11B2 
expressing V79 cells assay as well (IC50 value = 22.6 nM).  
The prediction of peroral drug absorption in vivo was performed by using a generally 
accepted in vitro model, Caco-2 monolayers (Yee, 1997). Permeability screening of the test 
compounds 21 and 53 and other active and selective inhibitors showed that almost all of the 
ihydro)naphthalenes and indenes were medium to highly permeable. When halogens were 
e naphthalene ring, the permeability was completely gone. 
 values (< 1.0 e-5). However, 
(d
introduced to the naphthalene core the permeability dropped substantially. With an ester 
group on th
Two physicochemical parameters have a very strong influence on drug-like properties of a 
compound: i.e. aqueous solubility, which is critical to drug delivery, and hydrophobicity 
(logP), which plays a key role in drug absorption, transport and distribution. The aqueous 
solubility of our inhibitors was in the range between 1.3 e-6 and 2.3 e-4 mol/l at pH 7.4. A 
good compound must be able to reach its target at effective concentrations. Therefore, the 
lowest acceptable solubility of a compound is related to its pharmacological potency and its 
permeability. The compounds 28, 32 and 34 had low solubility
due to their very high potency towards CYP11B2, these inhibitors might still be possible drug 
candidates. All the CYP11B2 inhibitors exhibited favourable logP values lower than 5, except 
the benzyloxy naphthalene 32, which was also poorly soluble in water (4.4 e-6) and the 
dihydronaphthalenes 57 and 60. Our most potent CYP11B2 inhibitors 33 and 53 had logP 
values of 3.3 and 4.4, respectively. The logP of the most selective inhibitor 52 (selectivity 
factor = 1421) was 4. 
Based on the permeability and metabolic stability results, we can conclude that the test 
compounds 21 and 53 have some favourable pharmacokinetic properties: they display 
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metabolic stability and oral bioavailability. So what can be the reason for the low in vivo 
activity? 
To answer this question, in vivo pharmacokinetic studies were performed with a series of in 
vitro highly active and selective inhibitors, including the compounds 21 and 53. After peroral 
cassette dosing of five compounds to adult male rats, the plasma drug levels were measured 
using LC-MS/MS and pharmacokinetic parameters, like Cmax, t1/2, Cl and AUC were 
calculated. Since the compounds were given at the same dose, it is possible to compare their 
disposition in the body. Comparing the different AUC values, which indicate the total amount 
of compound absorbed, the best absorbed inhibitors could be determined. The compounds 
tested in the first in vivo assay, 21 and 53, displayed very low AUC values and thus low 
disposition. As their metabolic stability was high in rat liver microsomes, the low disposition 
is mainly due to lower absorption and not to rapid elimination from the plasma. A possible 
 of drug metabolizing enzymes (75-80% inhibition towards CYP2B6 (5 
ns. The indene 52, one of 
e compounds in the second cassette, turned out to have only moderate activity towards these 
B6 (5 µM) and CYP2C19 (2 µM), 
explanation for the low activity in vivo could be the unfavourable absorption properties of 
compounds 21 and 53. Based on the pharmacokinetic results obtained in the above described 
cassette dosing studies, it is possible to determine the most promising compounds for further 
in vivo testing. Because of their favourable pharmacokinetic properties the 
dihydronaphthalene compounds 51 and 59, the unsubstituted indene 50 and naphthalene 27, 
and SU20A should be more suitable compounds to test in vivo than the methoxy compounds 
21 and 53. 
Another interesting point to mention is the difference in plasma concentrations of compound 
51 in two different cassette dosing studies (Cmax 1st study = 3940.9 ng/ml; Cmax 2nd study = 
440.4 ng/ml). Cytochrome P450 inhibition studies showed that compounds SU11A and TS3 
are strong inhibitors
µM) and CYP2C19 (2 µM); 26-40% inhibition towards CYP2C9 (0.3 µM); unpublished 
results, U. Müller-Vieira). In the first cassette dosing, these compounds probably inhibited the 
metabolism of compound 51 leading to higher plasma concentratio
th
CYP enzymes (28 and 12% inhibition towards CYP2
respectively; no inhibition towards CYP2C9 (0.3 µM)) and could therefore not influence the 
metabolism process, explaining the lower Cmax value. All the inhibitors tested in the drug 
metabolizing P450 inhibition assay showed only small activity towards CYP3A4. This P450 
enzyme is the most important drug metabolizing enzyme in human liver, responsible for the 
metabolism of 40-50% of drugs in clinical use. 
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IV. Discussion 
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 of 93% at the gene level (Taymans et a
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Synthesis and evaluation of CYP11B2 inhibitors 
uanabenz-related amidinohydrazones were described in the literature as potent non-azole 
t assay as 
ell as in experiments with the NCI-H295R cell line, which is able to produce all the 
espect to activity and 
electivity. The replacement of the 3-pyridine ring by 5-oxazole, 5-imidazole, 5-pyrimidine or 
he activity. The bad influence of the 4-pyridine ring is in good 
orrelation with previous results (Ulmschneider et al., 2005b). For an optimal orbital overlap 
of the nitrogen of the inhibitor with the heme Fe, the pyridyl moiety should be located 
perpendicular to the heme group. In case of the 4-pyridine substituted naphthalene, the angle 
between the ligand and the plane of the heme is distorted. This change of geometry weakens 
the Fe-N interaction and leads to lower inhibitory potencies. Some 1-imidazole compounds 
showed high activity but the selectivity towards CYP11B2 was quite low (selectivity factor: 
4-35). 
Another important parameter which we evaluated was the impact of substitution of the 
G
inhibitors of aldosterone biosynthesis in rat adrenal gland fragments (Soll et al., 1994). By 
combining the tetrahydronaphthalene or indane core with an amidinohydrazone moiety, we 
wanted to find out if these amidinohydrazones are able to inhibit our target enzyme 
CYP11B2. The compounds showed to be inactive towards CYP11B2 in the yeas
w
adrenocortical steroids (Voets et al., 2004). A plausible explanation is that the strong basic 
amidinohydrazones are not able to penetrate the cell membrane under physiological 
conditions. Thus, the aminoguanidine moiety is not a good alternative for a nitrogen 
containing heterocycle, which can complex with the heme iron of the CYP enzyme. 
Supported by these results, we decided to focus again on compounds substituted with nitrogen 
containing heterocycles. Structural modifications of the core structure of the lead structure 
resulted in a new class of CYP11B2 inhibitors, the heteroaryl substituted naphthalenes. 
Comparative studies revealed that the 3-pyridine moiety is ideal with r
s
4-pyridine was disastrous for t
c
naphthalene core on the inhibitory activity. Different substituents were introduced to 
investigate the influence of the position, size and chain length. The 6-position turned out to be 
appropriate for high activity and selectivity, as long as the substituents were not too big. The 
6-propoxy and 6-benzyloxycompounds 31 and 32, for instance, showed very low percent 
inhibition values (36 and 3%, respectively). A loss of activity was also observed for 
compounds with subsituents in 3- or 7-position.  
The 3-pyridine substituted naphthalene compounds exhibited high inhibitory activities 
towards CYP11B2 and displayed better selecitivity profiles than the 
(pyridylmethylene)tetrahydronaphthalenes and indanes. The 6-cyano naphthalene 33 turned 
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out to be the most potent inhibitor with an IC50 value of 2.9 nM. The 6-ethoxy naphthalene 30 
had a remarkable selectivity factor of 451. 
In order to discover even more selective CYP11B2 inhibitors, we modified the 3-pyridine 
substituted napthalenes. Instead of introducing an unsaturated bridge into the ring, which 
yielded the aromatic naphthalene compounds, we introduced a saturated bridge to mimic the 
aliphatic ring in the tetrahydronapthalene and indane compounds. In this way, we found a new 
lass of active and selective CYP11B2 inhibitors, the 3-pyridine substituted 
nes. The structure-activity relationships concerning the heme 
omplexing heterocycles and substitution of the dihydronaphthalene core structure were 
similar to the ones described above. Most of the 3-pyridine substituted dihydronaphthalenes 
nd indenes turned out to be very active and highly selective CYP11B2 inhibitors. The 6-
ted annealing procedures. After optimization, docking and 
olecular dynamics studies were used to verify the homology modelled CYP11B2 structure 
ns simulate the motion of the ligand in the binding 
ocket to obtain information about its time-dependent properties. The results of the MD study 
e and 1-imidazole substituted naphthalenes showed a good 
c
dihydronaphthalenes and inde
c
a
methoxy substituted dihydronaphthalene 4 was the most active inhibitor with an IC50 value of 
2 nM. The methoxy substituted indene 3 was a very potent (IC50 value = 4 nM) and the most 
selective compound with a remarkable selectivity factor of 1421. This compound displays the 
highest selectivity towards CYP11B2 described until now. 
 
Docking and molecular dynamics studies using the homology modelled CYP11B2 
structure 
The 3D structure of the CYP11B2 enzyme has not been solved yet by X-ray crystallography. 
Therefore a homology protein model of CYP11B2 has been established (Ulmschneider et al., 
2005a-b). The recently resolved 3D structure of CYP2C9 was used as template. Several 
known inhibitors were docked and the binding pocket geometry was further refined through 
energy minimization and simula
m
and to explain some interesting structure-activity relationships.  
CYP11B2 inhibitors are predominantly bound through hydrophobic interactions except for 
the nitrogen-metal interaction with the heme iron. The strongest interactions are formed with 
residues of the α-helix I. Former studies have shown that this I-helix is essential for the 
binding of the compounds (Rupasinghe et al., 2003). These finding are also confirmed by site 
directed mutagenesis experiments, which indicate that the I-helix of CYP11B2 and CYP11B1 
is important for substrate binding (Böttner et al., 1996a-b). 
Molecular dynamics (MD) calculatio
p
with some pairs of 3-pyridin
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correlation between the position of the docked compounds after 1ns of MD simulations and 
the potency of these inhibitors. Highly potent inhibitors remained stable throughout the 
simulations. Less active compounds reoriented themselves and moved away from the heme, 
breaking their Fe-N interactions. The 3-methoxy substituted 1-imidazole compound 18, for 
instance, docked well in the active site of the protein model. Its 3-methoxy substituent fitted 
perfectly in a hydrophobic groove formed by hydrophobic amino acid residues. However, the 
methoxy substituent of the corresponding 3-pyridine compound 40 did not fit into this groove, 
due to the larger size of the pyridyl ring and the different geometry needed to form the 
oordinate bond with the heme group. This led to an energetically unfavourable position of 
hydronaphthalene compound 
1, on the other hand, contains only half of the aromatic rings and can make fewer 
erefore, it tries to enhance its binding affinity by forming 
dditional aromatic-hydrophobic interactions via its imidazole ring. This leads to a shift of the 
imidazole with respect to the iron of the heme, eakening the Fe-N interactions, and explains 
the lower activity of 61 towards CYP11B2. These observations show that hydrophobic 
interactions play an important role for the positioning of inhibitors into the active site of the 
11B2 inhibitors exhibit the same 
otency and selectivity in vivo, the rat model of Häusler et al. was used. After stimulation of 
c
the ligand close to the I-helix. During MD simulations, compound 40 tried to minimize the 
contacts of his aromatic region with the hydrophilic/hydrophobic amino acid residues of the I-
helix and lost contact with the heme group.  
Docking studies were able to explain the difference in potency of the 1-imidazole substituted 
naphthalene and dihydronaphthalene and showed the importance of hydrophobic interactions 
in the binding pocket. The highly active naphthalene compound 17 formed strong phenyl-CH3 
interactions with both aromatic rings of the naphthalene. The di
6
interactions with its core. Th
a
w
CYP11B2 enzyme. 
At the start of the aldosterone synthase project, synthesized CYP11B2 inhibitors were used to 
optimize the homology modelled CYP11B2 structure. Now, this protein model demonstrates 
predictive value and could be used as a tool for drug optimization. 
 
Evaluation of in vivo activity of CYP11B2 inhibitors 
To test if our in vitro potent and highly selective CYP
p
the gluco- and mineralocorticoid biosynthesis with ACTH, the test compounds were 
administered intraperitoneally and after two hours, the plasma aldosterone and corticosterone 
levels were determined. It is important to provide a stress-free environment for the test 
animals. Stress stimulates the glucocorticoid biosynthesis and this would lead to false-positive 
 86
  DISCUSSION  
results. The rats were applied with water ad libitum, as thirst leads also to false-positive 
aldosterone serum levels. 
The results of the reference compound fadrozole were in good correlation with the published 
patic metabolism could be not the reason for the low in vivo 
activity. Additionally, permeability screening using Caco-2 cells showed that they were 
medium to highly permeable. We can thus assume that these compounds would be intestinal 
absorbed. The metabolic stability and oral bioavailability of compounds 21 and 53, found by 
in vitro pharmacokinetic studies, could not explain the low in vivo activity.  
Therefore, their pharmacokinetic profiles (absorption and clearance) were investigated in 
vivo. Experiments were carried out with male Wistar rats, which were dosed perorally (5 
mg/kg) with the test compounds 21 and 53 and a series of other in vitro highly active and 
selective CYP11B2 inhibitors in cassettes (n = 5). Blood samples were collected at different 
time points from the jugular vein and plasma concentrations of the test compounds were 
measured by LC-MS/MS. Compounds 21 and 53 turned out to have a low compound 
disposition. Since the compounds display high metabolic stability in liver microsomes, we 
assume that the low disposition is mainly due to lower absorption. This is in good correlation 
with their low Cmax and AUC values. This low absorption of the 6-methoxy compounds could 
be the reason for the low in vivo activity. Based on the pharmacokinetic results obtained in the 
cassette dosing studies, more promising in vivo candidates could be determined. The 
unsubstituted naphthalene 27, the dihydronaphthalenes 51 and 59, as well as the indene 50 
exhibited more favourable pharmacokinetic properties and will be tested in further in vivo 
experiments. 
Although the inhibitors 21 and 53 did not show significant reduction of the plasma 
aldosterone levels in vivo yet, we believe that the in vivo assay according to Häusler et al. is a 
useful tool to provide proof of principle for our treatment concept. Indeed, some previously 
tested unselective and selective CYP11B2 inhibitors were able to reduce the aldosterone 
and/or corticosterone levels in the rat (Müller-Vieira, 2005). 
data (Häusler et al., 1989). The in vitro very active 6-methoxy substituted naphthalene 21 and 
dihydronaphthalene 53, on the other hand, turned out to reduce the aldosterone level with only 
17.1 and 13.1 %, respectively. Although the corticosterone level was not influenced, 
exhibiting thus some selectivity, the test compounds did not show any significant effect on the 
aldosterone concentrations in the blood. By using higher doses of inhibitor, these results 
might improve in further experiments. 
Determination of half-life values revealed that both of the test compounds had sufficient 
metabolic stability. The fast he
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Future perspectives 
 
¾ The in vitro activities of our test compounds 21 and 53 were measured in yeast and 
V79 cell assays expressing human CYP11B2. The rat CYP11B2 and human 
CYP11B2 have a homology of 69.6% (the homology between rat and human 
CYP11B1 is 64.5%). Therefore, it might be possible that due to interspecies 
differences active inhibitors towards human CYP11B2 are not able to exhibit the same 
potency towards rat CYP11B2. This could mean that a rat model is not useful to test 
¾ The 5-imidazole substituted naphthalene 14 and the (Z)-(phenylvinyl)pyridine 64 
0.7 and 0.4, respectively. These compounds are more 
active towards CYP11B1 than CYP11B2 and can be used as lead compounds in the 
search of CYP11B1 inhibitors. These inhibitors could be used in the treatment of 
diseases related to increased cortisol levels, like Cushing’s syndrome and the 
metabolic syndrome. The drugs used in the treatment of pituitary-dependent Cushing’s 
disease act at the hypothalamic-pituitary level and decrease corticotropin secretion. 
The neuromodulatory compounds used so far, like bromocriptine and somastatin are 
not so effective. The treatment of adrenal Cushing’s disease, caused by a cortisol 
producing tumour in the adrenal cortex, is either the surgical removal of the tumour, or 
our compounds in vivo. To check this hypothesis, an in vitro assay with rat adrenal 
glands (Häusler et al., 1989) could be performed. The prepared rat adrenal fragments 
are incubated with test compound and ACTH. ACTH stimulates the corticosterone 
production; the aldosterone production is almost not stimulated by ACTH. The K+-
containing buffer used in the assay, however, is sufficient to stimulate aldosterone 
production. After incubation, the concentrations of aldosterone and corticosterone in 
the samples are measured using RIA. At the moment, experiments with fadrozole and 
compounds 21 and 53 are being performed to investigate their inhibitory activity 
towards rat CYP11B2 and CYP11B1. 
 
displayed selectivity factors of 
using steroid biosynthesis inhibitors. The most common inhibitors used are 
aminoglutethimide, metyrapone and ketoconazole and they reduce cortisol secretion 
by blocking one or more steroidogenic P450s. This mode of action has little selectivity 
and results in extra-adrenal side effects. Thus, the development of highly selective 
CYP11B1 inhibitors would be major improvement for the treatment of patients 
suffering from Cushing’s syndrome. 
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V. Summary 
 
The aim of this work was to design and synthesize potent and highly selective CYP11B2 
inhibitors, which could be used for the treatment of congestive heart failure and myocardial 
fibrosis. Our efforts were focused on non steroidal compounds, which were evaluated in vitro 
and in vivo to determine their biological activity and selectivity towards CYP11B2. 
 
In Chapter 3.1., the synthesis and biological evaluation of a series of amidinohydrazones 1-13 
is described (Figure 33). These compounds were synthesized by condensation of the 
appropriate ketones with aminoguanidine nitrate or sulfate in the presence of sulfuric acid. 
hey showed almost no inhibitory effect towards human CYP11B2. Compound 11 was tested 
I-H295R, but was not able to influence the formation 
f the adrenocorticoid steroids, aldosterone, cortisol, androstenedione and DHEA, produced 
by these tumour cells (Figure 33). The amidinohydrazones are strong bases and are probably 
ot able to permeate the cell membrane under physiological conditions. 
T
in the adrenocortical tumour cell line NC
o
n
 
Figure 33. General structures 
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Based on several reports, which support the positive effects of nitrogen containing 
heterocycles as suitable groups to form the necessary coordinate bond with the heme of CYP 
enzymes, we have synthesized different heteroaryl substituted naphthalenes 14-23 as 
escribed in Chapter 3.2. (Figure 34). This new class of CYP11B2 inhibitors was found by 
imidazole with arylboronic acids. The Suzuki reaction of 2-bromo-6-methoxynaphthalene 21a 
d
modifying the core of the lead structure, e.g. the (imidazolylmethylene)tetrahydronaphthalene. 
The 5-azole substituted naphthalenes 14-16 were prepared either by condensation of 
bromoacetonaphthone 14a with formamide at high temperature or by treating naphthaldehyde 
16a and its corresponding N-methyl imine 15a with tosylmethylisocyanide. The 1-imidazolyl 
compounds 17-20 were obtained by a copper salt catalyzed cross-coupling reaction of 
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with pyri(mi)dylboronic acids yielded the pyri(mi)dine substituted compounds 21-23. The 
compounds were tested for inhibitory activity towards human CYP11B2 and the active 
inhibitors were also tested towards CYP11B1 to obtain information about selectivity. The best 
compound was the 3-(6-methoxy-2-naphthyl)pyridine 21 exhibiting an IC50 value of 6 nM 
nd a selectivity factor of 263 (Figure 34). It represents a new lead structure for the 
ibitors. 
Figure 34. General structures 
 
a
development of selective CYP11B2 inh
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NHet
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hapter 3.3. dealt with the rational optimization of the new lead compound 21. Different 
2 3
pound 29 and the treatment of the methyl ester 41 with formamide and 
aOMe yielded the amides 43 and 44. The compounds were tested for activity towards 
e not a good 
The 6-cyano compound 33 was the most potent 
50 value of 3 nM. The 6-ethoxy naphthalene 30 was the most 
C
substituents were introduced on the naphthalene ring to investigate the influence of the chain 
length, size and position of these substituents on the inhibitory activity. The quino(xa)lines 
46-48 were synthesized as well to check the influence of the naphthalene core (Figure 35). 
The key step in the reaction of these compounds was the Pd-catalyzed Suzuki coupling of 
bromo- or triflate naphthalenes with 3-pyridylboronic acid in the presence of potassium 
carbonate. The triflates 33,37-39a were prepared by reacting the corresponding naphthols 
33,37-39b with Tf O. Demethylation of the methoxy compound 21 with BBr  gave the 
hydroxylated com
N
CYP11B2 and CYP11B1. Selectivity towards other steroidogenic CYP enzymes, CYP19 and 
CYP17, was evaluated as well.  
 
The structure-activity relationships revealed that substitution in the 6-position is ideal in order 
to obtain highly active and selective CYP11B2 inhibitors. However, the available space in the 
binding pocket seems to be limited, since bigger substituents like propoxy or benzyloxy 
decrease the activity drastically. The quino(xa)line structure turned out to b
alternative for the naphthalene core. 
CYP11B2 inhibitor with an IC
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selective inhibitor with a remarkable selectivity factor 451 (Figure 35). Additionally, CYP19 
and CYP17 were almost not affected. 
 
Figure 35. General structures 
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30 R=6-EtO
IC50 CYP11B2=12 nM
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d dehydration.  
Figure 36. General structures 
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The synthesis of a series of heteroaryl substituted dihydronaphthalenes and indenes as new 
CYP11B2 inhibitors has been described in Chapter 3.4. (Figure 36). Two alternative 
pathways for the synthesis of the 3-pyridine substituted dihydronaphthalenes and indenes 50-
55,58-60 are reported. The Grignard reaction of the 3-pyridine substituted tetralone 56b, 
followed by dehydration with HCl, yielded the 1-alkyl substituted analogues 56-57. The 1-
imidazole substituted compounds 61-63 were prepared by treating the bromo compounds 50-
51,53c with imidazole, followed by reduction an
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50-55
61-63
56-60
 
 
 
The 3-pyridine substituted dihydronaphthalenes and indenes 50-60 turned out to be more 
potent than the imidazole compounds 61-63. Substitution in the 6-position was more 
favourable than the 7-position, but small alkyl groups in 1,3 or 4-position did not influence 
the high activity of this class of compounds. The 6-methoxy dihydronaphthalene 53 showed 
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the best potency (IC50 CYP11B2 = 2 nM); the 5-methoxy indene 52, on the other hand, was 
ery active (IC50 CYP11B2 = 4 nM) and had an exceptional selectivity factor of 1421, 
vity profile described until now. 
. The docking studies in Chapter 3.4. 
howed that hydrophobic interactions play an important role for the positioning of inhibitors 
he potent and selective compounds 21 and 53 were tested in adult male rats after stimulation 
bility screening using Caco-2 cells and metabolic 
tability studies with rat liver microsomes could not explain this lower in vivo activity. 
. Therefore, the absorption of other CYP11B2 inhibitors was evaluated 
nd compounds with good pharmacokinetic properties were selected as possible candidates 
v
displaying the best selecti
 
Docking and molecular dynamics studies using the homology modelled CYP11B2 protein 
model were performed to explain some very interesting structure-activity relationships. In 
Chapter 3.3., a correlation was found between the stability of the docked poses during 
molecular dynamics simulations and the IC50 values
s
into the active site of the CYP11B2 enzyme.  
 
T
with ACTH (see 3.5.). Despite their good in vitro profile, they decreased the blood 
aldosterone levels only marginally. Permea
s
However, in vivo pharmacokinetic studies in rats indicated that compounds 21 and 53 were 
not optimally absorbed
a
for future in vivo experiments. 
 92
  ZUSAMMENFASSUNG  
VI. Zusammenfassung 
 
Das Ziel dieser Arbeit war das Design und die Synthese potenter und hochselektiver 
hibitoren, potentielle Therapeutika zur Behandlung von Herzinsuffizienz und 
ngen hatten nichtsteroidale Verbindungen zum Gegenstand, die 
 vitro und in vivo evaluiert wurden, um ihre biologische Aktivität und Selektivität 
. wird die Synthese und biologische Testung einer Serie von 
midinohydrazonen 1-13 beschrieben (Abb. 33). Diese Verbindungen wurden durch 
minoguanidinnitrat oder -sulfat in Gegenwart 
igten beinahe keine Hemmpotenz gegenüber humanem 
YP11B2. Verbindung 11 wurde an der adrenokortikalen Tumorzelllinie NCI-H295R 
 stellte sich heraus, dass die Verbindung nicht in der Lage war, die 
ildung der adrenocorticoiden Steroide Aldosteron, Cortisol, Androstendion und DHEA zu 
idinohydrazone sind 
tarke Basen, liegen als solche protoniert vor und sind vermutlich nicht befähigt die 
3. Allgemeine Strukturen 
CYP11B2 In
Myokardfibrose. Die Bemühu
in
gegenüber CYP11B2 zu bestimmen.  
 
In Kapitel 3.1
A
Kondensation der entsprechenden Ketone mit A
von Schwefelsäure hergestellt. Sie ze
C
getestet. Allerdings
B
beeinflussen, die von diesen Tumorzellen produziert werden. Die Am
s
Zellmembran unter physiologischen Bedingungen zu permeieren.  
 
Abbildung 3
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Effekte von stickstoffhaltigen 
 das Hämeisen von CYP-Enzymen zu komplexieren, 
 (Abb. 34) verschiedene Heteroaryl-substituierte Naphthaline 14-23 
Hemmstoffen wurde durch die Modifizierung der 
14-16 wurden entweder durch Kondensation von 
 
Aufgrund der breiten Erfahrungen im Arbeitskreis über positive 
Heterozyklen als geeigneten Gruppen um
wurden in Kapitel 3.2.
hergestellt. Diese neue Klasse an CYP11B2 
Kern-Leitstruktur gefunden, nämlich von (Imidazolylmethylen)tetrahydronaphthalin. Die 5-
Azol-substituierten Naphthaline 
Bromacetonaphthon 14a mit Formamid bei hoher Temperatur hergestellt, oder durch 
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Behandlung von Naphthaldehyd 16a und sein korrespondierendes N-Methyl Imin 15a mit 
1-Imidazolyl Verbindungen 17-20 wurden durch eine 
upfersalzkatalysierte Kupplungsreaktion von Imidazol mit Arylboronsäuren erhalten. Die 
m CYP11B2 getestet und die aktiven Inhibitoren 
urden ebenfalls gegenüber CYP11B1 evaluiert, um Informationen über die Selektivität zu 
ethoxy-2-naphthyl)pyridin 21, das einen IC50-
tsfaktor von 263 (Abb. 34) aufwies. Diese Verbindung 
tellt eine neue Leitstruktur für die Entwicklung von selektiven CYP11B2 Inhibitoren dar.  
bbildung 34. Allgemeine Strukturen 
Tosylmethylisocyanid. Die 
k
Suzuki-Reaktion von 2-Brom-6-methoxynaphtalin 21a mit Pyri(mi)dylboronsäuren führte zu 
den Pyri(mi)din-substituierten Verbindungen 21-23. Diese Verbindung wurde auf 
Hemmaktivität gegenüber menschliche
w
erhalten. Die beste Verbindung war das 3-(6-M
Wert von 6 nM und einen Selektivitä
s
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Kapitel 3.3. handelt von der rationalen Optimierung der neuen Leitverbindung 21. 
Naphthalinring  eingeführt, um den Einfluss 
en, sowie Größe und Position dieser Substituenten auf die 
emmaktivität. Die Chino(xa)line 46-48 wurden auch synthetisiert, um den Einfluss des 
N
r  
 3-Pyridinboronsäure in Gegenwart von Kaliumcarbonat. Die Triflate 
3,37-39a wurden durch Reaktion der korrespondierenden Naphthole 33,37-39b mit Tf2O 
 21 mit BBr3 ergab die hydroxylierte 
es Methylesters 41 mit Formamid und NaOMe führte zu 
en Amiden 43 und 44. Die Verbindungen wurden auf Aktivität gegenüber CYP11B2 und 
elektivität gegenüber anderen steroidogenen CYP Enzymen, CYP19 und 
YP17, wurde ebenfalls ermittelt. 
ie Untersuchungen zu den Strukturwirkungsbeziehungen zeigten, dass Substitution in 6-
osition ideal ist, um hochaktive und selektive CYP11B2 Hemmstoffe zu erhalten. Jedoch 
Unterschiedliche Substituenten wurden in den 
der Kettenlänge zu erforsch
H
aphthalinkerns  zu überprüfen (Abb. 35). Der Schlüsselschritt in der Reaktion dieser 
Verbindungen war eine Pd-katalysierte Suzuki-Kupplung von Brom- ode
Triflatnaphthalinen mit
3
hergestellt. Demethylierung der Methoxyverbindung
Verbindung 29 und die Behandlung d
d
CYP11B1 getestet. S
C
 
D
P
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scheint der verfügbare Raum in der Bindungstasche limitiert zu sein, da größere Substituenten 
wie Propoxy oder Benzyloxy die Aktivität drastisch vermindern. Die Chino(xa)lin-Struktur 
tellte sich als keine gute Alternative für den Naphthalinkern heraus. Die 6-Cyano-
en 
elektivitätsfaktor von 451 (Abb. 35). Festzustellen bleibt ferner, dass die Enzyme CYP19 
urch die Verbindung praktisch nicht beeinflusst wurden. 
 Allgemeine Strukturen 
 
s
Verbindung 33 war der potenteste CYP11B2 Hemmstoff mit einem IC50-Wert von 3 nM. Das 
6-Ethoxy Naphthalin 30 war der selektivste Hemmstoff mit einem bemerkenswert
S
und CYP17 d
 
Abbildung 35.
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27-48 (III) 33 R=6-CN
IC50 CYP11B2=3 nM
IC50 CYP11B1=691 nM
Selektivitätsfaktor = 238 
30 R=6-EtO
IC50 CYP11B2=12 nM
IC50 CYP11B1=5419 nM
Selektivitätsfaktor = 451  
e einer Serie von Heteroaryl-substituierten Dihydronaphthalinen und Indenen als 
eue CYP11B2 Inhibitoren wurde in Kapitel 3.4. beschrieben (Abb. 36). Zwei alternative 
chrieben. Die Grignard-Reaktion des 3-Pyridin-substituierten Tetralons 
6b, gefolgt von Wasserabspaltung mit HCl, ergab die 1-Alkyl-substituierten Analoga 56-57. 
zol-substituierten Verbindungen 61-63 wurden durch Behandlung der 
c mit Imidazol gefolgt von Reduktion und Dehydrierung 
ergestellt. 
ht die hohe Aktivität 
ieser Verbindungsklasse. Das 6-Methoxy-Dihydronaphthalin 53 zeigte die beste Potenz (IC50 
y-Inden 52, war auf der anderen Seite sehr aktiv (IC50 
 einen extrem hohen Selektivitätsfaktor von 1421. Diese 
erbindung ist somit die selektivste Verbindung, die bislang entwickelt wurde. 
 
Die Synthes
n
Routen für die Synthese der 3-Pyridin-substituierten Dihydronaphthaline und Indene 50-
55,58-60 wurden bes
5
Die 1-Imida
Bromverbindungen 50-51,53
h
 
Die 3-Pyridin-substituierten Dihydronaphthaline und Indene 50-60 erwiesen sich als stärker 
wirksam als die Imidazolverbindungen 61-63. Substitution in 6-Position war günstiger als in 
7-Position. Kleine Alkylgruppen in 1,3 oder 4-Position beeinflussten nic
d
CYP11B2 = 2 nM); das 5-Methox
CYP11B2 = 4 nM) und hatte
V
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Abbildung 36. Allgemeine Strukturen 
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ischen der Stabilität der gedockten 
erbindungen während einer Molekulardynamiksimulation und den IC50-Werten festgestellt. 
, dass hydrophobe Wechselwirkungen eine 
ung der Hemmstoffe im aktiven Zentrum des CYP11B2 
nzyms spielt.  
ie potenten und selektiven Hemmstoffe 21 und 53 wurden an erwachsenen männlichen 
ils 
ldosteronspiegel nur geringfügig. Ein Permeabilitätsscreening unter 
erwendung von CaCo-2-Zellen und Studien zum Metabolismus mit Rattenlebermikrosomen 
21 und 53 nicht optimal resorbiert 
urden. Deshalb wurde die Absorption von anderen CYP11B2 Inhibitoren bestimmt und 
 mit einem guten pharmakokinetischen Profil wurden als mögliche Kandidaten 
ente ausgewählt. 
 
Docking und Moleküldynamikstudien wurden mit einer Homologie modellierten CYP11B2 
Proteinstruktur durchgeführt, um einige der interessanten Strukturwirkungsbeziehungen zu 
erklären. In Kapitel 3.3. wurde eine Korrelation zw
V
Die Dockingstudien in Kapitel 3.4. zeigten
bedeutende Rolle für die Bind
E
 
D
Ratten nach Stimulation mit ACTH getestet (siehe 3.5.). Trotz ihres guten in vitro Prof
reduzierten sie die Bluta
V
konnten die niedrige in vivo Aktivität nicht erklären. Jedoch zeigten in vivo 
Pharmakokinetikstudien an Ratten, dass die Verbindungen 
w
Verbindungen
für zukünftige in vivo Experim
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VII. Experimental section 
 
A. General description 
DRX-500 (500 MHz) instrument in DMSO-d6 or 
) are given in 
z. The abbreviations of the signals are: s (singlet), br s (broad singlet), d (doublet), dd 
lemental analyses were performed at the Department of Instrumental analysis and 
niversity of the Saarland. 
 spectra were measured neat on a Bruker Vector 33FT-infrared spectrometer. The 
ntum (Thermo 
innigan) instrument.  
d on a Mettler FP1 melting point apparatus and are uncorrected.  
hy (CC) was performed using silica gel (70-200 µm), and the reaction 
rogress was followed by TLC analyses on ALUGRAM SIL G/UV254 (Macherey-Nagel). 
eagents and solvents were used as obtained from commercial suppliers (Acros, Aldrich, 
 procedure and characterization 
ethod 1 
o a mixture of 1-indanone 1a (800 mg, 6.05 mmol) and aminoguanidine nitrate (830 mg, 
uric acid (0.33 mL, 6.05 mmol). The reaction 
 
1H NMR spectra were recorded on a Bruker 
CDCl3. Chemical shifts are given in parts per million. All coupling constants (J
H
(double doublet), t (triplet), q (quartet), m (multiplet). 
 
E
Bioanalysis, U
 
IR
absorption bands are expressed in cm-1 (ν). 
 
Mass spectra (electron spray ionization (ESI)) were measured on a TSQ qua
F
 
Melting points were measure
 
Column chromatograp
p
 
R
Fluka and others) without further purification. 
 
A.I. Synthetic
 
M
 
2-(2,3-Dihydro-1H-inden-1-ylidene)hydrazinecarboximidamide nitrate (1). 
 
T
6.05 mmol) in methanol was added conc. sulph
 97
  EXPERIMENTAL SECTION  
was stirred at 50°C for 3 hours. The precipitate was filtered off, washed thoroughly with 
ater and diethyl ether and dried in open air. 
ield: 91%. 
hite solid, mp 261-262 °C. 
d6) : δ 2.79-2.82 (m, 2H, H-3), 3.12-3.14 (m, 2H, H-2), 7.34 (td, 1H, 3J = 
2-7.45 (m, 2H, Ar H), 7.88 (d, 1H, 3J = 7.6 Hz, Ar H), 10.35 
r s, 1H, NH).  
: νmax = 3449, 3328, 3166, 1676, 1609 cm-1.  
ynthesized from 1-tetralone 2a as described in the literature (Pitzele et al., 1988). 
 183-185 °C. 
, 1H, 3J = 7.6 Hz, Ar H). 
m-1.  
S: m/z = 203 (MH+), 144, 101, 79. 
11H14N4 (202.26) 
-(5-Methoxy-2,3-dihydro-1H-inden-1-ylidene)hydrazinecarboximidamide sulfate (3) 
y-1-indanone 3a. The reaction was stirred at 50°C overnight.  
w
 
Y
W
 
1H NMR (DMSO-
7.6 Hz, 4J = 1.9 Hz, Ar H), 7.4
(b
 
IR
MS: m/z = 189 (MH+), 130, 101, 79. 
 
C10H12N4 (188.24) 
 
2-(3,4-Dihydronaphthalen-1-ylidene)hydrazinecarboximidamide (2) 
 
S
 
Yield: 23%. 
Red solid, mp
 
1H-NMR (CDCl3): δ 1.90-1.92 (m, 2H, H-3), 2.77 (t, 2H, 3J = 6.0 Hz, H-4), 2.85 (t, 2H, 3J = 
6.3 Hz, H-2), 5.68 (br s, 1H, NH), 7.12 (d, 1H, 3J = 7.6 Hz, Ar H), 7.17-7.23 (m, 2H, Ar H), 
8.07 (d
 
IR: νmax = 3438, 3403, 3277, 3108, 1656, 1571 c
M
 
C
 
2
 
Synthesized from 5-methox
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  EXPERIMENTAL SECTION  
Yield: 78%. 
White solid, mp 243-244 °C. 
S: m/z = 219 (MH+), 160, 101, 79. 
11H14N4O (218.26) 
)-ylidene)hydrazinecarboximidamide sulfate 
) 
rom 6-methoxy-1-tetralone 4a. The reaction was stirred for 3 hours at room 
n was diluted with diethyl ether to obtain the precipitated product.  
d6): δ 1.84-1.86 (m, 2H, H-3), 2.58 (t, 2H, 3J = 6.4 Hz, H-4), 2.74 (t, 2H, 3J 
, 2H, Ar H), 8.26 (d, 1H, 3J = 8.5 Hz, Ar H), 
0.36 (br s, 1H, NH).  
: νmax = 3449, 3310, 3213, 2837, 1667, 1586 cm-1. 
S: m/z = 233 (MH+), 174, 101, 79. 
12H16N4O (232.29) 
 
1H-NMR (DMSO-d6): δ 2.72-2.73 (m, 2H, H-3), 3.01-3.03 (m, 2H, H-2), 3.73 (s, 3H, OCH3), 
6.85 (dd, 1H, 3J = 8.5 Hz, 4J = 2.5 Hz, Ar H), 6.91 (d, 1H, 4J = 2.5 Hz, Ar H), 7.70 (d, 1H, 3J 
= 8.5 Hz, Ar H), 10.17 (br s, 1H, NH).  
 
IR: νmax = 3459, 3357, 3192, 2838, 1656 cm-1.  
M
 
C
 
 
2-(6-Methoxy-3,4-dihydronaphthalen-1(2H
(4
 
Synthesized f
temperature. The solutio
 
Yield: 45%.  
White solid, mp 212-213 °C. 
 
1H-NMR (DMSO-
= 6.3 Hz, H-2), 3.78 (s, 3H, OCH3), 6.77-6.80 (m
1
 
IR
M
 
C
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2-(7-Methoxy-3,4-dihydronaphthalen-1(2H)-ylidene)hydrazinecarboximidamide sulfate 
(5) 
 
Synthesized from 7-methoxy-1-tetralone 5a. The reaction was stirred overnight at room 
her to obtain the precipitated product. 
hite solid, mp 176-178 °C. 
1 ): 
J = 2.2 Hz, Ar H), 10.63 (br s, 1H, NH).  
S: m/z = 233 (MH+), 174, 101, 79. 
12H16N4O (232.29) 
-[5-(Pyridin-3-ylmethoxy)-2,3-dihydro-1H-inden-1-ylidene) hydrazinecarboximidamide 
e 6a. The reaction was stirred overnight 
ield: 77%.  
r H), 7.80-7.84 
, 2H, Pyr.H-5, Ar H), 8.33 (d, 1H, 3J = 7.9 Hz, Pyr.H-4), 8.76 (dd, 1H, 3J = 5.4 Hz, 4J = 1.6 
 (br s, 1H, NH).  
, 1673, 1616. 
S: m/z = 296 (MH ), 237, 93. 
16H17N5O (295.35) 
temperature. The solution was diluted with diethyl et
 
Yield: 25%.  
W
 
H-NMR (DMSO-d6 δ 2.01-2.05 (m, 2H, H-3), 2.81 (m, 2H, H-4), 2.90 (m, 2H, H-2), 4.00 
(s, 3H, OCH3), 7.13 (d, 1H, 3J = 8.2 Hz, Ar H), 7.34 (d, 1H, 3J = 8.2 Hz, Ar H), 8.00 (d, 1H, 
4
 
IR: νmax = 3436, 3320, 3207, 2833, 1683, 1592 cm-1.  
M
 
C
 
2
sulfate (6) 
 
Synthesized from 5-(pyridin-3-ylmethoxy)indan-1-on
at 50°C. 
 
Y
White solid, mp 225-226 °C. 
 
1H-NMR (DMSO-d6): δ 2.79-2.82 (m, 2H, H-3), 3.08-3.10 (m, 2H, H-2), 5.32 (s, 2H, O-
CH2), 7.05 (dd, 1H, 3J = 8.5 Hz, 4J = 2.2 Hz, Ar H), 7.11 (d, 1H, 4J = 2.2 Hz, A
(m
Hz, Pyr.H-6), 8.89 (d, 1H, 4J = 1.6 Hz, Pyr.H-2), 10.32
 
IR: νmax = 3418, 3187
+M
 
C
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2-(6-(3-Pyridin-3-ylmethoxy)-3,4-dihydronaphthalen-1(2H)-ylidene) hydrazinecar- 
oximidamide sulfate (7) 
ynthesized from 6-(pyridin-3-ylmethoxy)-3,4-dihydronaphthalen-1(2H)-one 7a. The 
hite solid, mp 208-210 °C. 
H, 3J = 5.4 Hz, 
yr.H-6), 8.98 (s, 1H, Pyr.H-2), 10.37 (br s, 1H, NH).  
: νmax = 3421, 3326, 2939, 1668, 1592 cm-1. 
zinecarbo- 
imidamide sulfate (8) 
from 7-(pyridin-3-ylmethoxy)-3,4-dihydronaphthalen-1(2H)-one 8a. The 
 stirred overnight at 50°C.  
4), 2.70 (m, 2H, H-2), 5.33 (s, 2H, 
CH2), 7.04 (d, 1H, 3J = 8.2 Hz, Ar H), 7.17 (d, 1H, 3J = 8.2 Hz, Ar H), 7.85 (m, 1H, Pyr.H-
-4), 8.87 (d, 1H, 3J = 5.4 Hz, Pyr.H-6), 
.90 (s, 1H, Pyr.H-2), 10.44 (br s, 1H, NH).  
b
 
S
reaction was stirred overnight at 50°C.  
 
Yield: 76%.  
W
 
1H-NMR (DMSO-d6): δ 1.86-1.88 (m, 2H, H-3), 2.60 (t, 2H, 3J = 6.3 Hz, H-4), 2.77 (t, 2H, 3J 
= 5.7 Hz, H-2), 5.36 (s, 2H, OCH2), 6.93-6.95 (m, 2H, Ar H), 7.97-8.00 (m, 1H, Pyr.H-5), 
8.32 (d, 1H, 3J = 8.8 Hz, Ar H), 8.50 (d, 1H, 3J = 7.9 Hz, Pyr.H-4), 8.86 (d, 1
P
 
IR
MS: m/z = 310 (MH+), 101, 79. 
 
C17H19N5O (309.37) 
 
2-(7-(3-Pyridin-3-ylmethoxy)-3,4-dihydronaphthalen-1(2H)-ylidene) hydra
x
 
Synthesized 
reaction was
 
Yield: 45%.  
Red solid, mp 174-176 °C. 
 
1H-NMR (DMSO-d6): δ 1.84 (m, 2H, H-3), 2.60 (m, 2H, H-
O
5), 7.94 (s, 1H, Ar H), 8.36 (d, 1H, 3J = 7.2 Hz, Pyr.H
8
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IR: νmax = 3422, 3185, 2946, 2869, 1662 cm-1. 
S: m/z = 310 (MH+), 101, 79. 
17H19N5O (309.37) 
duct.  
p 194 °C. 
d6): δ 3.93 (s, 3H, OCH3), 3.97 (s, 3H, OCH3), 7.02 (d, 1H, 3J = 7.8 Hz, Ar 
).  
S: m/z = 299 (MH+), 240. 
16H18N4O2 (298.35) 
ren-9-ylidene)hydrazinecarboximidamide sulfate (12) 
°C.  
: νmax. = 3436, 3318, 3166, 1684, 1570 cm-1. 
M
 
C
 
2-[bis(3-methoxyphenyl)methylene]hydrazinecarboximidamide nitrate (10) 
 
Synthesized from bis(3-methoxy-phenyl)methanone 10a. The reaction was stirred overnight 
at 50°C. The solution was diluted with diethyl ether to obtain the precipitated pro
 
Yield: 36%.  
White solid, m
 
1H-NMR (DMSO-
H), 7.07 (s, 1H, Ar H), 7.17-7.20 (m, 2H, Ar H), 7.34 (dd, 1H, 3J = 8.5 Hz, 4J = 2.5 Hz, Ar H), 
7.44-7.47 (m, 2H, Ar H), 7.72 (t, 1H, 3J = 8.2 Hz, Ar H), 9.82 (br s, 1H, NH
 
IR: νmax = 3506, 3314, 3151, 2834, 1668. 
M
 
C
 
2-(9H-Fluo
 
Synthesized from 9H-fluorenone 12a. The reaction was stirred overnight at 60
 
Yield: 55%.  
Yellow solid, mp 124-126 °C. 
 
1H-NMR (DMSO-d6): δ 7.38 (t, 1H, 3J = 7.2 Hz, Ar H), 7.46-7.49 (m, 2H, Ar H), 7.59 (t, 1H, 
3J = 7.5 Hz, Ar H), 7.84 (d, 1H, 3J = 7.2 Hz, Ar H), 7.94 (d, 1H, 3J = 7.5 Hz, Ar H), 8.09 (d, 
1H, 3J = 7.5 Hz, Ar H), 8.23 (d, 1H, 3J = 7.5 Hz, Ar H), 10.78 (br s, 1H, NH).  
 
IR
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MS: m/z = 237 (MH+), 178, 101, 79. 
 
C14H12N4 (236.28) 
 
 
Method 2 
 
5-Hydroxy-1-indanone (6b) 
 
Compounds 6b-8b were prepared according to the literature (Woo et al., 1998). 
 suspension of AlCl3 (2.04 g, 13.35 mmol) in dry toluene (40 mL) was stirred at room 
trogen atmosphere. 5-Methoxy-1-indanone 3a (1 g, 6.14 mmol) was 
lowly added. After reflux for 2 hours, the reaction was cooled and cautiously quenched with 
ed 
ith water exhaustively, dried (MgSO4), filtered and evaporated in vacuo. The residue was 
9H8O2 (148.16) 
(2H)-one (7b) 
ethoxy-1-tetralone 4a. 
sed without purification. 
 
A
temperature under ni
s
water. The resulting mixture was extracted with ethyl acetate. The organic layer was wash
w
washed with ethyl acetate and the resulting solid was air-dried. 
 
Used without purification. 
Yield: 66%.  
White solid. 
 
1H-NMR (DMSO-d6): δ 2.52-2.54 (m, 2H, H-3), 2.98 (t, 2H,3J =6.0 Hz, H-2), 6.79 (dd, 1H, 3J 
= 8.5 Hz, 4J = 1.6 Hz, Ar H), 6.84 (s, 1H, Ar H), 7.47 (d, 1H, 3J = 8.5 Hz, Ar H), 10.45 (s, 1H, 
OH). 
 
IR: νmax. = 3130, 2927, 1675, 1597, 1270 cm-1. 
 
C
 
6-Hydroxy-3,4-dihydronaphthalen-1
 
Synthesized from 6-m
U
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Yield: 60%.  
hite solid. 
d6): δ 1.95-2.00 (m, 2H, H-3), 2.48 (t, 2H, 3J = 6.3 Hz, H-4), 2.83 (t, 2H, 3J 
.19) 
-Hydroxy-3,4-dihydronaphthalen-1(2H)-one (8b) 
ification. 
ield: 70%.  
d6): δ 1.96-2.01 (m, 2H, H-3), 2.53 (t, 2H, 3J = 6.3 Hz, H-4), 2.81 (t, 2H, 3J 
dd, 1H, 3J = 8.5 Hz, 4J = 2.5 Hz, Ar H), 6.15 (d, 1H, 3J = 8.5 Hz, Ar H), 
.23 (d, 1H, 4J = 2.5 Hz, Ar H), 9.54 (s, 1H, OH). 
3191, 2943, 1650, 1574, 1298 cm-1. 
 mixture of 5-hydroxy-1-indanone 6b (600 mg, 4.05 mmol) and K2CO3 (1.40 g, 10.13 
osphere. After 10 min, picolyl chloride 
W
 
1H-NMR (DMSO-
= 6.3 Hz, H-2), 6.65 (s, 1H, Ar H), 6.71 (dd, 1H, 3J = 8.5 Hz, 4J = 2.2 Hz, Ar H), 7.74 (d, 1H, 
3J = 8.5 Hz, Ar H), 10.29 (s, 1H, OH). 
 
IR: νmax. = 3130, 3026, 2936, 1645, 1574, 1248 cm-1. 
 
C10H10O2 (162
 
7
 
Synthesized from 7-methoxy-1-tetralone 5a. 
 
Used without pur
Y
Beige solid. 
 
1H-NMR (DMSO-
= 6.0 Hz, H-2), 6.95 (
7
 
IR: νmax. = 
 
C10H10O2 (162.19) 
 
 
Method 3 
 
5-(Pyridin-3-ylmethoxy)indan-1-one (6a) 
 
A
mmol) in DMF (20 mL) was stirred under nitrogen atm
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  EXPERIMENTAL SECTION  
hydrochloride (665 mg, 4.05 mmol) was added in portions. The reaction was stirred for 3 
C. Water was added and the mixture was extracted with dichloromethane. The 
rganic layer was dried (MgSO4), filtered and evaporated in vacuo.  
hite solid. 
3): δ 2.67-2.70 (m, 2H, H-3), 3.10 (t, 2H, 3J = 6.0 Hz, H-2), 5.20 (s, 2H, 
, 2H, Ar H), 7.44 (m, 1H, Pyr. H-5), 7.72 (d, 1H, 3J = 7.5 Hz, Ar H), 
.88 (d, 1H, 3J = 7.5 Hz, Pyr. H-4), 8.65 (d, 1H, 3J = 5.0 Hz, Pyr. H-6), 8.76 (s, 1H, Pyr. H-2). 
: νmax. = 3052, 2954, 2932, 1698, 1610, 1260 cm-1. 
15H13NO2 (239.28) 
-ylmethoxy)-3,4-dihydronaphthalen-1(2H)-one (7a) 
ynthesized from 6-hydroxy-3,4-dihydronaphthalen-1(2H)-one 7b. 
hite solid. 
3): δ 2.12-2.15 (m, 2H, H-3), 2.63 (t, 2H, 3J = 6.4 Hz, H-4), 2.95 (t, 2H, 3J = 
s, 2H, OCH2), 6.81 (d, 1H, 4J = 2.0 Hz, Ar H), 6.91 (dd, 1H, 3J = 8.8 Hz, 
 = 2.2 Hz, Ar H), 7.50 (m, 1H, Pyr. H-5), 7.95 (d, 1H, 3J = 8.3 Hz, Ar H), 8.03 (d, 1H, 3J = 
, 8.78 (s, 1H, Pyr. H-2). 
, 1596, 1267 cm-1. 
hours at 100°
o
 
Purification: CC (dichloromethane/methanol 97:3).  
Yield: 73%.  
W
 
1H-NMR (CDCl
OCH2), 6.98-6.99 (m
7
 
IR
 
C
 
6-(Pyridin-3
 
S
 
Purification: CC (dichloromethane/methanol 90:10).  
Yield: 75%.  
W
 
1H-NMR (CDCl
6.0 Hz, H-2), 5.20 (
4J
3.5 Hz, Pyr. H-4), 8.66 (d, 1H, 3J = 4.4 Hz, Pyr. H-6)
 
IR: νmax. = 3057, 2946, 2877, 1672
 
C16H15NO2 (253.30) 
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7-(Pyridin-3-ylmethoxy)-3,4-dihydronaphthalen-1(2H)-one (8a) 
 
Synthesized from 7-hydroxy-3,4-dihydronaphthalen-1(2H)-one 8b. 
 
Purification: CC (dichloromethane/methanol 95:5).  
hite solid. 
3): δ 2.10-2.15 (m, 2H, H-3), 2.65 (t, 2H, 3J = 6.6 Hz, H-4), 2.92 (t, 2H, 3J = 
 2.8 Hz, Ar H), 7.20 (d, 1H, 
 = 8.2 Hz, Ar H), 7.41 (m, 1H, Pyr. H-5), 7.60 (d, 1H, 4J = 2.8 Hz, Ar H), 7.87 (d, 1H, 3J = 
r. H-6), 8.72 (s, 1H, Pyr. H-2). 
, 1494, 1276 cm-1. 
253.30) 
ield: 42%.  
z, 4J = 2.2 Hz, Ar H), 7.40-
.44 (m, 4H, Ar H, Pyr. H-5), 7.48 (t, 2H, 3J = 7.2 Hz, Ar H), 7.60 (t, 1H, 3J = 7.2 Hz, Ar H), 
J = 7.8 Hz, Pyr. H-4), 8.62 (dd, 1H, 3J = 4.7 Hz, 
 = 1.6 Hz, Pyr. H-6), 8.73 (d, 1H, 4J = 1.6 Hz, Pyr. H-2). 
61, 2928, 2872, 1657, 1595, 1278 cm-1. 
19H15NO2 (289.34) 
 
Yield: 76%.  
W
 
1H-NMR (CDCl
6.1 Hz, H-2), 5.14 (s, 2H, OCH2), 7.13 (dd, 1H, 3J = 8.5 Hz, 4J =
3J
7.9 Hz, Pyr. H-4), 8.61 (d, 1H, 3J = 3.8 Hz, Py
 
IR: νmax. = 2990, 2922, 1680, 1608
 
C16H15NO2 (
 
Phenyl[3-(pyridin-3-ylmethoxy)phenyl]methanone (11a) 
 
Synthesized from (3-hydroxyphenyl)(phenyl)methanone 11b. 
 
Purification: CC (dichloromethane/methanol 99:1).  
Y
Brown oil. 
 
1H-NMR (CDCl3): δ 5.16 (s, 2H, OCH2), 7.22 (dt, 1H, 3J = 7.2 H
7
7.79 (d, 2H, 3J = 7.2 Hz, Ar H), 7.87 (d, 1H, 3
4J
 
IR: νmax. = 30
 
C
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Method 4 
 
(3-Hydroxyphenyl)(phenyl)methanone (11b) 
 
BBr3 (2.17 mL, 22.92 mmol) was slowly added to (3-methoxyphenyl)(phenyl) methanone 9a 
egash et al., 1997) (2 g, 10.42 mmol) in dry CH2Cl2 at -78°C under nitrogen atmosphere. 
ing, the cooling was stopped and the reaction was stirred at room 
mperature overnight. The reaction was slowly quenched with methanol and then washed 
orated in vacuo. 
93:7). 
ield: 86%.  
MSO-d6): δ 5.45 (br s, 1H, OH), 7.09 (dt, 1H, 3J = 7.3 Hz, Ar H), 7.33-7.35 (m, 
H, Ar H), 7.48 (t, 2H, 3J = 8.2 Hz, Ar H), 7.80 (d, 2H, 3J = 8.2 Hz, Ar H). 
l)(phenyl)methylene]hydrazinecarboximidamide (9) 
o a mixture of (3-methoxyphenyl)phenyl methanone 9a (820 mg, 3.87 mmol) and 
idine hemisulfate (950 mg, 3.87 mmol) in methanol (20 mL), conc. sulphuric acid 
.21 mL, 3.87 mmol) was added. After stirring overnight at reflux, extra aminoguanidine 
s added to the reaction and stirring was continued for 1 
ay at reflux. The reaction was basified with sodium hydroxide solution (6%) and then 
(N
After 30 min of stirr
te
with water. The organic layer was dried (MgSO4), filtered, evap
 
Purification: CC (dichloromethane/methanol 
Y
White solid. 
 
1H-NMR (D
3
 
IR: νmax. = 3341, 3062, 2958, 1643, 1595, 1288 cm-1. 
 
C13H10O2 (198.22) 
 
 
Method 5 
 
2-[(3-methoxypheny
 
T
aminoguan
(0
hemisulfate (470 mg, 1.91 mmol) wa
d
extracted with dichloromethane. The organic layer was dried (MgSO4), filtered and 
evaporated in vacuo.  
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Purification: CC (dichloromethane/methanol/NH4OH 84:14:2). 
Yield: 88% (mixture of isomers). 
White crystals, mp 96-97 °C. 
DCl3): δ 3.77 (s, 6H, OCH3, OCH3’), 5.90 (br s, 2H, NH, NH’), 6.75 (m, 1H, Ar 
Hz, Ar H), 6.87 (dd, 1H, 3J = 8.2 Hz, 4J = 2.7 Hz, Ar H), 6.96 (dd, 
H, 3J = 8.2 Hz, 4J = 2.7 Hz, Ar H), 7.02 (d, 1H, 3J = 7.9 Hz, Ar H), 7.09 (m, 1H, Ar H), 
: νmax. = 3452, 3354, 2988, 1571 cm-1. 
. 
15H16N4O (268.36) 
-{Phenyl[3-(pyridin-3ylmethoxy)phenyl]methylene}hydrazinecarboximidamide (11) 
ridin-3-ylmethoxy)phenyl]methanone 11a. 
oromethane/methanol/NH4OH 84:14:2). 
ixture of isomers).  
d, mp 89-91 °C. 
3 2 2’), 5.54 (br s, 2H, NH, NH’), 6.84 (d, 1H, 3J = 
, 1H, Ar H), 6.92 (dd, 1H, 3J = 7.5 Hz, 4J = 2.5 Hz, Ar H), 7.00 (dd, 
ν -1
), 287, 195, 167. 
20H19N5O (345.41) 
 
 
1H-NMR (C
H), 6.80 (d, 1H, 3J = 7.3 
1
7.18-7.45 (m, 10H, Ar H), 7.50 (d, 2H, 3J = 8.2 Hz, Ar H).  
 
IR
MS: m/z = 269 (MH+), 210, 101, 79
 
C
 
2
 
Synthesized from phenyl[3-(py
 
Purification: CC (dichl
Yield: 72% (m
Yellow soli
 
1H-NMR (CDCl ): δ 5.04 (d, 4H, OCH , OCH
7.5 Hz, Ar H), 6.88 (m
1H, 3J = 7.5 Hz, 4J = 2.5 Hz, Ar H), 7.04 (d, 1H, 3J = 7.5 Hz, Ar H), 7.16-7.43 (m, 13H, Ar 
H), 7.48-7.49 (m, 2H, Ar .H), 7.73 (dd, 2H, 3J = 7.8 Hz, 4J = 1.9 Hz, Pyr.H-4), 8.51 (dd, 1H, 
3J = 4.7 Hz, 4J = 1.9 Hz, Pyr.H-6), 8.55 (dd, 1H, 3J = 4.7 Hz, 4J = 1.9 Hz, Pyr.H-6), 8.63 (br s, 
2H, Pyr.H-2).  
 
IR: max. = 3454, 3308, 3081, 1570, 1528 cm . 
+MS: m/z = 346 (MH
 
C
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Method 6 
 
9H-Fluoren-9-one semicarbazone hydrochloride (13) 
ide (280 mg, 2.5 mmol), sodium acetate (205 mg, 2.5 
mol) and water (2.5 mL) was added slowly to a stirred solution of 9H-fluorenone 12a (450 
0 mL). The reaction mixture was stirred at room temperature 
vernight. The precipitate was collected, washed with water and diethyl ether and air-dried. 
d6): δ 7.34 (t, 1H, 3J = 7.2 Hz, 4J = 0.9 Hz, Ar H), 7.41 (q, 2H, 3J = 7.2 Hz, 
 = 7.5 Hz, Ar H), 7.82 (d, 1H, 3J = 7.5 Hz, Ar H), 7.90 (d, 
H, 3J = 7.5 Hz, Ar H), 8.00 (d, 1H, 3J = 7.5 Hz, Ar H), 8.25 (d, 1H, 3J = 7.5 Hz, Ar H), 10.00 
8 (MH+), 179. 
14H11N3O (237.26) 
 
ethod 7 
) 
thone 14b (2 g, 11.75 mmol) in dichloromethane/methanol (140 
3 (6.23 g, 12.92 mmol) at room temperature. The mixture was 
range solution took place. The solvent was removed in vacuo 
 extracted with diethyl ether. The ether layer was dried 
4), filtered and evaporated in vacuo. 
ethane/hexane 45:55). 
 
A mixture of semicarbazide hydrochlor
m
mg, 2.5 mmol) in ethanol (1
o
 
Yield: 73%.  
Yellow solid, mp 232-234 °C. 
 
1H-NMR (DMSO-
4J = 0.9 Hz, Ar H), 7.51 (t, 1H, 3J
1
(br s, 1H, NH).  
 
IR: νmax. = 1700, 1670, 1573 cm-1. 
MS: m/z = 23
 
C
 
M
 
2-bromo-1-(2-naphthyl)ethanone (14a
 
To a solution of 2’-acetonaph
mL/56 mL) was added TBA Br
stirred until decoloration of the o
and the obtained precipitate was
(MgSO
 
Purification: CC (dichlorom
 109
  EXPERIMENTAL SECTION  
Yield: 78%. 
White solid. 
DCl3): δ 4.58 (s, 1H, CH2), 7.89 (d, 1H, 3J = 8.2 Hz, Ar H), 7.92 (d, 1H, 3J = 8.2 
-Bromoindan-1-one (50c)  
rom 1-indanone 1a. 
urification: CC (dichloromethane). 
3): δ 3.44 (dd, 1H, 2J = 18.0 Hz, 3J = 3.0 Hz, H-3), 3.86 (dd, 1H, 2J = 18.0 Hz, 
 Hz, H-2), 7.44-7.48 (m, 2H, Ar H), 7.68 
, 1H, 3J = 7.6 Hz, Ar H), 7.86 (d, 1H, 3J = 7.6 Hz, Ar H).  
: νmax = 3061, 1721, 1604, 1464, 1426, 1272 cm-1. 
1.06) 
alen-1-one (51c) 
%. 
ellow oil. 
 
1H NMR (C
Hz, Ar H), 7.98 (d, 1H, 3J = 8.2 Hz, Ar H), 8.02 (dd, 1H, 3J = 8.8 Hz, 4J = 1.9 Hz, Ar H), 8.51 
(d, 1H, 4J = 1.2 Hz, Ar H). 
 
IR: νmax = 3002, 2950, 1689 cm-1. 
 
C12H9BrO (249.11) 
 
2
 
Synthesized f
 
P
Yield: 78%. 
Yellow oil. 
 
1H NMR (CDCl
3J = 7.6 Hz, H-3’), 4.67 (dd, 1H, 3J = 7.6 Hz, 3J = 3.0
(t
 
IR
 
C9H7BrO (21
 
2-Bromo-3,4-dihydro-2H-naphth
 
Synthesized from 1-tetralone 2a. 
 
Purification: CC (dichloromethane).  
Yield: 50
Y
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1H NMR (CDCl3): δ 2.45-2-57 (m, 2H, H-4), 2.92 (dt, 1H, 2J = 17.0 Hz, 3J = 4.4 Hz, H-3), 
, 1H, H-3’), 4.73 (t, 1H, 3J = 4.4 Hz, H-2), 7.28 (d, 1H, 3J = 7.6 Hz, Ar H), 7.36 
, 7.52(td, 1H, 3J = 7.6 Hz, 4J = 1.3 Hz, Ar H), 8.10 (dd, 1H, 3J = 7.9 
z, 4J = 1.3 Hz, Ar H).  
10H9BrO (225.09) 
alen-1-one (53c)  
-1-tetralone 4a. 
n. 
3 dt, 1H, 2J = 17.0 Hz, 3J = 4.4 Hz, H-3), 
), 4.69 (t, 1H, 3J = 4.4 Hz, H-2), 6.72 (d, 1H, 4J = 
3J = 8.8 Hz, Ar H).  
. 
11 11 2
2-Bromo-7-methoxy-3,4-dihydro-2
eige solid. 
3.29-3.36 (m
(t, 1H, 3J = 7.6 Hz, Ar H)
H
 
IR: νmax = 3069, 2933, 1665, 1595 cm-1. 
 
C
 
2-Bromo-6-methoxy-3,4-dihydro-2H-naphth
 
Synthesized from 6-methoxy
 
Used without further purificatio
Yield: 95%.  
Yellow oil. 
 
1H NMR (CDCl ): δ 2.42-2-54 (m, 2H, H-4), 2.86 (
3.27-3.32 (m, 1H, H-3’), 3.87 (s, 3H, OCH3
2.3 Hz, Ar H), 6.87 (dd, 1H, 3J = 8.8 Hz, 4J = 2.3 Hz, Ar H), 8.06 (d, 1H, 
 
IR: ν  = 2944, 2837, 1674, 1596, 1495, 1258 cm-1max
 
C H BrO  (255.11) 
 
H-naphthalen-1-one (54c)  
 
Synthesized from 7-methoxy-1-tetralone 5a. 
 
Purification: CC (dichloromethane).  
Yield: 60%.  
B
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1H NMR (CDCl3): δ 2.43-2-54 (m, 2H, H-4), 2.86 (dt, 1H, 2J = 16.7 Hz, 3J = 4.4 Hz, H-3), 
(s, 3H, OCH3), 4.72 (t, 1H, 3J = 4.4 Hz, H-2), 7.11 (dd, 1H, 3J = 
 (d, 1H, 3J = 8.5 Hz, Ar H), 7.55(d, 1H, 4J = 2.8 Hz, Ar H).  
: νmax = 2940, 2837, 1681, 1609, 1497, 1243 cm-1. 
11H11BrO2 (255.11) 
-Bromo-4-methyl-3,4-dihydronaphthalen-1(2H)-one (59c) 
ield: 96% (mixture of two isomers). 
.47 (d, 3H, 3J = 7.0 Hz, CH3), 1.49 (d, 3H, 3J = 7.0 Hz, CH3’), 2.16-
.25 (m, 2H, H-3), 2.35-2.40 (m, 1H, H-3), 2.62-2.69 (m, 1H, H-3’), 3.29 (m, 2H, H-4, H-4’), 
: νmax = 2965, 1688, 1601, 1458 cm-1. 
ethod 8 
  
o-1-(2-naphthyl)ethanone 14a (500 mg, 2.01 mmol) in formamide (2.4 
s. After cooling, the mixture was poured into hot, diluted 
n (12 mL) and active charcoal was added. After stirring for 15 min, the mixture 
3.21-3.27 (m, 1H, H-3’), 3.84 
8.5 Hz, 4J = 2.8 Hz, Ar H), 7.19
 
IR
 
C
 
2
 
Synthesized from 4-methyl-1-tetralone 59d. 
 
Used without further purification. 
Y
Brown oil. 
 
1H NMR (CDCl3): δ = 1
2
4.78 (dd, 1H, 3J = 14.2 Hz, 3J = 4.7 Hz, H-2), 4.91 (dd, 1H, 3J = 13.5 Hz, 3J = 4.7 Hz, H-2’), 
7.36 (t, 2H, 3J = 7.9 Hz, Ar H), 7.41 (d, 2H, 3J = 7.9 Hz, Ar H), 7.58 (td, 2H, 3J = 7.9 Hz, 4J = 
1.6 Hz, Ar H), 8.11 (d, 2H, 3J = 7.9 Hz, Ar H). 
 
IR
 
C11H11BrO (239.11) 
 
 
M
 
5-(2-Naphthyl)-1H-imidazole (14)
 
A solution of 2-brom
mL) was stirred at 185°C for 2 hour
HCl solutio
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  EXPERIMENTAL SECTION  
was filtered and basified with an aqueous ammonia solution and extracted with ethyl acetate. 
he organic layer was dried (MgSO4), filtered and evaporated in vacuo.  
urification: CC (dichloromethane).  
 = 8.5 
z, 4J = 1.9 Hz, Ar H), 7.74-7.81 (m, 4H, Ar H, Im. H-2), 8.13 (s, 1H, Ar H).  
25, 3044, 2852 cm-1.  
8, 141.  
bs. 80.00 5.64 14.13 
ethod 9 
-Methyl-5-(2-naphthyl)-1H-imidazole (15) 
n-2-ylmethylene-amine 15a (300 mg, 1.77 mmol), tosylmethyl 
2CO3 (490 mg, 3.55 mmol) in absolute methanol (30 
L) was stirred at room temperature overnight. Methanol was evaporated in vacuo and 
ichloromethane was added to the crude product. After washing with water, the organic layer 
gSO4), filtered and evaporated in vacuo.  
l 97:3). 
ield: 18%. 
T
 
P
Yield: 9%.  
White solid, mp 171 ºC.  
 
1H NMR (CDCl3): δ 7.38 (s, 1H, Im. H-4), 7.39-7.45 (m, 2H, Ar H), 7.73 (dd, 1H, 3J
H
 
IR: νmax = 31
MS: m/z = 195 (MH+), 16
 
C13H10N2 (194.24)·0.05H2O 
 
 C H N 
Calc. 79.99 5.22 14.35 
O
 
 
M
 
1
 
A mixture of methyl-naphthale
isocyanide (570 mg, 2.95 mmol) and K
m
d
was dried (M
 
Purification: CC (dichloromethane/methano
Y
White solid, mp 103 ºC.  
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1H NMR (CDCl3): δ 3.75 (s, 3H, CH3), 7.22 (s, 1H, Im. H-4), 7.49-7.53 (m, 3H, Ar H), 7.68 
(s, 1H, Im. H-2), 7.85-7.87 (m, 3H, Ar H), 7.91 (d, 1H, 3J = 8.5 Hz, Ar H).  
 
IR: νmax = 3083, 3053, 2952, 1600, 1490 cm-1.  
MS: m/z = 209 (MH+), 167, 139, 115.  
14H12N2 (208.27)·0.19H2O 
ynthesized from 2-naphthaldehyde 16a. 
urification: CC (dichloromethane/methanol 97:3). 
DCl3): δ 7.47 (s, 1H, Im. H-4), 7.49-7.54 (m, 2H, Ar H), 7.73 (dd, 1H, 3J = 8.5 
r H), 7.97 (s, 1H, Im. H-2), 8.14 (s, 1H, Ar H).  
S: m/z = 196 (MH+), 167, 139, 115.  
5.22)·0.08H2O 
C H N 
 
 
 
C
 
 C H N 
Calc. 79.41 5.90 13.23 
Obs. 79.39 5.74 12.90 
 
 
5-(2-naphthyl)-1,3-oxazole (16)  
 
S
 
P
Yield: 28%. 
White solid, mp 121 ºC.  
 
1H NMR (C
Hz, 4J = 1.6 Hz, Ar H), 7.83-7.90 (m, 3H, A
 
IR 1: νmax = 3128, 3055, 2952, 1630, 1497 cm-.  
M
 
C13H9NO (19
 
 
Calc. 79.38 4.70 7.12 
Obs. 79.37 4.80 7.22 
 
 114
  EXPERIMENTAL SECTION  
Method 10 
 
2-Methoxy-3-naphthylboronic acid (18a) 
oxynaphthalene 18b (1.58 g, 10 mmol) in dry THF (20 mL) under 
itrogen atmosphere at –20°C, nBuLi (2.5 M in hexane, 4 mL, 10 mmol) was slowly added. 
5 hours at room temperature, the mixture was cooled to –60°C and 
rimethylborate (1.37 mL, 12 mmol) was slowly added. After 1 hour at –60°C and overnight 
tion (2M) was added and the reaction was stirred for 30 min. 
with ethyl acetate, dried (MgSO4), filtered and evaporated in 
ield: 45%. 
H, Ar H), 7.37 (td, 1H, 3J = 8.2 Hz, 4J = 
), 7.50 (td, 1H, 3J = 8.2 Hz, 4J = 1.3 Hz, Ar H), 7.74 (d, 1H, 3J = 8.2 Hz, Ar H), 
r H), 8.41 (s, 1H, Ar H). 
I
-Naphthyl)-1H-imidazole (17) 
17a (420 mg, 2.44 mmol), imidazole (200 mg, 2.93 
 of copper(I)iodide in dry methanol (20 mL) was refluxed for 3 
f air. Subsequently, the reaction mixture was evaporated in 
.  
 
To a mixture of 2-meth
n
After stirring for 2.
t
at room temperature, a HCl solu
The mixture was extracted 
vacuo. 
 
No further purification necessary. 
Y
Light brown solid. 
 
1H NMR (CDCl3): δ 4.30 (s, 3H, OCH3), 7.16 (s, 1
1.3 Hz, Ar H
7.84 (d, 1H, 3J = 8.2 Hz, A
 
R: νmax = 3375, 2926, 2839, 1598, 1469, 1346 cm-1. 
 
C14H12N2O (224.26) 
 
 
Method 11 
 
(2
 
A mixture of 2-naphthyl boronic acid 
mmol) and a catalytic amount
hours under an atmosphere o
vacuo
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Purification: CC (dichloromethane/methanol 98:2). 
ield: 51%. 
, 1H, Im. H-5), 7.51-7.58 (m, 3H, Ar H), 
4J = 1.5 Hz, Ar H), 7.88 (t, 2H, 3J = 7.6 Hz, Ar H), 7.96 (d, 1H, 3J = 7.6 Hz, Ar 
 
2O 
bs. 79.79 5.13 14.28 
-(3-Methoxynaphthalen-2-yl)-1H-imidazole (18) 
-3-naphthaleneboronic acid 18a. 
urification: CC (dichloromethane/methanol 97:3). 
hite solid, mp 217 °C. 
3): δ = 3.97 (s, 3H, OCH3), 7.21 (s, 1H, Im. H-4), 7.30 (s, 2H, Ar H, Im. H-5), 
(td, 1H, 3J = 8.2 Hz, 4J = 1.3 Hz, Ar H), 
r H), 7.79 (d, 2H, 3J = 8.5 Hz, Ar H), 7.87 (s, 1H, Im. H-2). 
: νmax = 3059, 2940, 2839, 1506 cm-1. 
 
Y
White solid, mp 123 ºC.  
 
1H NMR (CDCl3): δ 7.26 (s, 1H, Im. H-4), 7.40 (s
7.82 (d, 1H, 
H), 8.05 (s, 1H, Im. H-2). 
 
IR: νmax = 3116, 3058, 1688, 1602, 1493 cm-1.  
MS: m/z = 195 (MH+), 167, 139, 115, 77, 51.  
 
C13H10N2 (194.24)·0.08H
 
 C H N 
Calc. 79.80 5.23 14.32 
O
 
1
 
Synthesized from 2-methoxy
 
P
Yield: 13%. 
W
 
1H NMR (CDCl
7.24 (td, 1H, 3J = 8.2 Hz, 4J = 1.3 Hz, Ar H), 7.51 
7.74 (s, 1H, A
 
IR
MS: m/z = 225 (MH+). 
 
C14H12N2O (224.26)·HCl·0.22H2O 
 116
  EXPERIMENTAL SECTION  
 C H N 
Calc. 63.54 5.14 10.59 
Obs. 63.53 5.03 10.50 
ethod 12 
-(6-Methoxynaphthalen-2-yl)-1H-imidazole (19)  
aphthyl boronic acid 19a (260 mg, 1.29 mmol), imidazole (50 
etate (170 mg, 0.96 mmol), pyridine (100 mg, 1.29 mmol) and 
Å molecular sieve in anhydrous dichloromethane (5 mL) was stirred at room temperature for 
elite and evaporated in vacuo.  
ield: 13%. 
 (s, 3H, OCH3), 7.18 (d, 1H, 4J = 2.5 Hz, Ar H), 7.24 (dd, 1H, 3J = 
.5 Hz, 4J = 2.5 Hz, Ar H), 7.28 (s, 1H, Im. H-4), 7.38 (s, 1H, Im. H-5), 7.48 (dd, 1H, 3J = 8.5 
H
14H12N2O (224.26)·0.13H2O 
alc. 74.21 5.45 12.36 
11.97 
 
 
M
 
1
 
A mixture of 6-methoxy-2-n
mg, 0.75 mmol), copper(II)ac
4
two days. The mixture was filtered over c
 
Purification: CC (dichloromethane/methanol 99:1). 
Y
White solid, mp 85 ºC.  
 
1H NMR (CDCl3): δ 3.95
8
z, 4J = 2.5 Hz, Ar H), 7.76 (s, 1H, Ar H), 7.77 (d, 1H, 3J = 8.5 Hz, Ar H), 7.85 (d, 1H, 3J = 
8.5 Hz, Ar H), 8.07 (s, 1H, Im. H-2).  
 
IR: νmax = 3113, 3003, 2962, 2842, 1607 cm-1.  
MS: m/z = 225 (MH+), 210, 126.  
 
C
 
 C H N 
C
Obs. 74.20 5.96 
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Method 13 
 
3-Imidazol-1-yl-quinoline (20) 
 
A mixture of 3-bromoquinoline 20a (0.50 g, 2.40 mmol), imidazole (0.17 g, 2.56 mmol), 
 g, 2.30 mmol) and Cu(II)O (13 mg, 0.16 mmol) in nitrobenzene (4 mL) was 
ith heavy stirring. After cooling, the mixture was extracted with 
hloroform and the organic layer was dried (MgSO4), filtered and evaporated in vacuo. 
1H, 4J = 1.3 Hz, Im. H-4), 7.44 (t, 1H, 4J = 1.5 Hz, Im. H-5), 
.66 (td, 1H, 3J = 8.2 Hz, 4J = 1.3 Hz, Ar H), 7.79 (td, 1H, 3J = 8.2 Hz, 4J = 1.5 Hz, Ar H), 
), 8.18-8.19 (m, 2H, Ar H), 
 Ar H). 
2, 1608, 1497 cm-1. 
S: m/z = 196 (MH+), 169, 77, 51. 
C H N 
bs. 72.86 4.76 21.07 
l)pyridine (21)  
Pd(PPh3)4 (0.02 eq) in ethylene glycol dimethyl ether or toluene was stirred overnight at 80°C 
K2CO3 (0.32
refluxed for 24 hours w
c
 
Purified by CC (dichloromethane/methanol 97:3). 
Yield: 18%. 
White solid, mp 146 °C. 
 
1H NMR (CDCl3): δ = 7.34 (t, 
7
7.90 (dd, 1H, 3J = 8.2 Hz, 4J = 1.6 Hz, Ar H), 8.17 (s, 1H, Im. H-2
9.04 (d, 1H, 4J = 1.8 Hz,
 
IR: νmax = 3102, 296
M
 
C H N  (195.23)·0.14H O 12 9 3 2
 
 
Calc. 72.88 4.73 21.25 
O
 
 
Method 14 
 
3-(6-Methoxy-2-naphthy
 
A mixture of substituted 2-bromo-6-methoxy naphthalene 21a (480 mg, 2.02 mmol), 3-
pyridylboronic acid 24 (373 mg, 3.04 mmol), aqueous Na2CO3 (451 mg, 4.25 mmol) and 
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under nitrogen. The reaction was cooled to room temperature and water was added. The 
mixture was extracted with ethyl acetate, dried (MgSO4), filtered and evaporated in vacuo. 
 
Purification: CC (dichloromethane/methanol 97:3).  
ield: 77%. 
DCl3): δ 3.95 (s, 1H, OCH3), 7.17 (d, 1H, 4J = 2.5 Hz, Ar H), 7.22 (dd, 1H, 3J = 
 Ar H), 7.45-7.47 (m, 1H, Pyr. H-5), 7.67 (dd, 1H, 3J = 8.5 Hz, 4J = 1.8 
z, Ar H), 7.81 (d, 1H, 3J = 8.5 Hz, Ar H), 7.85 (d, 1H, 3J = 8.5 Hz, Ar H), 7.98 (s, 1H, Ar 
, 8.61 (dd, 1H, 3J = 4.7 Hz, 4J = 1.3 Hz, Pyr. H-6), 8.97 (s, 1H, 
: ν  = 3058, 2938, 1605, 1489 cm-1.  
C H N 
 5.37 5.62 
-(6-Methoxy-2-naphthyl)pyridine (22)  
hite solid, mp 159 ºC.  
7 (s, 3H, OCH3), 7.19 (d, 1H, 4J = 2.5 Hz, Ar H), 7.25 (dd, 1H, 3J = 
.8 Hz, 4J = 2.5 Hz, Ar H), 7.76 (dd, 1H, 3J = 8.5 Hz, 4J = 1.9 Hz, Ar H), 7.86 (d, 1H, 3J = 8.5 
1H, 3J = 8.5 Hz, Ar H), 7.94 (dd, 1H, 3J = 6.6 Hz, 4J = 1.6 Hz, Pyr. H-3, 
Y
White solid, mp 120 ºC.  
 
1H NMR (C
8.8 Hz, 4J = 2.2 Hz,
H
H), 8.04-8.06 (m, 1H, Pyr. H-4)
Pyr. H-2).  
 
IR max
MS: m/z = 236 (MH+).  
 
C16H13NO (235.29)·0.04H2O 
 
 
Calc. 81.68 5.57 5.95 
Obs. 81.10
 
4
 
Synthesized from 2-bromo-6-methoxy naphthalene 21a and 4-pyridylboronic acid 25. 
 
Purification: CC (dichloromethane/methanol 97:3). 
Yield: 60%. 
W
 
1H NMR (CDCl3): δ 3.9
8
Hz, Ar H), 7.90 (d, 
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Pyr. H-5), 8.15 (d, 1H, 4J = 1.9 Hz, Ar H), 8.75 (dd, 1H, 3J = 6.3 Hz, 4J = 1.3 Hz, Pyr. H-2, 
: νmax = 3040, 2938, 2840, 1699, 1621, 1488, 1210 cm-1.  
C H N 
 6.20 5.91 
-(6-Methoxy-2-naphthyl)pyrimidine (23)  
4%. 
hite solid, mp 155 ºC.  
.19 (d, 1H, 4J = 2.5 Hz, Ar H), 7.24 (dd, 1H, 3J = 
.8 Hz, J = 2.5 Hz, Ar H), 7.67 (dd, 1H, J = 8.5 Hz, 4J = 1.9 Hz, Ar H), 7.84 (d, 1H, 3J = 8.5 
r , 3J = 8.5 Hz, Ar H), 8.02 (d, 1H, 4J = 1.9 Hz, Ar H), 9.15 (s, 2H, Pyr. 
-4, Pyr. H-6), 9.26 (s, 1H, Pyr. H-2).  
1626, 1606, 1487, 1210 cm-1.  
alc. 75.48 5.18 11.74 
Pyr. H-6).  
 
IR
MS: m/z = 236 (MH+).  
 
C16H13NO (235.29) 
 
 
Calc. 81.68 5.57 5.95 
Obs. 81.59
 
5
 
Synthesized from 2-bromo-6-methoxy naphthalene 21a and 5-pyrimidylboronic acid 26. 
 
Purification: CC (dichloromethane/methanol 97:3). 
Yield: 2
W
 
1H NMR (CDCl3): δ 3.96 (s, 3H, OCH3), 7
4 38
Hz, A  H), 7.90 (d, 1H
H
 
IR: νmax = 3034, 2940, 1694, 
MS: m/z = 237 (MH+).  
 
C15H12N2O (236.28)·0.13H2O, C,H,N. 
 
 C H N 
C
Obs. 75.47 5.36 11.91 
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3-(2-Naphthyl)pyridine (27)  
 
Synthesized from 2-bromonaphthalene 27a and 3-pyridylboronic acid 24. 
 
Purification: CC (dichloromethane/methanol 97:3). 
ield: 82%. 
3): δ 7.43-7.45 (m, 1H, Pyr. H-5), 7.51-7.56 (m, 2H, Ar H), 7.71 (dd, 1H, 3J = 
r H), 7.88-7.90 (m, 2H, Ar H), 7.96 (d, 1H, 3J = 8.5 Hz, Ar H), 8.03-
.05 (m, 2H, Ar H, Pyr. H-4), 8.63 (dd, 1H, 3J = 4.7 Hz, 4J = 1.6 Hz, Pyr. H-6), 8.99 (dd, 1H, 
599, 1484 cm-1.  
S: m/z = 206 (MH+), 178, 151, 77, 51.  
15H11N (205.26)·0.04H2O 
C H N 
alc. 87.77 5.40 6.82 
pyridine (28)  
, 1H, 3J = 8.5 Hz, 4J = 1.6 Hz, Ar H), 
z, 4J = 1.6 Hz, Ar H), 7.79 (d, 1H, 3J = 8.5 Hz, Ar H), 7.89 (d, 1H, 3J 
 8.5 Hz, Ar H), 8.02 (d, 1H, 4J = 1.5 Hz, Ar H), 8.06 (d, 1H, 4J = 1.5 Hz, Ar H), 8.11 (dt, 1H, 
Y
White solid, mp 101 ºC.  
 
1H NMR (CDCl
8.5 Hz, 4J = 1.6 Hz, A
8
4J = 1.6 Hz, Pyr. H-2).  
 
IR: νmax = 3392, 3051, 3029, 1
M
 
C
 
 
C
Obs. 87.44 5.63 6.68 
 
3-(6-Bromo-2-naphthyl)
 
Synthesized from 2,6-dibromonaphthalene 28a and 3-pyridylboronic acid 24. 
 
Purification: CC (dichloromethane/methanol 98:2).  
Yield: 21%. 
White solid, mp 105 ºC.  
 
1H NMR (CDCl3): δ 7.53 (m, 1H, Pyr. H-5), 7.62 (dd
7.73 (dd, 1H, 3J = 8.5 H
=
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3J = 7.9 Hz, 4J = 1.6 Hz, Pyr. H-4), 8.65 (dd, 1H, 3J = 5.0 Hz, 4J = 1.6 Hz, Pyr. H-6), 8.99 (d, 
H, 4J = 1.6 Hz, Pyr. H-2).  
482 cm-1.  
S: m/z = 286-284 (MH+).  
84.16)·0.36H2O 
C H N 
ne 30a and 3-pyridylboronic acid 24. 
urification: CC (dichloromethane/methanol 98:2). 
p 106 ºC.  
 3H, 3J = 6.9 Hz, CH3), 4.18 (q, 2H, 3J = 6.9 Hz, CH2), 7.17 (d, 
(dd, 1H, 3J = 8.8 Hz, 4J = 2.5 Hz, Ar H), 7.54-7.56(m, 1H, Pyr. 
-5), 7.66 (dd, 1H, 3J = 8.5 Hz, 4J = 1.9 Hz, Ar H), 7.82 (d, 1H, 3J = 8.8 Hz, Ar H), 7.85 (d, 
9 Hz, Ar H), 8.16 (dt, 1H, 3J = 7.9 Hz, 4J = 1.6 Hz, 
yr. H-4), 8.61 (dd, 1H, 3J = 5.0 Hz, 4J = 1.6 Hz, Pyr. H-6), 8.99 (d, 1H, 4J = 2.5 Hz, Pyr. H-
: νmax = 3021, 2995, 1601, 1489, 1252 cm-1.  
Obs. 81.56 5.91 5.58 
1
 
IR: νmax = 3032, 2963, 1
M
 
C15H10BrN (2
 
 
Calc. 61.99 3.72 4.82 
Obs. 61.95 3.75 4.83 
 
3-(6-Ethoxy-2-naphthyl)pyridine (30)  
 
Synthesized from 2-ethyloxy-6-bromonaphthale
 
P
Yield: 86%. 
White solid, m
 
1H NMR (CDCl3): δ 1.51 (t,
1H, 4J = 2.5 Hz, Ar H), 7.21 
H
1H, 3J = 8.8 Hz, Ar H), 7.98 (d, 1H, 4J = 1.
P
2).  
 
IR
MS: m/z = 250 (MH+), 221.  
 
C17H15NO (249.32) 
 
 C H N 
Calc. 81.90 6.06 5.62 
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3-(6-Propoxy-2-naphthyl)pyridine (31)  
 
Synthesized from 2-propyloxy-6-bromonaphthalene 31a and 3-pyridylboronic acid 24. 
thane/methanol 98:2).  
ield: 84%. 
ºC.  
, 3J = 7.2 Hz, CH3), 1.89 (q, 2H, 3J = 6.6 Hz, CH2), 4.07 (t, 
d, 1H, 4J = 2.5 Hz, Ar H), 7.21 (dd, 1H, 3J = 8.8 Hz, 4J = 2.5 Hz, 
 H-5), 7.67 (dd, 1H, 3J = 8.5 Hz, 4J = 1.9 Hz, Ar H), 7.82 (d, 1H, 
 = 8.5 Hz, Ar H), 7.83 (d, 1H, 3J = 8.8 Hz, Ar H), 7.97 (d, 1H, 4J = 1.9 Hz, Ar H), 7.98 (dt, 
 3J = 4.7 Hz, 4J = 1.6 Hz, Pyr. H-6), 8.96 
, 1H, 4J = 2.5 Hz, Pyr. H-2).  
max 78, 1629, 1604, 1491, 1389, 1254 cm-1.  
S: m/z = 264 (MH+).  
63.34) 
C H N 
hthyl]pyridine (32)  
a and 3-pyridylboronic acid 24. 
urification: CC (dichloromethane/methanol 97:3).  
hite solid, mp 130 ºC.  
2H, CH2), 7.26 (d, 1H, 4J = 2.5 Hz, Ar H), 7.30 (dd, 1H, 3J = 7.6 
t, 1H, 3J = 7.6 Hz, Ar H), 7.42 (t, 2H, 3J = 7.6 Hz, Ar H), 7.48-
 
Purification: CC (dichlorome
Y
White solid, mp 116 
 
1H NMR (CDCl3): δ 1.10 (t, 3H
2H, 3J = 6.6 Hz, CH2), 7.17 (
Ar H), 7.38-7.40 (m, 1H, Pyr.
3J
1H, 3J = 7.9 Hz, 4J = 1.6 Hz, Pyr. H-4), 8.60 (dd, 1H,
(d
 
IR: ν  = 2967, 2934, 28
M
 
C H NO (218 17
 
 
Calc. 82.10 6.51 5.32 
Obs. 81.88 6.62 5.23 
 
3-[6-(Benzyloxy)-2-nap
 
Synthesized from 2-benzyloxy-6-bromonaphthalene 32
 
P
Yield 76% 
W
 
1H NMR (CDCl3): δ 5.22 (s, 
Hz, 4J = 2.5 Hz, Ar H), 7.36 (
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  EXPERIMENTAL SECTION  
7.51 (m, 1H, Pyr. H-5, Ar H), 7.67 (dd, 1H, 3J = 8.5 Hz, 4J = 1.9 Hz, Ar H), 7.84 (d, 1H, 3J = 
.5 Hz, Ar H), 7.85 (d, 1H, 3J = 8.5 Hz, Ar H), 7.99 (s, 1H, Ar H), 8.10 (dt, 1H, 3J = 7.8 Hz, 
2 (MH+), 221.  
22H17NO (311.39) 
ynthesized from 6-cyano-2-naphthyl trifluoromethanesulfonate 33a and 3-pyridylboronic 
r 2.5 hours.  
ne/methanol 98:2).  
 H-5), 7.68 (dd, 1H, 3J = 8.5 Hz, 4J = 1.6 Hz, Ar 
), 7.84 (dd, 1H, 3J = 8.5 Hz, 4J = 1.6 Hz, Ar H), 8.01 (d, 1H, 3J = 8.5 Hz, Ar H), 8.04 (d, 1H, 
 Hz, Pyr. 
-4), 8.28 (s, 1H, Ar H), 8.70 (dd, 1H, 3J = 4.9 Hz, 4J = 1.5 Hz, Pyr. H-6), 9.01 (d, 1H, 4J = 
29, 1469, 1424 cm-1.  
S: m/z = 231 (MH+).  
8
4J = 1.6 Hz, Pyr. H-4), 8.62 (dd, 1H, 3J = 5.0 Hz, 4J = 1.6 Hz, Pyr. H-6), 8.98 (d, 1H, 4J = 1.6 
Hz, Pyr. H-2).  
 
IR: νmax = 3040, 1604, 1490 cm-1.  
MS: m/z = 31
 
C
 
 C H N 
Calc. 86.86 5.50 4.50 
Obs. 86.58 5.66 4.44 
 
6-Pyridin-3-yl-2-naphthonitrile (33)  
 
S
acid 24. The reaction was stirred fo
 
Purification: CC (dichlorometha
Yield. 71%. 
White solid, mp 122 ºC.  
 
1H NMR (CDCl3): δ 7.53-7.56 (m, 1H, Pyr.
H
3J = 8.5 Hz, Ar H), 8.10 (d, 1H, 4J = 1.6 Hz, Ar H), 8.12 (dt, 1H, 3J = 7.9 Hz, 4J = 1.5
H
2.4 Hz, Pyr. H-2).  
 
IR: νmax = 3032, 2224, 16
M
 
C16H10N2 (230.17) 
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  EXPERIMENTAL SECTION  
 C H N 
Calc. 83.46 4.38 12.17 
Obs. 83.27 4.54 12.14 
-2-naphthyl)pyridine (34)  
chloro-2-methoxynaphthalene 34a and 3-pyridylboronic acid 
4. 
thane/methanol 97:3).  
hite solid, mp 150 ºC.  
DCl3): δ 4.07 (s, 3H, OCH3), 7.39 (d, 1H, 3J = 9.1 Hz, Ar H), 7.63-7.66 (m, 1H, 
H, 4J = 1.9 Hz, Ar H), 8.26 (dt, 1H, 3J = 8.1 Hz, 4J = 1.6 Hz, Pyr. H-4), 8.36 (d, 1H, 3J = 
.8 Hz, Ar H), 8.65 (dd, 1H, 3J = 5.0 Hz, 4J = 1.6 Hz, Pyr. H-6), 9.02 (d, 1H, 4J = 2.2 Hz, Pyr. 
max 44, 1602, 1490, 1275 cm-1.  
S: m/z = 272-270 (MH+), 255, 227, 192.  
 
. 71.25 4.48 5.19 
bs. 71.19 4.18 5.18 
-2-naphthyl)pyridine (35)  
-dibromo-2-methoxynaphthalene 35a and 3-pyridylboronic acid 24. 
ne/methanol 98:2). 
 
3-(5-Chloro-6-methoxy
 
Synthesized from 6-bromo-1-
2
 
Purification: CC (dichlorome
Yield: 93%. 
W
 
1H NMR (C
Pyr. H-5), 7.79 (dd, 1H, 3J = 8.8 Hz, 4J = 2.2 Hz, Ar H), 7.89 (d, 1H, 3J = 8.8 Hz, Ar H), 8.04 
(d, 1
8
H-2).  
 
IR: ν  = 3033, 2955, 28
M
C16H12ClNO (269.73) 
 
 C H N 
Calc
O
 
3-(5-Bromo-6-methoxy
 
Synthesized from 1,6
 
Purification: CC (dichlorometha
Yield: 66%. 
White solid, mp 162 ºC.  
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1H NMR (CDCl3): δ 4.07 (s, 3H, OCH3), 7.36 (d, 1H, 3J = 8.8 Hz, Ar H), 7.60-7.63 (m, 1H, 
yr. H-5), 7.79 (dd, 1H, 3J = 8.8 Hz, 4J = 2.2 Hz, Ar H), 7.92 (d, 1H, 3J = 8.8 Hz, Ar H), 8.02 
 8.36 (d, 1H, 3J = 
.8 Hz, Ar H), 8.65 (dd, 1H, 3J = 5.0 Hz, 4J = 1.6 Hz, Pyr. H-6), 9.01 (d, 1H, 4J = 2.2 Hz, Pyr. 
32, 1601, 1488, 1272 cm-1.  
S: m/z = 317-314 (MH+), 270, 227, 191, 163.  
alc. 61.17 3.85 4.46 
,3'-(2-methoxynaphthalene-1,6-diyl)dipyridine (36)  
ynthesized from 1,6-dibromo-2-methoxynaphthalene 35a and 3-pyridylboronic acid 24 (3 
hane/methanol 98:2). 
ield: 5%. 
r. H-5), 7.54-7.56 (m, 
H, Ar H, Pyr. H-5), 7.62 (dd, 1H, 3J = 8.8 Hz, 4J = 1.9 Hz, Ar H), 7.86 (dt, 1H, 3J = 7.9 Hz, 
r.H-4), 8.07 (d, 1H, 4J = 1.6 Hz, Ar H), 
 3J = 5.0 Hz, Pyr. H-6), 8.68 (s, 1H, Pyr. H-2), 8.70 (d, 1H, 3J = 5.0 Hz, Pyr. H-6), 
C11H8Br2O (315.99) 
P
(d, 1H, 4J = 1.9 Hz, Ar H), 8.22 (dt, 1H, 3J = 7.9 Hz, 4J = 2.2 Hz, Pyr. H-4),
8
H-2).  
 
IR: νmax = 3045, 2955, 28
M
 
C16H12BrNO (314.18) 
 
 C H N 
C
Obs. 61.57 4.18 4.35 
 
3
 
S
eq). 
 
Purification: CC (dichloromet
Y
White solid, mp 173 ºC.  
 
1H NMR (CDCl3): δ 3.89 (s, 3H, OCH3), 7.43-7.46 (m, 2H, Ar H, Py
2
4J = 1.9 Hz, Pyr. H-4), 8.01-8.04 (m, 2H, Ar H, Py
8.62 (d, 1H,
8.97 (s, 1H, Pyr. H-2).  
 
IR: νmax = 3031, 2950, 2842, 1599, 1488, 1258 cm-1.  
MS: m/z = 313 (MH+). 
 
 126
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3-(1,5-Dichloro-6-methoxy-2-naphthyl)pyridine (37)  
 
Synthesized from 1,5-dichloro-6-methoxy-2-naphthyl trifluoromethanesulfonate 37a and 3-
urification: CC (dichloromethane/methanol 98:2). 
hite solid, mp 153 ºC.  
3): δ 4.10 (s, 3H, OCH3), 7.48 (d, 1H, 3J = 9.1 Hz, Ar H), 7.50 (d, 1H, 3J = 8.8 
: νmax = 3060, 2940, 2830, 1617, 1487 cm-1.  
07H2O 
ethoxy-2-naphthyl)pyridine (38)  
romethanesulfonate 38a and 3-pyridylboronic 
/methanol 97:3). 
, OCH3), 7.18-7 21 (m, 2H, Ar H), 7.47-7.49 (m, 1H, Pyr. H-
), 7.54 (dd, 1H, 3J = 8.2 Hz, 4J = 1.6 Hz, Ar H), 7.78 (d, 1H, 3J = 8.2 Hz, Ar H), 7.88 (d, 1H, 
pyridylboronic acid 24. 
 
P
Yield: 41%. 
W
 
1H NMR (CDCl
Hz, Ar H), 7.69-7.71 (m, 1H, Pyr. H-5), 8.18 (dt, 1H, 3J = 7.9 Hz, 4J = 1.6 Hz, Pyr. H-4), 8.30 
(d, 1H, 3J = 8.8 Hz, Ar H), 8.37 (d, 1H, 3J = 9.1 Hz, Ar H), 8.73 (dd, 1H, 3J = 5.3 Hz, 4J = 1.6 
Hz, Pyr. H-6), 8.85 (d, 1H, 4J = 1.6 Hz, Pyr. H-2).  
 
IR
MS: m/z = 307-304 (MH+), 270, 227, 191, 163.  
 
C16H11Cl2NO (304.18)·0.
 
 C H N 
Calc. 62.93 3.77 4.59 
Obs. 62.93 4.16 4.54 
 
3-(7-M
 
Synthesized from 7-methoxy-2-naphthyl trifluo
acid 24. The reaction was stirred for 8 hours.  
 
Purification: CC (dichloromethane
Yield: 31%. 
White solid, mp 100 ºC.  
 
1H NMR (CDCl3): δ 3.95 (s, 3H
5
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  EXPERIMENTAL SECTION  
3J = 8.2 Hz, Ar H), 7.95 (d, 1H, 4J = 1.8 Hz, Ar H), 8.08 (dt, 1H, 3J = 7.8 Hz, 4J = 1.6 Hz, Pyr. 
-4), 8.63 (dd, 1H, 3J = 5.0 Hz, 4J = 1.6 Hz, Pyr. H-6), 8.99 (d, 1H, 4J = 2.5 Hz, Pyr. H-2).  
16H13NO (235.29) 
H N 
 
bs. 81.40 5.71 5.78 
ynthesized from 1-chloro-7-methoxy-2-naphthyl trifluoromethanesulfonate 39a and 3-
urification: CC (hexane/ethyl acetate, 80:20). 
hite solid, mp 95 ºC.  
H, OCH3), 7.26-7.29 (m, 2H, Ar H), 7.58-7.60 (m, 1H, Pyr. H-
r H), 7.80 (d, 1H, 3J = 8.8 Hz, Ar H), 7.82 (d, 1H, 3J = 8.8 Hz, 
r H), 8.06 (dt, 1H, 3J = 7.9 Hz, 4J = 1.6 Hz, Pyr. H-4), 8.70 (d, 1H, 3J = 5.0 Hz, Pyr. H-6), 
S: m/z = 272-270 (MH+), 255, 191.  
(269.73)·0.13H2O 
C H N 
 
H
 
IR: νmax = 3030, 2973, 2835, 1626 cm-1.  
MS: m/z = 236 (MH+), 221.  
 
C
 
 C 
Calc. 81.68 5.57 5.95
O
 
3-(1-Chloro-7-methoxy-2-naphthyl)pyridine (39)  
 
S
pyridylboronic acid 24.  
 
P
Yield: 18%. 
W
 
1H NMR (CDCl3): δ 4.00 (s, 3
5), 7.64 (d, 1H, 4J = 2.5 Hz, A
A
8.82 (s, 1H, Pyr. H-2).  
 
IR: νmax = 3020, 2932, 2878, 1677, 1506, 1225 cm-1.  
M
 
C16H12ClNO 
 
 
Calc. 70.61 4.54 5.15 
Obs. 70.60 4.58 5.06 
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3-(3-Methoxy-2-naphthyl)pyridine (40)  
 
Synthesized from 3-bromopyridine 24a and 2-methoxy-3-naphthylboronic acid 18a. The 
urs. 
urification: (dichloromethane/methanol 98:2). 
hite solid, mp 189 ºC. 
3H, OCH3), 7.25 (s, 1H, Ar H), 7.35-7.40 (m, 2H, Ar H, Pyr. H-
4J = 1.3 Hz, Ar H), 7.77 (s, 1H, Ar H), 7.78 (d, 1H, 3J = 8.2 Hz, 
r H), 7.81 (d, 1H, 3J = 8.2 Hz, Ar H), 7.93 (dt, 1H, 3J = 7.9 Hz, 4J = 1.9 Hz, Pyr. H-4), 8.60 
 (s, 1H, Pyr. H-2).  
max
S: m/z = 236 (MH+).  
HCl·0.26H O 
C H N 
l 6-pyridin-3-yl-2-naphthoate (41)  
nd 3-pyridylboronic acid 24.  
urification: CC (dichloromethane/methanol 98:2). 
hite solid, mp 147 ºC.  
 3H, OCH3), 7.35-7.37 (m, 1H, Pyr. H-5), 7.71 (dd, 1H, 3J = 8.5 
d, 1H, 3J = 8.5 Hz, Ar H), 7.94 (dt, 1H, 3J = 7.9 Hz, 4J = 1.6 Hz, 
yr. H-4), 8.00 (d, 1H, 3J = 8.5 Hz, Ar H), 8.01 (s, 1H, Ar H), 8.05 (dd, 1H, 3J = 8.5 Hz, 4J = 
reaction was stirred at 90°C for 4 ho
 
P
Yield: 31%. 
W
 
1H NMR (CDCl3): δ 3.94 (s, 
5), 7.48 (td, 1H, 3J = 8.2 Hz, 
A
(dd, 1H, 3J = 4.9 Hz, 4J = 1.8 Hz, Pyr. H-6), 8.85
 
IR: ν  = 3054, 2962, 2832, 1631, 1599, 1504, 1466, 1410, 1254 cm-1.  
M
 
C H NO (235.29)·16 13 2
 
 
Calc. 69.54 5.29 5.15 
Obs. 69.52 5.43 5.07 
 
Methy
 
Synthesized from methyl 6-bromo-2-naphthoate 41a a
 
P
Yield: 10%. 
W
 
1H NMR (CDCl3): δ 3.93 (s,
Hz, 4J = 1.9 Hz, Ar H), 7.89 (
P
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  EXPERIMENTAL SECTION  
1.9 Hz, Ar H), 8.58 (s, 1H, Ar H), 8.59 (dd, 1H, 3J = 5.0 Hz, 4J = 1.6 Hz, Pyr. H-6), 8.92 (d, 
H, 4J = 2.2 Hz, Pyr. H-2).  
max = 3052, 2952, 1718, 1598, 1499, 1292 cm-1.  
S: m/z = 264 (MH+).  
0.20H2O 
C H N 
 42a and 3-pyridylboronic acid 
methanol 98:2). 
3H, OCH3), 4.03 (s, 3H, OCH3), 7.25 (s, 1H, Ar H), 7.40-7.42 
, 1H, Pyr. H-5), 7.76 (dd, 1H, 3J = 8.5 Hz, 4J = 1.6 Hz, Ar H), 7.85 (d, 1H, 3J = 8.8 Hz, Ar 
, 1H, 4J = 1.6 Hz, Ar H), 8.37 (s, 
H, Ar H), 8.62 (dd, 1H, 3J = 4.7 Hz, 4J = 1.6 Hz, Pyr. H-6), 8.95 (d, 1H, 4J = 2.2 Hz, Pyr. H-
: νmax = 3005, 2946, 1714, 1699, 1607, 1483, 1212 cm-1.  
Obs. 73.48 5.40 4.75 
1
 
IR: ν
M
 
C17H13NO2 (263.30)·
 
 
Calc. 76.50 5.06 5.25 
Obs. 76.49 4.96 5.41 
 
Methyl 3-methoxy-7-pyridin-3-yl-2-naphthoate (42) 
 
Synthesized from methyl 7-bromo-3-methoxy-2-naphthoate
24.  
 
Purification: CC (dichloromethane/
Yield: 15%. 
Yellow solid, mp 95 ºC.  
 
1H NMR (CDCl3): δ 3.97 (s, 
(m
H), 7.97 (dt, 1H, 3J = 7.9 Hz, 4J = 1.6 Hz, Pyr. H-4), 8.01 (d
1
2).  
 
IR
MS: m/z = 294 (MH+).  
 
C18H15NO3 (293.33) 
 
 C H N 
Calc. 73.71 5.15 4.78 
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3-(9-Phenanthryl)pyridine (45)  
 
Synthesized from 9-bromophenanthrene 45a and 3-pyridylboronic acid 24.  
romethane/methanol 98:2). 
ield: 94%. 
m, 2H, Ar H, Pyr. H-5), 7.66 (td, 1H, 3J = 8.2 Hz, 4J = 1.3 Hz, 
H), 7.77 (dd, 1H, 3J = 8.2 Hz, 4J = 0.9 Hz, Ar H), 7.92 (dd, 1H, 
H), 8.03 (dt, 1H, 3J = 7.9 Hz, 4J = 1.9 Hz, Pyr. H-4), 8.73-8.76 
, 2H, Ar H, Pyr. H-6), 8.81 (d, 1H, 3J = 8.5 Hz, Ar H), 8.85 (d, 1H, 4J = 2.2 Hz, Pyr. H-2).  
: νmax = 3055, 1659, 1535, 1456, 1247 cm-1.  
H N (255.32) 
H N 
bs. 89.23 5.02 5.55 
ynthesized from 3-bromoquinoline 46a and 3-pyridylboronic acid 24. 
romethane/methanol 97:3). 
ield: 3%. 
ºC.  
(m, 1H, Pyr. H-5), 7.62 (td, 1H, 3J = 8.2 Hz, 4J = 1.6 Hz, Ar 
 4J = 1.6 Hz, Ar H), 7.91 (d, 1H, 3J = 7.6 Hz, Ar H), 8.02 (dt, 1H, 
 H-4), 8.16 (d, 1H, 3J = 8.2 Hz, Ar H), 8.33 (d, 1H, 4J = 2.2 Hz, 
 
Purification: CC (dichlo
Y
White solid, mp 129 ºC.  
 
1H NMR (CDCl3): δ 7.56-7.61 (
Ar H), 7.70-7.74 (m, 3H, Ar 
3J = 7.9 Hz, 4J = 1.6 Hz, Ar 
(m
 
IR
MS: m/z = 256 (MH+).  
 
C19 13
 
 C 
Calc. 89.38 5.13 5.49 
O
 
3-Pyridin-3-yl-quinoline (46)  
 
S
 
Purification: CC (dichlo
Y
Beige solid, mp 103 
 
1H NMR (CDCl3): δ 7.45-7.48 
H), 7.77 (td, 1H, 3J = 8.5 Hz,
3J = 7.9 Hz, 4J = 2.2 Hz, Pyr.
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Ar H), 8.69 (dd, 1H, 3J = 4.7 Hz, 4J = 1.3 Hz, Pyr. H-6), 8.98 (d, 1H, 4J = 2.5 Hz, Pyr. H-2), 
.16 (d, 1H, 4J = 2.2 Hz, Ar H).  
S: m/z = 207 (MH+). 
.25) 
-Pyridin-3-yl-quinoline hydrochloride salt (47)  
9:1). 
hite solid, mp 180 ºC. 
H NMR (CDCl3): δ 7.68 (td, 1H, 3J = 7.9 Hz, 4J = 0.9 Hz, Ar H), 7.86 (td, 1H, 3J = 8.5 Hz, 4J 
3J = 8.2 Hz, 4J = 0.9 Hz, Ar H), 8.11-8.14 (m, 1H, Pyr. H-5), 
H), 8.34 (d, 1H, 3J = 8.5 Hz, Ar H), 8.57 (d, 1H, 3J = 8.5 Hz, Ar 
Pyr. H-4), 9.34 (d, 1H, 3J = 8.2 Hz, Pyr. H-6), 9.67 (s, 1H, Pyr. 
-2).  
53, 2931, 1596, 1548, 1506 cm-1. 
S: m/z = 207 (MH+).  
H N  (206.25)·HCl·0.83H2O 
C H N 
9
 
IR: νmax = 3055, 2930, 1494 cm-1.  
M
 
C14H10N2 (206
 
2
 
Synthesized from 2-bromoquinoline 47a and 3-pyridylboronic acid 24. After purification, the 
product was dissolved in of diethyl ether (4 mL) and one equivalent of HCl in diethyl ether 
(1M) was added. The resulting precipitate was filtered and washed thoroughly with diethyl 
ether. 
 
Purification: CC (dichloromethane/methanol 9
Yield: 43%. 
W
 
1
= 1.6 Hz, Ar H), 7.95 (dd, 1H, 
8.17 (d, 1H, 3J = 8.5 Hz, Ar 
H), 8.87 (d, 1H, 3J = 5.4 Hz, 
H
 
IR: νmax = 30
M
 
C14 10 2
 
 
Calc. 65.27 4.95 10.87 
Obs. 65.02 4.91 10.67 
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2-Pyridin-3-yl-quinoxaline hydrochloride salt (48)  
 
Synthesized from 2-bromoquinoxaline 48a and 3-pyridylboronic acid 24. After purification, 
the product was dissolved in diethyl ether (4 mL) and one equivalent of HCl in diethyl ether 
(1M) is added. The resulting precipitate was filtered and washed thoroughly with diethyl 
ether. 
 
Purification: CC (dichloromethane/methanol 99:1).  
Yield: 44%. 
White solid, mp 233 ºC.  
3): δ 7.79-7.82 (m, 2H, Ar H), 8.07-8.12 (m, 2H, Ar H), 8.14-8.17 (m,1H, 
yr. H-5), 8.92 (d, 1H, 3J = 5.0 Hz, Pyr. H-4), 9.33 (d, 1H, 3J = 7.9 Hz, Pyr. H-6), 9.46 (s, 1H, 
: νmax = 3066, 1604, 1547, 1499, 1313 cm-1.  
l·0.02H2O 
alc. 64.07 4.14 17.24 
-2-yl)pyridine (50)  
ynthesized from 2-bromo-1H-indene 50a and 3-pyridylboronic acid 24. 
urification: CC (dichloromethane/methanol 99:1).  
C.  
H NMR (CDCl3): δ 3.81 (s, 2H, H-3), 7.23 (td, 1H, 3J = 7.2 Hz, 4J = 0.9 Hz, Ar H), 7.29-
, 3H, H-1, Ar H, Pyr. H-5), 7.44 (d, 1H, 3J = 7.2 Hz, Ar H), 7.50 (d, 1H, 3J = 7.2 Hz, 
 
1H NMR (CDCl
P
Pyr. H-2), 9.71 (s, 1H, Ar H).  
 
IR
MS: m/z = 208 (MH+), 181, 102, 75, 51.  
 
C13H9N3 (207.24)·HC
 
 C H N 
C
Obs. 63.98 4.74 16.97 
 
3-(1H-Inden
 
S
 
P
Yield: 51%. 
Beige solid, mp 102 º
 
1
7.32 (m
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  EXPERIMENTAL SECTION  
Ar H), 7.89 (dt, 1H, 3J = 8.1 Hz, 4J = 1.9 Hz, Pyr. H-4), 8.50 (s, 1H, Pyr. H-6), 8.90 (s, 1H, 
yr. H-2).  
: νmax = 3054, 2916, 1533 cm-1.  
4 (MH+). 
14H11N (193.25) 
C H N 
bs. 87.10 5.51 6.84 
-(3,4-Dihydronaphthalen-2-yl)pyridine (51)  
 3-bromo-1,2-dihydronaphthalene 51a and 3-pyridylboronic acid 24. 
ield: 62%.  
, 1485, 1421 cm .  
S: m/z = 208 (MH+), 179, 101, 79. 
.28)·HCl·0.24H2O 
H N 
alc. 72.64 5.88 5.65 
O
 
P
 
IR
MS: m/z = 19
 
C
 
 
Calc. 87.01 5.74 7.25 
O
 
3
 
Synthesized from
 
Purification: CC (dichloromethane/methanol 97:3). 
Y
White solid, mp 199 °C (HCl salt). 
 
1H NMR (CDCl3): δ 2.73 (t, 2H, 3J = 8.3 Hz, H-4), 2.97 (t, 2H, 3J = 7.8 Hz, H-3), 6.89 (s, 1H, 
H-1), 7.13-7.19 (m, 4H, Ar H), 7.32-7.34 (m, 1H, Pyr H-5), 7.85 (td, 1H, 3J = 8.1 Hz, 4J = 1.5 
Hz, Pyr H-4), 8.49 (dd, 1H, 3J = 4.9 Hz, 4J = 1.5 Hz, Pyr H-2), 8.79 (d, 1H, 4J = 1.9 Hz, Pyr 
H-6).  
 
IR: νmax = 3022, 2935, 2885, 2831 -1
M
 
C15H13N (207
 
 C 
C
bs. 73.04 6.28 5.56 
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3-(6-Methoxy-3,4-dihydronaphthalen-2-yl)pyridine (53)  
o-7-methoxy-1,2-dihydronaphthalene 53a and 3-pyridylboronic acid 
4. 
urification: CC (dichloromethane/methanol 99:1). 
ellow solid, mp 80 ºC.  
Cl3): δ 2.73 (t, 2H, 3J = 8.5 Hz, H-3), 2.96 (t, 2H, 3J = 8.5 Hz, H-4), 3.82 (s, 3H, 
-6.75 (m, 2H, Ar H), 6.88 (s, 1H, H-1), 7.10 (d, 1H, 3J = 8.2 Hz, Ar H), 7.32-7.35 
, 1H, Pyr. H-5), 7.86 (dt, 1H, 3J = 8.2 Hz, 4J = 1.6 Hz, Pyr. H-4), 8.48 (dd, 1H, 3J = 4.7 Hz, 
: νmax = 3021, 2936, 2834, 1607, 1570, 1499, 1250 cm-1.  
0.03H2O 
alc. 80.78 6.38 5.89 
ridine (54)  
 3-bromo-6-methoxy-1,2-dihydronaphthalene 54a and 3-pyridylboronic acid 
. The reaction was stirred for 2 hours. 
p 168 °C (HCl salt). 
H NMR (CDCl3): δ 2.74 (t, 2H, J = 8.2 Hz, H-3), 2.92 (t, 2H, 3J = 8.2 Hz, H-4), 3.81 (s, 3H, 
87 (s, 1H, H-1), 7.09 (d, 1H, 3J = 8.2 Hz, Ar H), 7.35-7.38 
 
Synthesized from 3-brom
2
 
P
Yield: 89%. 
Y
 
1H NMR (CD
OCH3), 6.73
(m
4J = 1.6 Hz, Pyr. H-6), 8.79 (d, 1H, 4J = 2.5 Hz, Pyr. H-2).  
 
IR
MS: m/z = 238 (MH+), 223, 194,165. 
 
C16H15NO (237.30)·HCl·
 
 C H N 
C
Obs. 80.77 6.82 5.84 
 
3-(7-Methoxy-3,4-dihydronaphthalen-2-yl)py
 
Synthesized from
24
 
Purification: CC (dichloromethane/methanol 99:1). 
Yield: 79%.  
Yellow solid, m
 
1 3
OCH3), 6.73-6.75 (m, 2H, Ar H), 6.
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(m, 1H, Pyr. H-5), 7.88 (dt, 1H, 3J = 7.8 Hz, 4J = 1.9 Hz, Pyr. H-4), 8.51 (dd, 1H, 3J = 5.0 Hz, 
 = 1.6 Hz, Pyr. H-6), 8.80 (d, 1H, 4J = 1.6 Hz, Pyr. H-2).  
: νmax = 3025, 2934, 2833, 1604, 1571, 1497, 1255, 1040 cm-1.  
7.30)·HCl·0.79H2O 
 (55)  
ethoxy-1,2-dihydronaphthalene 53a and 4-pyridylboronic acid 
5. The reaction was stirred for 2 hours. 
 CC (dichloromethane/methanol 97:3). 
3 3  3.77 (s, 3H, 
CH3), 6.69-6.71 (m, 2H, Ar H), 7.09-7.11 (m, 2H, H-1, Ar H), 7.53 (dd, 1H, J = 6.6 Hz, 4J 
3 4
H N 
6.37 5.90 
6.33 5.83 
 
4J
 
IR
MS: m/z = 238 (MH+). 
 
C16H15NO (23
 
 C H N 
Calc. 66.64 6.14 4.86 
Obs. 66.56 6.06 4.82 
 
4-(6-Methoxy-3,4-dihydronaphthalen-2-yl)pyridine
 
Synthesized from 3-bromo-7-m
2
 
Purification:
Yield: 51%. 
Yellow solid, mp 108 ºC.  
 
1H NMR (CDCl3): δ 2.66 (t, 2H, J = 8.5 Hz, H-3), 2.91 (t, 2H, J = 8.5 Hz, H-4),
3O
= 1.6 Hz, Pyr. H-3, Pyr. H-5), 8.49 (dd, 1H, J = 6.6 Hz, J = 1.6 Hz, Pyr. H-2, Pyr. H-6).  
 
IR: νmax = 3040, 2939, 2835, 1599, 1504, 1209 cm-1.  
MS: m/z = 238 (MH+). 
 
C16H15NO (237.30) 
 
 C 
Calc. 80.98 
Obs. 80.93 
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3-(4-Methyl-3,4-dihydronaphthalen-2-yl)pyridine (59)  
ynthesized from 3-bromo-1-methyl-1,2-dihydronaphthalene 59a and 3-pyridylboronic acid 
tirred for 3 hours. 
urification: CC (dichloromethane/methanol 97:3). 
ellow solid, mp 189 °C (HCl salt). 
3): δ 1.32 (d, 3H, 3J = 6.9 Hz, CH3), 2.54 (ddd, 1H, 2J = 16.1 Hz, 3J = 7.6 Hz, 
-4), 8.52 (dd, 1H, 3J = 4.7 Hz, 4J = 1.6 Hz, Pyr. H-6), 8.82 
, 1H, 4J = 2.0 Hz, Pyr. H-2).  
63, 2854, 1613, 1518, 1231 cm-1
2 (MH+),203, 178, 77. 
alc. 73.62 6.32 5.37 
ethod 15 
24-26 were prepared according to the literature (Li et al., 2002). 
n-Butyllithium (2.5 M in hexanes, 19.2 mL, 48.0 mmol) was added dropwise via a septum 
 
S
24. The reaction was s
 
P
Yield: 68%.  
Y
 
1H NMR (CDCl
4J = 0.9 Hz, H-3), 2.87 (ddd, 1H, 2J = 16.1 Hz, 3J = 6.6 Hz, 4J = 1.6 Hz, H-3’), 3.11-3.17 (m, 
1H, H-4), 6.89 (s, 1H, H-1), 7.16-7.24 (m, 4H, Ar H), 7.33-7.35 (m, 1H, Pyr. H-5), 7.86 (td, 
1H, 3J = 8.1 Hz, 4J = 1.5 Hz, Pyr. H
(d
 
IR: νmax = 29
MS: m/z = 22
 
C16H15N (221.30)·HCl·0.18H2O 
 
 C H N 
C
Obs. 73.61 6.50 5.46 
 
 
M
 
Compounds 
 
3-Pyridylboronic acid (24) 
 
A three-necked flask was charged with 3-bromopyridine 24a (3.86 mL, 40.0 mmol) and 
triisopropyl borate (11.08 mL, 48.00 mmol) in toluene (64 mL) and THF (16 mL) and put 
under a nitrogen atmosphere. The mixture was cooled to -40°C using a dry ice/acetone bath. 
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and the mixture was stirred for an additional 0.5 h while the temperature was held at -40°C. 
The reaction was allowed to warm to -20°C before a 2N HCl solution (40 mL) was added. 
hen the mixture reached room temperature, the aqueous layer was separated and its pH was 
 solution. A white solid product precipitated as the pH 
. This mixture was saturated with NaCl (10 g) and extracted three times with 
 extracts were evaporated in vacuo to provide a solid. This solid was taken up 
 acetonitrile (16 mL) for crystallization. The resulting slurry was heated to 70°C, stirred for 
hite solid. 
H3OD): δ 7.74 (br s, 1H, Ar H), 8.44 (br s, 1H, Ar H), 8.55 (dd, 1H, 3J = 8.5 Hz, 
67 (br s, 1H, Ar H).  
m 4-bromopyridine 25a.  
3 (d, 2H, 3J = 6.6 Hz, Ar H). 
W
adjusted to 7 using a 5N NaOH
approached 7
THF. The THF
in
30 min and allowed to cool slowly to room temperature. After the slurry was stirred at 0°C for 
30 min, the solid was filtered off, washed with cold acetonitrile and dried in a desiccator. 
 
Yield: 85%. 
W
 
1H NMR (C
4J = 1.9 Hz, Ar H), 8.
 
IR: νmax = 3356, 1608, 1352, 1310 cm-1.  
 
C5H6BNO2 (122.92) 
 
4-Pyridylboronic acid (25) 
 
Synthesized fro
 
Yield: 70%. 
White solid. 
 
1H NMR (CH3OD): δ 8.07 (d, 2H, 3J = 6.3 Hz, Ar H), 8.5
 
IR: νmax = 3312, 1621, 1312 cm-1.  
 
C5H6BNO2 (122.92) 
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5-Pyrimidylboronic acid (26) 
 
Synthesized from 5-bromopyrimidine 26a.  
 
Yield: 64%. 
Brown solid. 
 
1H NMR (CH3OD): δ 8.71 (s, 2H, Ar H), 8.65 (s, 1H, Ar H).  
ethod 16 
-Cyano-2-naphthyl trifluoromethanesulfonate (33a) 
n of 6-cyano-2-naphthol 33b (0.5 g, 2.96 mmol) and pyridine (0.39 mL, 4.73 
mol) in dichloromethane/acetonitrile (15 mL/10 mL) at 0°C under nitrogen atmosphere was 
.65 mL, 3.84 mmol). The solution was 
llowed to slowly warm to room temperature and stirred overnight. The solution was cooled 
urification: CC (hexane/ethyl acetate 80:20). 
DCl3): δ 7.52 (dd, 1H, 3J = 8.8 Hz, 4J = 2.5 Hz, Ar H), 7.73 (dd, 1H, 3J = 8.5 Hz, 
4J = 1.6 Hz, Ar H), 7.83 (d, 1H, 4J = 2.5 Hz, Ar H), 7.99 (d, 1H, 3J = 8.5 Hz, Ar H) 8.02 (d, 
1H, 3J = 8.8 Hz, Ar H), 8.30 (s, 1H, Ar H). 
 
IR: νmax = 3315, 2959, 1667, 1406 cm-1.  
 
C4H5BN2O2 (123.91) 
 
 
M
 
6
 
To a solutio
m
added slowly trifluoromethanesulfonic anhydride (0
a
to 0°C and stirred with ice water to decompose excess anhydride. The mixture was made 
slightly basic with saturated NaHCO3 solution. The aqueous layer was extracted with 
dichloromethane and the combined organic layers were washed with water, dried (MgSO4), 
filtered and evaporated in vacuo. 
 
P
Yield: 60%. 
Yellow oil. 
 
1H NMR (C
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IR: νmax = 2232, 1632, 1427, 1216, 1140 cm-1. 
 
C12H6F3NO3S (301.25) 
 
1,5-Dichloro-6-methoxy-2-naphthyl trifluoromethanesulfonate (37a) 
ichloro-6-methoxy-2-naphthalen-2-ol 37b. 
ield: 30%. 
 3J = 8.8 Hz, Ar H), 8.26 (d, 1H, 3J = 8.8 Hz, Ar H). 
 1427, 1216, 1139 cm-1. 
 (340.71) 
hol 38b. 
ield: 88%. 
DCl3): δ 3.94 (s, 3H, OCH3), 7.14 (d, 1H, 4J = 2.5 Hz, Ar H), 7.21 (dd, 1H, 3J = 
2.5 Hz, Ar H), 7.22 (dd, 1H, 3J = 9.1 Hz, 4J = 2.5 Hz, Ar H), 7.64 (d, 1H, 4J = 2.5 
z, Ar H), 7.77 (d, 1H, 3J = 9.1 Hz, Ar H), 7.83 (d, 1H, 3J = 9.1 Hz, Ar H). 
: νmax = 3011, 2946, 2840, 1633, 1420, 1208, 1139 cm-1. 
 
Synthesized from 1,5-d
 
Purification: CC (hexane/ethyl acetate 80:20). 
Y
Yellow oil. 
 
1H NMR (CDCl3): δ 4.08 (s, 3H, OCH3), 7.48 (d, 1H, 3J = 8.8 Hz, Ar H), 7.50 (d, 1H, 3J = 8.8 
Hz, Ar H), 8.24 (d, 1H,
 
IR: νmax = 3025, 2942, 2835, 1599,
 
C12H8ClF3O4S
 
7-Methoxy-2-naphthyl trifluoromethanesulfonate (38a) 
 
Synthesized from 7-methoxy-2-napht
 
Purification: CC (hexane/ethyl acetate 90:10). 
Y
Colorless oil. 
 
1H NMR (C
9.1 Hz, 4J = 
H
 
IR
 
C12H9F3O4S (306.26) 
 140
  EXPERIMENTAL SECTION  
1-Chloro-7-methoxy-2-naphthyl trifluoromethanesulfonate (39a).  
 
Synthesized from 1-chloro-7-methoxy-naphthalen-2-ol 39b  
 
Purification: CC (hexane/ethyl acetate 90:10).  
), 7.76 (d, 1H, 3J = 9.1 Hz, Ar H), 
.78 (d, 1H, 3J = 8.8 Hz, Ar H).  
: νmax = 3009, 2945, 2834, 1628, 1423, 1206 cm-1. 
12H8ClF3O4S (340.71) 
 suspension of 6-methoxy-2-naphthol 37c (0.48 g, 2.77 mmol) and N-chlorosuccinimide 
 (15 mL) was stirred at room temperature overnight. Extra 
inimide (0.19 g, 1.50 mmol) was added and the reaction was further stirred at 
ure for 4 hours. The resulting solution was evaporated in vacuo. 
hite solid. 
DCl3): δ 4.03 (s, 3H, OCH3), 7.34 (d, 1H, 3J = 9.4 Hz, Ar H), 7.38 (d, 1H, 3J = 9.4 
, 3J = 9.4 Hz, Ar H), 8.12 (d, 1H, 3J = 9.4 Hz, Ar H). 
Yield: 52%.  
Colorless oil. 
 
1H NMR (CDCl3): δ 3.99 (s, 3H, OCH3), 7.26 (dd, 1H, 3J = 8.8 Hz, 4J = 2.5 Hz, Ar H), 7.30 
(d, 1H, 3J = 8.8 Hz, Ar H), 7.54 (d, 1H, 4J = 2.5 Hz, Ar H
7
 
IR
 
C
 
 
Method 17 
 
1,5-Dichloro-6-methoxy-2-naphthalen-2-ol (37b) 
 
Compound 37b was prepared according to the literature (Mewshaw et al., 2003). 
 
A
(0.41 g, 3.05 mmol) in acetonitrile
N-chlorosucc
room temperat
 
Purification: CC (hexane/ethyl acetate 80:20). 
Yield: 36%. 
W
 
1H NMR (C
Hz, Ar H), 8.01 (d, 1H
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IR: νmax = 3317, 1601, 1501, 1344, 1278, 1252 cm-1. 
S: m/z = 244 (MH+), 242, 240, 225, 112. 
11H8Cl2O2 (243.09) 
 suspension of 7-methoxy-2-naphthol 39c (0.75 g, 4.30 mmol) and N-chlorosuccinimide 
 (15 mL) was heated to reflux for 3 h. The resulting 
evaporated in vacuo. 
urification: CC (hexane/ethyl acetate 90:10).  
DCl3): δ 3.97 (s, 3H, OCH3), 7.04 (dd, 1H, 3J = 8.8 Hz, 4J = 2.4 Hz, Ar H), 7.11 
 Ar H), 7.62 (d, 1H, 3J = 8.8 Hz, Ar H), 
.67 (d, 1H, 3J = 8.8 Hz, Ar H).  
: νmax = 3379, 2832, 1609, 1174 cm-1. 
208.61) 
ethod 19 
0 minutes, ethyl bromide (1.03 g, 
.44 mmol) was added and the mixture was stirred at 100°C for 3.5 h. After cooling, water 
M
 
C
 
 
Method 18 
 
1-Chloro-7-methoxy-naphthalen-2-ol (39b)  
 
A
(0.63 g, 4.73 mmol) in acetonitrile
solution was 
 
P
Yield: 46%. 
White solid. 
 
1H NMR (C
(d, 1H, 3J = 8.8 Hz, Ar H), 7.33 (d, 1H, 4J = 2.4 Hz,
7
 
IR
 
C11H9ClO2 (
 
 
M
 
2-Ethyloxy-6-bromonaphthalene (30a). 
 
To a solution of 6-bromo-2-naphthol 49 (2.0 g, 8.58 mmol) in DMF (100 mL) under nitrogen 
atmosphere was added K2CO3 (2.96 g, 21.45 mmol). After 1
9
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was added and the resulting precipitate was filtered off, washed with water and dried in the 
sed without further purification. 
.16 (dd, 1H, 3J = 8.8 Hz, 4J = 2.5 Hz, Ar H), 7.48 (dd, 1H, 3J = 8.8 
z, 4J = 2.2 Hz, Ar H), 7.58 (d, 1H, 3J = 8.8 Hz, Ar H), 7.64 (d, 1H, 3J = 8.8 Hz, Ar H), 7.91 
: νmax = 2981, 1624, 1589, 1207 cm-1. 
12H11BrO (251.12) 
halene (31a). 
ynthesized from 6-bromo-2-naphthol 49 and propyl bromide. 
t further purification. 
ield: 70%. 
3  7.2 Hz, CH3), 1.87 (q, 2H, 3J = 6.9 Hz, CH2), 4.03 (t, 
3J = 6.9 Hz, CH ), 7.08 (d, 1H, 4J = 2.5 Hz, Ar H), 7.16 (dd, 1H, 3J = 8.8 Hz, 4J = 2.5 Hz, 
H BrO (265.15) 
dessicator. 
 
U
Yield: 96%.  
Yellow solid. 
 
1H NMR (CDCl3): δ 1.48 (t, 3H, 3J = 6.9 Hz, CH3), 4.14 (q, 2H, 3J = 6.9 Hz, CH2), 7.08 (d, 
1H, 4J = 2.5 Hz, Ar H), 7
H
(d, 1H, 4J = 1.9 Hz, Ar H).  
 
IR
 
C
 
2-Propyloxy-6-bromonapht
 
S
 
Used withou
Y
Yellow solid. 
 
1H NMR (CDCl ): δ 1.08 (t, 3H, 3J =
2H, 2
Ar H), 7.48 (dd, 1H, 3J = 8.5 Hz, 4J = 1.9 Hz, Ar H), 7.58 (d, 1H, 3J = 8.8 Hz, Ar H), 7.64 (d, 
1H, 3J = 8.8 Hz, Ar H), 7.91 (d, 1H, 4J = 1.9 Hz, Ar H).  
 
IR: νmax = 2926, 1628, 1591, 1208, 913, 742 cm-1. 
 
C13 13
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2-Benzyloxy-6-bromonaphthalene (32a).  
 
Synthesized from 6-bromo-2-naphthol 49 and benzyl chloride.  
 
Used without further purification. 
.17 (s, 2H, CH2), 7.19 (d, 1H, 4J = 2.5 Hz, Ar H), 7.25 (dd, 1H, 3J = 8.9 
z, 4J = 2.5 Hz, Ar H), 7.35 (t, 1H, 3J = 7.6 Hz, Ar H), 7.41 (t, 2H, 3J = 7.6 Hz, Ar H), 7.48 
 (d, 1H, 3J = 8.8 Hz, Ar H), 7.63 (d, 1H, 3J = 9.1 Hz, Ar H), 
, 7.92 (d, 1H, 4J = 2.2 Hz, Ar H).  
: νmax = 3042, 2962, 1586, 1257, 1203 cm-1. 
17H13BrO (313.20) 
hoxynaphthalene (34a).  
A
 ethyl acetate was added to the crude 
roduct. The precipitate was filtered off and the filtrate was evaporated in vacuo.  
/ethyl acetate 90:10).  
ield: 94%.  
Yield: 86%. 
Beige solid. 
 
1H NMR (CDCl3): δ 5
H
(t, 2H, 3J = 8.2 Hz, Ar H), 7.59
7.67 (d, 1H, 3J = 8.8 Hz, Ar H)
 
IR
 
C
 
 
Method 20 
 
6-Bromo-1-chloro-2-met
 
 suspension of 2-bromo-6-methoxynaphthalene 21a (0.50 g, 2.11 mmol) and freshly 
recrystallized N-chlorosuccinimide (0.39 g, 2.91 mmol) in THF (15 ml) was heated to reflux 
for 3 h. Extra N-chlorosuccinimide (0.15 g, 1.00 mmol) was added and the reaction was 
further refluxed for 3 h. After evaporation of the solvent,
p
 
Purification: CC (hexane
Y
Yellow solid. 
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1H NMR (CDCl3): δ 4.03 (s, 3H, OCH3), 7.31 (d, 1H, 3J = 9.1 Hz, Ar H), 7.61 (dd, 1H, 3J = 
.1 Hz, 4J = 2.2 Hz, Ar H), 7.68 (d, 1H, 3J = 9.1 Hz, Ar H), 7.94 (d, 1H, 4J = 2.0 Hz, Ar H), 
r H).  
ynthesized from 2-bromo-6-methoxynaphthalene 21a and N-bromosuccinimide. The 
ure for 2 h. The resulting solution was partly evaporated 
 adding hexane, the wanted compound precipitated and was filtered off, washed 
pen air.  
CH3), 7.29 (d, 1H, 3J = 8.8 Hz, Ar H), 7.61 (dd, 1H, 3J = 
.1 Hz, 4J = 1.9 Hz, Ar H), 7.73 (d, 1H, 1H, 3J = 8.8 Hz, Ar H), 7.94 (d, 1H, 4J = 1.9 Hz, Ar 
 9.1 Hz, Ar H).  
587, 1272 cm-1. 
,7-Dibromo-3-hydroxy-2-naphthoic acid (42c) 
cid 42d (5.0 g, 26.57 mmol) was suspended in glacial acetic acid (50 
L) and cooled to 0°C. To this stirred mixture was added dropwise a solution of bromine 
9
8.08 (d, 1H, 3J = 9.1 Hz, A
 
IR: νmax = 2924, 2841, 1586, 1494, 1274 cm-1. 
 
C11H8BrClO (271.54) 
 
2,5-Dibromo-6-methoxynaphthalene (35a).  
 
S
reaction was stirred at room temperat
in vacuo. By
and dried at o
 
Used without further purification. 
Yield: 70%.  
Yellow solid. 
 
1H NMR (CDCl3): δ 4.03 (s, 3H, O
9
H), 8.09 (d, 1H, 3J =
 
IR: νmax = 3060, 2939, 2841, 1
 
C11H8Br2O (315.99) 
 
 
Method 21 
 
4
 
3-Hydroxy-2-naphthoic a
m
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(10.62 g, 66.42 mmol) in glacial acetic acid (25 mL) while keeping the reaction temperature 
elow 5°C. The reaction was refluxed for 2 h, cooled and poured into ice water (500 mL). The 
off, washed with water and ether and air-dried. 
sed without further purification. 
ellow solid. 
D3OD): δ 7.77 (dd, 1H, 3J = 9.1 Hz, 4J = 1.8 Hz, Ar H), 8.08 (d, 1H, 3J = 9.1 Hz, 
ydroxy-2-naphthoic acid (42b) 
). The yellow product was 
ed off, washed with water and air-dried. 
sed without further purification. 
ellow solid. 
D3OD): δ 7.47 (s, 1H, Ar H), 7.77 (dd, 1H, 3J = 8.8 Hz, 4J = 1.9 Hz, Ar H), 7.84 
). 
, 1504, 1269 cm-1. 
67.08) 
b
product was filtered 
 
U
Yield: 75%. 
Y
 
1H NMR (C
Ar H), 8.16 (d, 1H, 4J = 1.8 Hz, Ar H), 8.57 (s, 1H, Ar H). 
 
IR: νmax = 3394, 3061, 1671, 1280 cm-1. 
 
C11H6Br2O3 (345.98) 
 
Method 22 
 
7-Bromo-3-h
 
The dibromo acid 42c (6.90 g, 19.94 mmol) was suspended in glacial acetic acid (100 mL) 
and 10 N HCl (30 mL) and tin powder (2.37 g, 19.94 mmol) were added. The reaction 
mixture was refluxed for 3h, cooled and diluted with water (100 mL
filter
 
U
Yield: 75%. 
Y
 
1H NMR (C
(d, 1H, 3J = 8.8 Hz, Ar H), 8.26 (s, 1H, Ar H), 8.69 (s, 1H, Ar H
 
IR: νmax = 3259, 3062, 1661
 
C11H7BrO3 (2
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Method 23 
 
Methyl 7-bromo-3-methoxy-2-naphthoate (42a) 
 
The bromo acid 42b (4.00 g, 14.98 mmol), K2CO3 (9.94 g, 71.91 mmol) and dimethyl sulfate 
(4.31 g, 34.16 mmol) in dry acetone (100 mL) were refluxed for 4 hours. The reaction was 
cooled, water (10 mL) was added and the mixture was stirred for 2 hours at 30°C to destroy 
ny remaining dimethyl sulfate. The precipitate was filtered off and the acetone was 
 dichloromethane, washed several times with 
ater, dried (MgSO4), filtered and evaporated in vacuo.  
urification: CC (dichloromethane). 
hite solid. 
DCl3): δ 3.96 (s, 3H, OCH3), 3.99 (s, 3H, OCH3), 7.17 (s, 1H, Ar H), 7.57 (dd, 
, 3J = 8.8 Hz, Ar H), 7.96 (d, 1H, 4J = 1.9 Hz, 
s, 1H, Ar H). 
: νmax = 2951, 2839, 1733, 1627, 1586, 1494 cm-1. 
ethod 24 
-Pyridin-3-yl-naphthalen-2-ol (29)  
Br3 (2.55 mL, 2.55 mmol) was slowly added to compound 21 (150 mg, 0.64 mmol) in dry 
n stirring, the cooling was 
topped and the reaction was stirred at room temperature overnight. The reaction was slowly 
n. The organic 
yer was dried (MgSO4), filtered and evaporated in vacuo.  
a
evaporated in vacuo. The residue was taken up in
w
 
P
Yield: 77%. 
W
 
1H NMR (C
1H, 3J = 8.8 Hz, 4J = 1.9 Hz, Ar H), 7.61 (d, 1H
Ar H), 8.18 (
 
IR
 
C13H11BrO3 (295.13) 
 
 
M
 
6
 
B
CH2Cl2 (25 mL) at -78°C under nitrogen atmosphere. After 30 mi
s
quenched with methanol and then washed with a saturated NaHCO3 solutio
la
 
 147
  EXPERIMENTAL SECTION  
Purification: CC (dichloromethane/methanol 99:1).  
hite solid, mp 253 ºC.  
.87 (d, 1H, 
 = 8.8 Hz, Ar H), 7.92 (d, 1H, 3J = 8.8 Hz, Ar H), 8.24 (s, 1H, Ar H), 8.29 (dt, 1H, 3J = 7.9 
Pyr. H-6), 9.08 (d, 1H, 4J = 1.6 Hz, Pyr. 
-2), 9.95 (s, 1H, OH).  
: νmax = 3634, 3021, 1594, 1489, 1308, 793 cm-1.  
5.13 6.21 
5.13 5.80 
ethod 25 
pounds 43 and 44 were prepared according to the literature (Jagdmann et al., 1990). 
-Pyridin-3-yl-2-naphthamide (43) 
ixture of the ester compound 41 (150 mg, 0.57 mmol) and formamide (86 mg, 1.90 
ydrous DMF (3 mL) and heated at 100°C. 
odium methoxide (21 mg, 0.40 mmol) was added and stirring was continued for 
ded (2 mL), then extracted with ethyl acetate, 
ried (MgSO4), filtered and evaporated in vacuo.  
ethane/methanol 95:5). 
White solid, mp 227 ºC.  
Yield: 65%. 
W
 
1H NMR (CDCl3): δ 7.20 (dd, 1H, 3J = 8.8 Hz, 4J = 1.9 Hz, Ar H), 7.23 (d, 1H, 4J = 1.9 Hz, 
Ar H), 7.60-7.62 (m, 1H, Pyr. H-5), 7.83 (dd, 1H, 3J = 8.5 Hz, 4J = 1.6 Hz, Ar H), 7
3J
Hz, 4J = 1.9 Hz, Pyr. H-4), 8.65 (d, 1H, 3J = 4.7 Hz, 
H
 
IR
MS: m/z = 222 (MH+).  
 
C15H11NO (221.26)·0.24H2O 
 
 C H N 
Calc. 79.86 
Obs. 79.80 
 
 
M
 
Com
 
6
 
A stirred m
mmol) under nitrogen was charged with anh
Methanolic s
1 h. The mixture was cooled and water was ad
d
 
Purification: CC (dichlorom
Yield: 61%. 
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  EXPERIMENTAL SECTION  
1H NMR (CDCl3): δ 7.42-7.45 (m, 1H, Pyr. H-5), 7.75 (dd, 1H, 3J = 8.5 Hz, 4J = 1.9 Hz, Ar 
), 7.90 (dd, 1H, 3J = 8.5 Hz, 4J = 1.9 Hz, Ar H), 7.96 (d, 1H, 3J = 8.8 Hz, Ar H), 8.01-8.04 
, Ar H), 8.59 
d, 1H, 3J = 4.7 Hz, 4J = 1.6 Hz, Pyr. H-6), 8.92 (d, 1H, 4J = 1.9 Hz, Pyr. H-2).  
5, 3066, 1664, 1590, 1426 cm-1.  
49 (MH+).  
N 
alc. 77.40 4.87 11.28 
pyridin-3-yl-2-naphthoate 41 and N-methylformamide. 
 CC (dichloromethane/methanol 95:5). 
ield: 83%. 
3), 6.33 (s, 1H, NH), 7.42-7.44 (m, 1H, Pyr. H-5), 7.77 
d, 1H, 3J = 8.5 Hz, 4J = 1.8 Hz, Ar H), 7.87 (dd, 1H, 3J = 8.5 Hz, 4J = 1.8 Hz, Ar H), 7.96-
 = 4.6 Hz, 4J = 1.5 Hz, Pyr. 
-6), 8.98 (d, 1H, 4J = 1.5 Hz, Pyr. H-2).  
: νmax = 3316, 3059, 2929, 1644, 1549, 1313 cm-1.  
262.31)·0.15H2O 
alc. 77.34 5.44 10.57 
10.54 
H
(m, 2H, Ar H, Pyr. H-4), 8.06 (d, 1H, 4J = 1.3 Hz, Ar H), 8.38 (d, 1H, 4J = 1.3 Hz
(d
 
IR: νmax = 333
MS: m/z = 2
 
C16H12N2O (248.29) 
 
 C H 
C
Obs. 77.15 5.14 11.08 
 
N-Methyl-6-pyridin-3-yl-2-naphthamide (44)  
 
Synthesized from methyl 6-
 
Purification:
Y
White solid, mp 158 ºC.  
 
1H NMR (CDCl3): δ 3.10 (s, 3H, OCH
(d
8.07 (m, 4H, Ar H, Pyr. H-4), 8.33 (s, 1H, Ar H), 8.65 (dd, 1H, 3J
H
 
IR
MS: m/z = 263 (MH+).  
 
C17H14N2O (
 
 C H N 
C
Obs. 77.04 5.84 
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  EXPERIMENTAL SECTION  
Method 26 
 
2-Bromoquinoline (47a) 
 
POBr3 (1.30 g, 4.55 mmol) was added to quinolin-2-ol 47b (0.28 g, 1.96 mmol) in a flask 
enser and CaCl2-tube. The reaction was heated at 155°C for 4 hours. After 
om temperature, some water was added and the resulting red solution was 
eutralised with solid sodium bicarbonate and basified with 10% sodium hydroxide solution. 
and active charcoal was added to the organic 
yer. After filtration, the organic layer was dried (MgSO4), filtered and evaporated in vacuo. 
urification: CC (dichloromethane). 
ield: 78%. 
1H, 3J = 8.5 Hz, Ar H), 7.58 (td, 1H, 3J = 8.1 Hz, 4J = 1.3 Hz, Ar 
), 7.75 (td, 1H, 3J = 8.5 Hz, 4J = 1.6 Hz, Ar H), 7.81 (dd, 1H, 3J = 8.2 Hz, 4J = 1.3 Hz, Ar 
9H6BrN (208.06) 
axoline (48a)  
ynthesized from to quinoxalin-2-ol 48b. 
ellow solid. 
3): δ 7.80-7.82 (m, 2H, Ar H), 8.04-8.06 (m, 1H, Ar H), 8.10-8.12 (m, 1H, Ar 
r H).  
with air cond
cooling to ro
n
The solution was extracted with diethyl ether 
la
 
P
Y
Beige solid. 
 
1H NMR (CDCl3): δ 7.53 (d, 
H
H), 8.01 (d, 1H, 3J = 8.5 Hz, Ar H), 8.07 (d, 1H, 3J = 8.5 Hz, Ar H). 
  
IR: νmax = 3068, 1583, 1082 cm-1. 
 
C
 
2-Bromoquin
 
S
 
Purification: CC (dichloromethane).  
Yield: 83%. 
Y
 
1H NMR (CDCl
H), 8.63 (s, 1H, A
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  EXPERIMENTAL SECTION  
IR cm-1: νmax = 3064, 2936, 1537. 
 
C8H5BrN2 (209.05) 
 
 
Method 27 
 
2-Bromo-1,2,3,4-tetrahydro-naphthalen-1-ol (51b) 
mmol) in 
nhydrous methanol/tetrahydrofuran (1:1, 6 mL) was stirred under nitrogen in an icebad. 
After stirring for 15 minutes at 0°C and 
.5 hour at room temperature, the mixture was poured into water and extracted with diethyl 
layer was dried (MgSO4), filtered and evaporated in vacuo.  
ield: 88%. 
0-2.57 (m, 1H, H-3’), 2.86-2.92 (m, 1H, H-4), 
, 1H, H-4’), 4.71-4.74 (m, 1H, H-2), 4.81 (d, 1H, 3J = 3.5 Hz, H-1), 7.12-7.14 
 H), 7.25-7.28 (m, 2H, Ar H), 7.49-7.50 (m, 1H, Ar H).  
10H11BrO (227.10) 
-Methoxy-2-pyridin-3-yl-indan-1-ol (52a) 
ynthesized from 5-methoxy-2-pyridin-3-yl-indan-1-one 52b. 
sed without purification. 
hite solid. 
 
A solution of the 2-bromo-3,4-dihydro-2H-naphthalen-1-one 51c (400 mg, 1.77 
a
NaBH4 (47 mg, 1.24 mmol) was added portionwise. 
0
ether. The organic 
 
Used for further reaction without purification. 
Y
White solid. 
 
1H NMR (CDCl3) δ 2.28-2.34 (m, 1H, H-3), 2.5
3.01-3.15 (m
(m, 1H, Ar
 
IR: νmax = 3413, 3022, 2955, 2923, 2849, 1603, 1490, 1455, 1225 cm-1. 
 
C
 
5
 
S
 
U
Yield: 53 %.  
W
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  EXPERIMENTAL SECTION  
1H NMR (CDCl3): δ 2.98 (dd, 1H, 2J = 15.8 Hz, 3J = 8.2 Hz, H-3), 3.21 (dd, 1H, 2J = 15.8 Hz, 
-3), 3.29-3.44 (m, 3H, H-3, H-3, H-2), 3.69-3.73 (m, 1H, H-2), 5.17 (d, 1H, 3J = 
, 5.23 (d, 1H, 3J = 5.6 Hz, H-1), 6.79-6.86 (m, 4H, Ar H, Ar H), 7.26-7.29 (m, 
H, Pyr. H-5), 7.32-7.34 (m, 2H, Pyr. H-5, Ar H), 7.36 (d, 1H, 3J = 8.5 Hz, Ar H), 7.68 (dt, 
-1-ol (53b)  
. 
 
, 1H, 3J = 8.5 Hz, Ar H).  
: νmax = 3305, 2830, 1610, 1499, 1248 cm-1.  
11H13BrO2 (257.13) 
-Bromo-7-methoxy-1,2,3,4-tetrahydro-naphthalen-1-ol (54b)  
ynthesized from 2-bromo-7-methoxy-3,4-dihydro-2H-naphthalen-1-one 54c. 
3J = 7.9 Hz, H
6.6 Hz, H-1)
1
1H, 3J = 7.9 Hz, 4J = 1.9 Hz, Pyr. H-4), 7.76 (dt, 1H, 3J = 7.9 Hz, 4J = 1.9 Hz, Pyr. H-4), 8.41-
8.43 (m, 2H, Pyr. H-6, Pyr. H-6), 8.53 (d, 1H, 4J = 2.2 Hz, Pyr. H-2), 8.54 (d, 1H, 4J = 2.2 Hz, 
Pyr. H-2). 
 
IR: νmax = 3226, 2940, 1609, 1492, 1252 cm-1. 
 
C15H15NO2 (241.29) 
 
2-Bromo-6-methoxy-1,2,3,4-tetrahydro-naphthalen
 
Synthesized from 2-bromo-6-methoxy-3,4-dihydro-2H-naphthalen-1-one 53c
 
Used for further reaction without purification. 
Yield: 86%. 
White solid.
 
1H NMR (CDCl3): δ 2.25-2.29 (m, 1H, H-3), 2.49-2.53 (m, 1H, H-3’), 2.82-2.87 (m, 1H, H-
4), 3.03-3.08 (m, 1H, H-4’), 3.79 (s, 3H, OCH3), 4.65-4.68 (m, 1H, H-2), 4.75 (d, 1H, 3J = 3.2 
Hz, H-1), 6.63 (d, 1H, 4J = 2.4 Hz, Ar H), 6.80 (dd, 1H, 3J = 8.5 Hz, 4J = 2.4 Hz, Ar H), 7.37 
(d
 
IR
 
C
 
2
 
S
 
Used for further reaction without purification. 
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  EXPERIMENTAL SECTION  
Yield: 84%. 
White solid. 
 
1H NMR (CDCl3): δ 2.17-2.23 (m, 1H, H-3), 2.38-2.44 (m, 1H, H-3’), 2.69-2.75 (m, 1H, H-
4), .94-3.00 (m, 1H, H-4’), 3.73 (s, 3H, OCH3), 4.64-4.67 (m, 1H, H-2), 4.68 (d, 1H, 3J = 3.5 
Hz, H-1), 6.81 (dd, 1H, 3J = 8.5 Hz, 4J = 2.5 Hz, Ar H), 7.02-7.04 (m, 2H, Ar H).  
 
IR: νmax = 3441, 2945, 2838, 1612, 1502, 1244 cm-1. 
 
C11H13BrO2 (257.13) 
 
3-Methyl-2-pyridin-3-yl-1,2,3,4-tetrahydronaphthalen-1-ol (58a)  
 
Synthesized from 3-methyl-2-pyridin-3-yl-3,4-dihydro-2H-naphthalen-1-one 58b. 
 
Used without purification. 
Yield: 72%.  
5, 1483, 1429 cm-1. 
hthalen-1-ol (59b) 
phthalen-1(2H)-one 59c. 
ther reaction without purification. 
ield: 91%. 
White solid. 
 
IR: νmax = 3183, 293
 
C16H17NO (239.32) 
 
2-Bromo-4-methyl-1,2,3,4-tetrahydronap
 
Synthesized from 2-bromo-4-methyl-3,4-dihydrona
 
Used for fur
Y
Yellow solid. 
 
IR: νmax = 3395, 2960, 2871. 
 
C11H13BrO (241.13) 
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  EXPERIMENTAL SECTION  
4-Ethyl-2-pyridin-3-yl-1,2,3,4-tetrahydronaphthalen-1-ol (60a)  
ethyl-2-pyridin-3-yl-3,4-dihydronaphthalen-1(2H)-one 60b. 
ield: 100%. 
, 1428 cm-1. 
253.35) 
ellow oil. 
: νmax = 3541, 3032, 1660, 1504, 1276, 1084 cm-1.  
12H12N2O (200.24) 
-(1H-imidazol-1-yl)-1,2,3,4-tetrahydronaphthalen-1-ol (62a)  
ynthesized from 2-(1H-imidazol-1-yl)-3,4-dihydronaphthalen-1(2H)-one 62b. 
purification. 
  
ellow oil. 
C13H14N2O (214.17) 
 
Synthesized from 4-
 
Used without purification. 
Y
Yellow oil. 
 
IR: νmax = 3355, 3063, 2961, 2928, 2873, 1578, 1484
 
C17H19NO (
 
2-(1H-imidazol-1-yl)indan-1-ol (61a)  
 
Synthesized from 2-(1H-imidazol-1-yl)indan-1-one 61b. 
 
Used without purification. 
Yield: 96%.  
Y
 
IR
 
C
 
2
 
S
 
Used without 
Yield: 91%.
Y
 
IR: νmax = 3114, 2932, 1676, 1504, 1231, 1084 cm-1.  
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  EXPERIMENTAL SECTION  
2-(1H-imidazol-1-yl)-6-methoxy-1,2,3,4-tetrahydronaphthalen-1-ol (63a)  
 
Synthesized from 2-(1H-imidazol-1-yl)-6-methoxy-3,4-dihydronaphthalen-1(2H)-one 63b. 
 
Used without purification. 
hite solid. 
: νmax = 3104, 2955, 2838, 1598, 1031 cm-1. 
ethod 28 
ed at reflux (with Dean-Starktrap) for 2 hours to remove 
ny water. The mixture was washed with saturated sodium bicarbonate and water. The 
SO4), filtered and evaporated in vacuo. 
 CC (hexane).  
ield: 47%.  
4J = 1.9 Hz, H-1), 7,17 (td, 1H, 3J = 7.6 
z, 4J = 1.3 Hz, Ar H), 7.24 (t, 1H, 3J = 7.6 Hz, ArH), 7.31 (d, 1H, 3J = 7.6 Hz, Ar H), 7.38 
Yield: 83%.  
W
 
IR
 
C14H16N2O2 (244.30) 
 
 
M
 
2-Bromo-1H-indene (50a)  
 
A mixture of 2-bromoindan-1-ol 50b (5.20 g, 24.40 mmol) and p-toluenesulphonic acid (464 
mg, 2.44 mmol) in toluene was heat
a
organic layer was dried (Mg
 
Purification:
Y
Colorless oil. 
 
1H NMR (CDCl3): δ 3.61 (s, 2H, H-3), 6.94 (t, 1H, 
H
(d, 1H, 3J = 7.6 Hz, Ar H).  
 
IR: νmax = 3072, 2897, 1556 cm-1. 
 
C H Br (195.06) 9 7
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  EXPERIMENTAL SECTION  
3-Bromo-1,2-dihydronaphthalene (51a)  
 
Synthesized from 2-bromo-1,2,3,4-tetrahydro-naphthalen-1-ol 51b. 
 
Purification: CC (hexane).  
.77 (t, 2H, 3J = 8.2 Hz, H-3), 2.95 (t, 2H, 3J = 8.2 Hz, H-4), 6.79 (s, 1H, 
-1), 6.96-6.98 (m, 1H, Ar H), 7.08-7.10 (m, 1H, Ar H), 7.14-7.16 (m, 2H, Ar H).  
: νmax = 3017, 2943, 2890, 2833, 1662, 1485 cm-1. 
10H9Br (209.09) 
ethoxy-1,2-dihydronaphthalene (53a)  
ynthesized from 2-bromo-6-methoxy-1,2,3,4-tetrahydro-naphthalen-1-ol 53b. 
urification: CC (hexane/ethyl acetate 80:20).  
eige oil. 
3): δ 2.73 (t, 2H, 3J = 8.5 Hz, H-3), 2.92 (t, 2H, 3J = 8.5 Hz, H-4), 3.79 (s, 3H, 
, 3J = 7.9 Hz, Ar H).  
, 1607, 1498, 1247 cm-1. 
239.11) 
-dihydronaphthalene (54a)  
romo-7-methoxy-1,2,3,4-tetrahydro-naphthalen-1-ol 54b. 
Yield: 81%.  
Colorless oil. 
 
1H NMR (CDCl3): δ 2
H
 
IR
 
C
 
3-Bromo-7-m
 
S
 
P
Yield: 60%. 
B
 
1H NMR (CDCl
OCH3), 6.67-6.69 (m, 2H, Ar H), 6.74 (s, 1H, H-1), 6.91 (d, 1H
 
IR: νmax = 3000, 2939, 2833
 
C11H11BrO (
 
3-Bromo-6-methoxy-1,2
 
Synthesized from 2-b
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  EXPERIMENTAL SECTION  
Purification: CC (hexane/ethyl acetate 80:20).  
ield: 58%. 
54 cm-1. 
ethyl-1,2-dihydronaphthalene (59a) 
ellow oil. 
DCl3): δ 1.29 (d, 3H, 3J = 6.9 Hz, Me), 2.54 (ddd, 1H, 2J = 17.3 Hz, 3J = 6.9 Hz, 
3 (ddd, 1H, 2J = 17.0 Hz, 3J = 6.9 Hz, 4J = 1.6 Hz, H-3’), 3.09 (m, 1H, 
-4), 6.79 (s, 1H, Ar H), 6.98 (dd, 1H, 3J = 6.9 Hz, 4J = 1.6 Hz, Ar H), 7.14-7.20 (m, 3H, Ar H). 
: νmax = 3066, 2963, 1629, 1447 cm-1. 
11H11Br (223.11) 
-(3-Methoxy-phenyl)-2-pyridin-3-yl-propionitrile (52d) 
Y
Yellow oil. 
 
1H NMR (CDCl3): δ 2.75 (t, 2H, 3J = 8.5 Hz, H-3), 2.88 (t, 2H, 3J = 8.5 Hz, H-4), 3.78 (s, 3H, 
OCH3), 6.54 (d, 1H, 4J = 2.5 Hz Ar H), 6.69 (dd, 1H, 3J = 8.2 Hz, 4J = 2.5 Hz, Ar H), 6.74 (s, 
1H, H-1), 6.99 (d, 1H, 3J = 8.2 Hz, Ar H).  
 
IR: νmax = 3000, 2938, 2831, 1604, 1498, 12
 
C11H11BrO (239.11) 
 
3-Bromo-1-m
 
Synthesized from 2-bromo-4-methyl-1,2,3,4-tetrahydronaphthalen-1-ol 59b. 
 
Purification: CC (hexane/dichloromethane 90:10).  
Yield: 59%. 
Y
 
1H NMR (C
4J = 1.3 Hz, H-3), 2.9
H
 
IR
 
C
 
Method 29 
 
3
 
To a suspension of NaNH2 (408 mg, 9.40 mmol) in anhydrous DMF (20 mL) (three-
neckflask, refluxcooler, gasinlet and droppingfunnel with septum) under nitrogen was added 
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  EXPERIMENTAL SECTION  
dropwise 3-pyridyl acetonitrile (1.0 g, 8.46 mmol) while stirring and cooling with anicebad. 
After stirring for 1 hour at room temperature and 1 hour at 80°C, the mixture was cooled with 
n icebad and 3-methoxybenzyl chloride 52e (1.25 g, 7.99 mmol) was added dropwise. The 
and then 1 hour at 80°C. After cooling, 
n excess of water was added and the mixture was extracted exhaustively with diethyl ether. 
s washed with water, dried (MgSO4), filtered and evaporated in vacuo.  
ield: 26%. 
, 3H, OCH3), 4.20 (t, 1H, 3J = 7.2 Hz, H-
, 4J = 2.2 Hz, Ar H), 6.67 (d, 1H, 3J = 7.6 Hz, Ar H), 6.82 (dd, 1H, 3J = 8.2 Hz, 
Ar H), 7.21 (t, 1H, 3J = 8.2 Hz, Ar H), 7.43-7.46 (m, 1H, Pyr. H-5), 7,74 (dt, 1H, 
 = 8.2 Hz, 4J = 1.9 Hz, Pyr. H-4), 8.61 (d, 1H, 4J = 2.5 Hz, Pyr. H-2), 8.62 (dd, 1H, 3J = 5.0 
-Phenyl-2-pyridin-3-yl-butyronitrile (56d) 
ynthesized from phenethyl bromide 56e. 
urification: CC (dichloromethane/methanol 99:1) 
range oil. 
DCl3): δ 2.15-2.22 (m, 1H, H-3), 2.69-2.34 (m, 1H, H-3’), 2.80-2.90 (m, 2H, H-
(d, 2H, 3J = 7.9 Hz, Ar H), 7.25 (d, 1H, 
 Hz, Ar H), 7.38-7.41 (m, 1H, Pyr. H-5), 7.77 (dt, 1H, 
 = 2.2 Hz, Pyr. H-4), 8.58 (d, 1H, 4J = 2.5 Hz, Pyr. H-2), 8.61(dd, 1H, 3J = 5.0 
z, 4J = 1.6 Hz, Pyr. H-6).  
a
reaction was stirred for 3 hours at room temperature 
a
The organic layer wa
 
Purification: CC (dichloromethane/methanol 99:1). 
Y
Yellow oil. 
 
1H NMR (CDCl3): δ 3.13-3.25 (m, 2H, H-3), 3.76 (s
2), 6.65 (t, 1H
4J = 2.2 Hz, 
3J
Hz, 4J = 1.6 Hz, Pyr. H-6).  
 
IR: νmax = 3030, 2938, 2837, 2244, 1602, 1491, 1264 cm-1. 
 
C15H14N2  (238.29) 
 
4
 
S
 
P
Yield: 14%. 
O
 
1H NMR (C
4), 3.81 (dd, 1H, 3J = 9.5 Hz, 3J = 5.7 Hz, H-2), 7.20 
3J = 7.9 Hz, Ar H), 7.32 (t, 2H, 3J = 7.9
3J = 7.9 Hz, 4J
H
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IR: νmax = 3029, 2971, 2242, 1603, 1577, 1496, 1426 cm-1. 
 
C15H14N2  (222.29) 
 
3-Methyl-4-phenyl-2-pyridin-3-yl-butyronitrile (58d)  
 
Synthesized from 2-bromo-1-phenylpropane 58e. 
 
Purification: CC (dichloromethane/methanol 99:1). 
Yield: 29% (mixture of two isomers).  
DCl3): δ 0.97-1.01 (m, 6H, CH3), 1.88-1.97 (m, 1H, H-4), 2.19-2.26 (m, 1H, H-4), 
, 1H, H-4), 2.80-2.83 (m, 2H, H-3), 2.89-2.94 (m, 1H, H-4), 3.85-3.88 (m, 2H, 
-2), 7.10 (d, 2H, 3J = 7.6 Hz, Ar H), 7.23-7.29 (m, 6H, Ar H), 7.35 (t, 2H, 3J = 7.6 Hz, Ar 
, Pyr. H-4), 7.78 (m, 1H, Pyr. H-4), 8.50 (d, 2H, 
 = 2.2 Hz, Pyr. H-2), 8.59 (dd, 1H, 3J = 4.7 Hz, 4J = 1.6 Hz, Pyr. H-6), 8.63 (dd, 1H, 3J = 4.7 
16H16N2  (236.32) 
yridin-3-yl-hexanenitrile (60d)  
ynthesized from 1-(bromomethyl)propyl]benzene 60e. 
1 3  3H, 3J = 7.2 Hz, CH3), 1.64-1.71 
 (m, 2H, H-3), 2.25-2.31 (m, 2H, H-3), 2.39-2.41 (m, 1H, H-4), 2.84-
.90 (m, 1H, H-4), 3.42 (dd, 1H, 2J = 12.0 Hz, 3J = 4.4 Hz, H-2), 3.57 (m, 1H, H-2), 7.07 (d, 
Brown oil. 
 
1H NMR (C
2.30-2.40 (m
H
H), 7.38-7.41 (m, 2H, Pyr. H-5), 7.72 (m, 1H
4J
Hz, 4J = 1.6 Hz, Pyr. H-6).  
 
IR: νmax = 3030, 2968, 2875, 2241, 1577, 1426 cm-1. 
 
C
 
4-Phenyl-2-p
 
S
 
Purification: CC (dichloromethane/methanol 98:2).  
Yield: 59%.  
Brown oil. 
 
H NMR (CDCl3): δ 0.71 (d, 3H, J = 7.2 Hz, CH3), 0.83 (d,
(m, 4H, CH2), 1.96-2.02
2
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  EXPERIMENTAL SECTION  
1H, 3J = 7.6 Hz, Ar H), 7.16-7.40 (m, 11H, Ar H, Pyr. H-5), 7.64 (dt, 1H, 3J = 8.2 Hz, 4J = 1.9 
z, Pyr. H-4), 7.67 (dt, 1H, 3J = 8.2 Hz, 4J = 1.9 Hz, Pyr. H-4), 8.41 (d, 1H, 4J = 2.2 Hz, Pyr. 
Pyr. H-2), 8.56 (dd, 1H, 3J = 5.0 Hz, 4J = 1.6 Hz, Pyr. H-6), 
: νmax = 3059, 2961, 2242, 1654, 1599, 1455, 1252 cm-1. 
17H18N2  (250.35) 
-yl-propionic acid (52c) 
filtration, evaporated in vacuo.  
ellow oil. 
: νmax = 2939, 2836, 2526, 1721, 1585, 1491 cm-1. 
-Phenyl-2-pyridin-3-yl-butyric acid (56c) 
ynthesized from 4-phenyl-2-pyridin-3-yl-butyronitrile (56d). 
sed without purification. 
H
H-2), 8.42 (d, 1H, 4J = 2.2 Hz, 
8.60 (dd, 1H, 3J = 5.0 Hz, 4J = 1.6 Hz, Pyr. H-6).  
 
IR
 
C
 
 
Method 30 
 
3-(3-Methoxy-phenyl)-2-pyridin-3
 
To a solution of 3-(3-methoxy-phenyl)-2-pyridin-3-yl-propionitrile 52d (486 mg, 2.04 mmol) 
in ethanol (3 mL) was added NaOH (898 mg, 22.46 mmol) in water (1 mL). After reflux for 
24 hours, some water was added and the pH was adjusted to 5 with 2N HCl solution and 
aqueous acetic acid. The mixture was extracted with ethyl acetate and, after drying (MgSO4) 
and 
 
Used without purification. 
Yield: 86%.  
Y
 
IR
 
C15H15NO3 (257.29) 
 
4
 
S
 
U
Yield: 74%. 
White oil. 
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  EXPERIMENTAL SECTION  
1H NMR (CDCl3): δ 2.06-2.14 (m, 1H, H-3), 2.49-2.55 (m, 1H, H-3’), 2.59-2.68 (m, 2H, H-
), 3.66-3.69 (m, 1H, CH), 7.14 (d, 2H, 3J = 7.9 Hz, Ar H), 7.17-7.20 (m, 1H, Ar H), 7.26-
-Methyl-4-phenyl-2-pyridin-3-yl-butyric acid (58c)  
ynthesized from 3-methyl-4-phenyl-2-pyridin-3-yl-butyronitrile 58d. 
rown oil. 
: νmax = 3028, 2967, 2930, 2479, 1676, 1427 cm-1. 
16H17NO2 (255.32) 
yridin-3-yl-hexanoic acid (60c)  
ynthesized from 4-phenyl-2-pyridin-3-yl-hexanenitrile 60d. 
ellow oil. 
 
4
7.29 (m, 2H, Ar H), 7.45-7.48 (m, 1H, Pyr. H-5), 7.92 (dt, 1H, 3J = 7.9 Hz, 4J = 2.2 Hz, Pyr. 
H-4), 8.54 (d, 1H, 3J = 4.4 Hz, Pyr. H-6), 8.68 (s, 1H, Pyr. H-2). 
 
IR: νmax = 3028, 2952, 1717 cm-1. 
MS: m/z = 242 (MH+), 179, 101, 79.  
 
C15H15NO2 (241.29) 
 
3
 
S
 
Used without purification. 
Yield: 99%.  
B
 
IR
 
C
 
4-Phenyl-2-p
 
S
 
Used without purification. 
Yield: 99%.  
Y
 
MS: m/z = 268 (M-H+). 
 
C17H19NO2 (269.35)
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  EXPERIMENTAL SECTION  
Method 31 
 
5-Methoxy-2-pyridin-3-yl-indan-1-one (52b)  
 
A mixture of polyphosphoric acid (2.2 g) and 3-(3-methoxy-phenyl)-2-pyridin-3-yl-propionic 
for 20 minutes. The reaction was poured 
 and neutralized with 6% NaOH solution. The pH was adjusted to 8 with sodium 
xtracted with diethyl ether. The organic layer was dried 
gSO4), filtered and evaporated in vacuo. 
olorless oil. 
0 (dd, 1H, 2J = 17.3 Hz, 3J = 4.1 Hz, H-3), 3.67 (dd, 1H, 2J = 17.3 Hz, 
 = 8.5 Hz, H-3’), 3.90-3.92 (m, 4H, OCH3, H-2), 6.96-6.98 (m, 2H, Ar H), 7.28-7.31 (m, 
8.2 Hz, 4J = 1.9 Hz, Pyr. H-4), 7.74 (d, 1H, 3J = 8.2 Hz, Ar 
), 8.50-8.51 (m, 2H, Pyr. H-6, Pyr. H-2).  
599, 1261 cm-1. 
H NO  (239.28) 
-Pyridin-3-yl-3,4-dihydro-2H-naphthalen-1-one (56b) 
3-yl-butyric acid (56c). 
 1.5 Hz, Ar H), 7.61 (dt, 1H, 3J = 
acid 52c (0.53 g, 2.05 mmol) was stirred at 110°C 
into ice water
bicarbonate, and the solution was e
(M
 
Purification: CC (dichloromethane/methanol 97:3).  
Yield: 48%. 
C
 
1H NMR (CDCl3): δ 3.2
3J
1H, Pyr. H-5), 7,57 (dt, 1H, 3J = 
H
 
IR: νmax = 2945, 2841, 1702, 1
 
C15 13 2
 
2
 
Synthesized from 4-phenyl-2-pyridin-
 
Purification: CC (dichloromethane/methanol 97:3).  
Yield: 90%. 
Colorless oil. 
 
1H NMR (CDCl ): δ 2.42-2.47 (m, 2H, H-4), 3.10 (dt, 1H, 3 2J = 16.6 Hz, 3J = 3.9 Hz, H-3); 
3.17-3.24 (m, 1H, H-3’), 3.85 (t, 1H, 3J = 8.3 Hz, H-2), 7.31 (d, 1H, 3J = 7.8 Hz, Ar H), 7.34-
7,37 (m, 2H, Ar H, Pyr. H-5), 7.53 (td, 1H, 3J = 7.8 Hz, 4J =
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  EXPERIMENTAL SECTION  
7.8 Hz, 4J = 1.9 Hz, Pyr. H-4), 8.08 (dd, 1H, 3J = 7.8 Hz, 4J = 1.5 Hz, Ar H), 8.51 (d, 1H, 4J = 
(dd, 1H, 3J = 4.9 Hz, 4J = 1.5 Hz, Pyr. H-6).  
99, 1425, 1226 cm-1. 
ihydro-2H-naphthalen-1-one (58b) 
ynthesized from 3-methyl-4-phenyl-2-pyridin-3-yl-butyric acid 58c. 
urification: CC (dichloromethane/methanol 96:4).  
ellow oil. 
7 (dt, 1H, 3J = 7.9 Hz, 4J = 1.8 Hz, 
yr. H-4), 8.04 (dd, 1H, 3J = 7.9 Hz, 4J = 1.2 Hz, Ar H), 8.44 (d, 1H, 4J = 1.8 Hz, Pyr. H-2), 
max
-1. 
C
yridin-3-yl-hexanoic acid 60c. 
ield: 63% (mixture of two isomers). 
1.9 Hz, Pyr. H-2), 8.55 
 
IR: νmax = 3057, 2933, 1682, 15
 
C15H13NO (223.28) 
 
3-Methyl-2-pyridin-3-yl-3,4-d
 
S
 
P
Yield: 38%.  
Y
 
1H NMR (CDCl3): δ 0.97 (d, 3H, 3J = 6.7 Hz, CH3), 2.53-2.61 (m, 1H, H-4), 2.95 (dd, 1H, 2J 
= 16.5 Hz, 3J = 11.5 Hz, H-3), 3.12 (dd, 1H, 2J = 16.5 Hz, 3J = 4.0 Hz, H-3’), 3.46 (d, 1H, 3J 
= 12.0 Hz, H-2), 7.30 (d, 1H, 3J = 7.6 Hz, Ar H), 7.35 (t, 1H, 3J = 7.6 Hz, Ar H), 7.40 (m, 1H, 
Pyr. H-5), 7.54 (td, 1H, 3J = 7.6 Hz, 4J = 1.2 Hz, Ar H), 7.5
P
8.57 (dd, 1H, 3J = 4.9 Hz, 4J = 1.5 Hz, Pyr. H-6).  
 
IR: ν  = 3028, 2970, 2927, 1682, 1602, 1270 cm
 
16H15NO (237.30) 
 
4-Ethyl-2-pyridin-3-yl-3,4-dihydronaphthalen-1(2H)-one (60b)  
 
Synthesized from 4-phenyl-2-p
 
Purification: CC (dichloromethane/methanol 97:3).  
Y
Colorless oil. 
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  EXPERIMENTAL SECTION  
1H NMR (CDCl3): δ 1.00 (t, 3H, 3J = 7.6 Hz, CH3), 1.10 (t, 3H, 3J = 7.6 Hz, CH3), 1.82-1.92 
, 4H, CH2), 2.16-2.20 (m, 1H, H-3), 2.36-2.44 (m, 2H, H-3), 2.56-2.62 (m, 1H, H-3), 2.96-
3J = 4.4 Hz, H-2), 7.17 (m, 2H, Ar H), 7.24-7.38 (m, 4H, Ar H, Pyr. H-
), 7.49-7.61 (m, 4H, Ar H, Pyr. H-4), 8.06 (dd, 1H, 3J = 7.9 Hz, 4J = 1.6 Hz, Ar H), 8.08 (dd, 
 1.8 Hz, Pyr. H-2), 8.54 (dd, 1H, 3J = 4.7 
z, Pyr. H-6), 8.57 (dd, 1H, 3J = 4.7 Hz, 4J = 1.6 Hz, Pyr. H-6).  
: νmax = 3029, 2956, 1683, 1599, 1425, 1252, 1173 cm-1. 
acid (4.60 mL), sulphuric acid (0.64 mL) and 5-methoxy-2-pyridin-3-yl-
dan-1-ol 52a (434 mg, 1.80 mmol) was stirred at 100°C for 1 hour. The reaction was poured 
 ice water and basified with a 6% NaOH solution. After extractions with dichloromethane, 
ayer was dried (MgSO4), filtered and evaporated in vacuo.  
ield: 45%. 
, 7.34 (d, 1H, 3J = 8.2 Hz, Ar H), 
.36-7.39 (m, 1H, Pyr. H-5), 7.94 (dt, 1H, 3J = 7.9 Hz, 4J = 1.5 Hz, Pyr. H-4), 8.46 (dd, 1H, 3J 
8 Hz, Pyr. H-2).  
07, 1493, 1259 cm-1.  
S: m/z = 224 (MH+). 
 
(m
2.99 (m, 1H, H-4), 3.22-3.24 (m, 1H, H-4), 3.83 (dd, 1H, 3J = 13.6 Hz, 3J = 4.4 Hz, H-2), 4.00 
(dd, 1H, 3J = 13.6 Hz, 
5
1H, 3J = 7.9 Hz, 4J = 1.6 Hz, Ar H), 8.51 (d, 2H, 4J =
Hz, 4J = 1.6 H
 
IR
 
C17H17NO (251.33) 
 
 
Method 32 
 
3-(6-Methoxy-1H-inden-2-yl)pyridine (52) 
 
A mixture of acetic 
in
in
the organic l
 
Purification: CC (dichloromethane/methanol 98:2). 
Y
Beige solid, mp 82 ºC.  
 
1H NMR (CDCl3): δ 3.77 (s, 2H, H-3), 3 85 (s, 3H, OCH3), 6.86 (dd, 1H, 3J = 8.2 Hz, 4J = 2.2 
Hz, Ar H), 7.09 (d, 1H, 4J = 1.5 Hz, Ar H), 7.30 (s, 1H, H-1)
7
= 4.9 Hz, 4J = 1.5 Hz, Pyr. H-6), 8.85 (d, 1H, 4J = 1.
 
IR: νmax = 3059, 2905, 2836, 1685, 16
M
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  EXPERIMENTAL SECTION  
C15H13NO (223.28)·0.02H2O 
 
 C H N 
Calc. 80.09 5.91 6.23 
Obs. 80.08 6.15 6.13 
onaphthalen-2-yl)pyridine (58)  
idin-3-yl-1,2,3,4-tetrahydronaphthalen-1-ol 58a. 
ne/methanol 98:2). 
salt). 
 (dd, 1H, 2J = 15.4 Hz, 3J = 2.2 Hz, 
-4), 3.00-3.06 (m, 1H, H-3), 3.23 (dd, 1H, 2J = 15.4 Hz, 3J = 6.9 Hz, H-4’), 6.86 (s, 1H, H-
 4J = 1.6 Hz, 
yr. H-4), 8.52 (dd, 1H, 3J = 4.7 Hz, 4J = 1.9 Hz, Pyr. H-6), 8.85 (d, 1H, 4J = 1.9 Hz, Pyr. H-
453, 1216 cm-1.  
S: m/z = 222 (MH+). 
alc. 72.45 6.41 5.28 
0 5.31 
-(4-Ethyl-3,4-dihydronaphthalen-2-yl)pyridine (60)  
ynthesized from 4-ethyl-2-pyridin-3-yl-1,2,3,4-tetrahydronaphthalen-1-ol 60a. 
thane/methanol 98:2). 
 
3-(3-Methyl-3,4-dihydr
 
Synthesized from 3-methyl-2-pyr
 
Purification: CC (dichlorometha
Yield 63%.  
White solid, mp 169 °C (HCl 
 
1H NMR (CDCl3): δ 1.03 (d, 3H, 3J = 6.9 Hz, CH3), 2.76
H
1), 7.16-7.22 (m, 2H, Ar H), 7.36 (m, 1H, Pyr. H-5), 7.92 (dt, 1H, 3J = 7.9 Hz,
P
2).  
 
IR: νmax = 3020, 2962, 2924, 1564, 1
M
 
C16H15N (221.30)·HCl·0.43H2O 
 
 C H N 
C
Obs. 72.30 6.0
 
3
 
S
 
Purification: CC (dichlorome
Yield 55%.  
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  EXPERIMENTAL SECTION  
Beige solid, mp 174 °C (HCl salt). 
Hz, CH3), 1.56-1.69 (m, 2H, CH2), 2.68 (dd, 1H, 2J 
 16.4 Hz, 3J = 3.8 Hz, H-3), 2.83-2.86 (m, 1H, H-4), 2.93 (dd, 1H, 2J = 16.4 Hz, 3J = 2.5 Hz, 
: νmax = 3035, 2962, 2931, 1682, 1569, 1486, 1456, 1022 cm-1.  
5.33)·HCl·0.19H2O 
-(1H-inden-2-yl)-1H-imidazole (61)  
ynthesized from 2-(1H-imidazol-1-yl)indan-1-ol 61a. The reaction was stirred for 4 hours.  
urification: CC (dichloromethane/methanol 97:3). 
eige solid, mp 64 °C. 
DCl3): δ 3.87 (s, 2H, H-3), 6.78 (s, 1H, H-1), 7.22-7.24 (m, 2H, Im. H-4, Ar H), 
 7.6 Hz, Ar H), 7.45 (d, 1H, 3J = 7.6 Hz, 
s, 1H, Im. H-2).  
: νmax = 2940, 1707, 1616, 1498, 1264, 1238 cm-1.  
 
1H NMR (CDCl3): δ 0.92 (t, 3H, 3J = 7.6 
=
H-3’), 6.86 (d, 1H, 4J = 2.5 Hz, H-1), 7.16-7.22 (m, 4H, Ar H), 7.32-7.34 (m, 1H, Pyr. H-5), 
7.84 (dt, 1H, 3J = 7.9 Hz, 4J = 1.6 Hz, Pyr. H-4), 8.52 (dd, 1H, 3J = 4.7 Hz, 4J = 1.6 Hz, Pyr. 
H-6), 8.82 (d, 1H, 4J = 1.9 Hz, Pyr. H-2).  
 
IR
MS: m/z = 236 (MH+). 
 
C17H17N (23
 
 C H N 
Calc. 74.21 6.73 5.09 
Obs. 74.20 7.36 4.98 
 
1
 
S
 
P
Yield: 70%.  
B
 
1H NMR (C
7.30-7.33 (m, 2H, Im. H-5, Ar H), 7.38 (d, 1H, 3J =
Ar H), 8.09 (
 
IR
MS: m/z = 183 (MH+). 
 
C12H10N2 (182.23) 
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  EXPERIMENTAL SECTION  
1-(3,4-dihydronaphthalen-2-yl)-1H-imidazole (62)  
1H-imidazol-1-yl)-1,2,3,4-tetrahydronaphthalen-1-ol 62a. The reaction 
as stirred for 4 hours.  
urification: CC (dichloromethane/methanol 98:2).  
rown solid, mp 186 °C (HCl salt). 
Cl3): δ 2.83 (t, 2H, 3J = 8.2 Hz, H-4), 3.08 (t, 1H, 3J = 8.2 Hz, H-3), 6.57 (s, 1H, 
, 1H, 3J = 7.8 Hz, Ar H), 7.18-7.22 (m, 4H, Im. H-4, Ar H), 7.28 (s, 1H, Im. H-
), 7.95 (s, 1H, Im. H-2).  
13H12N2 (196.25)·HCl·0.82H2O 
C H N 
11.32 
bs. 62.82 6.51 10.98 
H-imidazole (63)  
ol-1-yl)-6-methoxy-1,2,3,4-tetrahydronaphthalen-1-ol 63a. 
3): δ 2.79 (t, 2H, 3J = 8.2 Hz, H-4), 2.96 (t, 1H, 3J = 8.2 Hz, H-3), 3.75 (s, 3H, 
CH3), 6.76-6.77 (m, 2H, Ar H), 6.81 (s, 1H, H-1), 7.04 (s, 1H, Im. H-4), 7.07 (d, 1H, 3J = 
.2 Hz, Ar H), 7.64 (s, 1H, Im. H-5), 8.10 (s, 1H, Im. H-2).  
 
Synthesized from 2-(
w
 
P
Yield: 96%.  
B
 
1H NMR (CD
H-1), 7.12 (d
5
 
IR: νmax = 3006, 3990, 1650, 1484, 1295, 1045 cm-1.  
MS: m/z = 197 (MH+). 
 
C
 
 
Calc. 63.08 5.96 
O
 
1-(6-methoxy-3,4-dihydronaphthalen-2-yl)-1
 
Synthesized from 2-(1H-imidaz
The reaction was stirred for 4 hours.  
 
Purification: CC (dichloromethane/methanol 98:2).  
Yield: 54%.  
White solid, mp 106 °C. 
 
1H NMR (CDCl
O
8
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  EXPERIMENTAL SECTION  
IR: νmax = 2924, 1729, 1646, 1604, 1495, 1459, 1298, 1253 cm-1.  
S: m/z = 227 (MH+). 
14H14N2O (226.28)·0.36H2O 
naphthalen-1-ol (56a)  
in-3-yl-3,4-dihydronaphthalen-1-one 56b (0.15 g, 0.65 mmol) in dry 
toluene (15 mL) was added methylmagnesium chloride, 3M in THF (0.44 mL, 1.31 mmol) 
dropwise under nitrogen atmosphere. After stirring at reflux for 3 hours and at room 
temperature overnight, an NH4Cl solution was added. The mixture was extracted with ethyl 
acetate, dried (MgSO4), filtered and evaporated in vacuo.  
 
Purification: CC (dichloromethane/methanol 98:2). 
Yield: 41%. 
Colorless oil. 
 
1H NMR (CDCl3): δ 1.07 (s, 3H, CH3), 2.04-2.08 (m, 1H, H-3), 2.25-2.31 (m, 1H, H-3’), 
2.96-2.30 (m, 2H, H-4), 3.28-3.31 (m, 2H, H-2, OH), 7.03 (d, 1H, 3J = 7.9 Hz, Ar H), 7.12 (t, 
1H, 3J = 7.9 Hz, Ar H), 7.17 (t, 1H, 3J = 7.9 Hz, Ar H), 7.56 (d, 1H, 3J = 7.9 Hz, Ar H), 7.69-
7.71 (m, 1H, Pyr. H-5), 8.14 (d, 1H, 3J = 7.9 Hz, Pyr. H-4), 8.54 (d, 1H, 3J = 5.4 Hz, Pyr. H-
6), 8.65 (s, 1H, Pyr. H-2).  
 
IR: νmax = 3316, 3065, 2934, 1687, 1603, 1428 cm-1. 
 
C16H17NO (239.32) 
 
M
 
C
 
 C H N 
Calc. 72.22 6.38 12.03 
Obs. 72.16 6.63 11.68 
 
 
Method 33 
 
1-Methyl-2-pyridin-3-yl-1,2,3,4-tetrahydro
 
To a solution of 2-pyrid
 168
  EXPERIMENTAL SECTION  
1-Ethyl-2-pyridin-3-yl-1,2,3,4-tetrahydronaphthalen-1-ol (57a)  
 
Synthesized from 2-pyridin-3-yl-3,4-dihydronaphthalen-1-one 56b and ethylmagnesium 
bromide, 1M in THF. 
 
Purification: CC (dichloromethane/methanol 99:1). 
Yield: 20%. 
Colorless oil. 
 
1H NMR (CDCl3): δ 0.79 (t, 3H, CH3), 1.58-1.65 (m, 1H, CH2), 1.92-1.95 (m, 1H, H-3), 2.03-
2.08 (m, 1H, CH2), 2.32-2.37 (m, 1H, H-3), 2.91-2.93 (m, 2H, H-4), 3.15 (dd, 1H, 3J = 11.6 
Hz, 3J = 3.0 Hz, H-2), 7.16 (d, 1H, 3J = 7.6 Hz, Ar H), 7.22-7.28 (m, 3H, Ar H, Pyr. H-5), 
7.51 (dd, 1H, 3J = 7.6 Hz, 4J = 1.8 Hz, Ar H), 7.70 (dt, 1H, 3J = 7.6 Hz, 4J = 1.8 Hz, Pyr. H-
4), 8.49 (dd, 1H, 3J = 4.9 Hz, 4J = 1.8 Hz, Pyr. H-6), 8.54 (d, 1H, 4J = 1.8 Hz, Pyr. H-2).  
 
IR: νmax = 3268, 2927, 1574, 1428,1262 cm-1. 
 
C17H19NO (253.35) 
 
 
Method 34 
 
3-(1-Methyl-3,4-dihydronaphthalen-2-yl)-pyridine (56) 
 
A mixture of 1-methyl-2-pyridin-3-yl-1,2,3,4-tetrahydronaphthalen-1-ol 56a (60 mg, 0.25 
mmol) and HCl (1 mL) was stirred at 100°C for 2 hours. The reaction was poured in ice water 
and basified with a 6% NaOH solution. After extractions with dichloromethane, the organic 
layer was dried (MgSO4), filtered and evaporated in vacuo.  
 
Purification: CC (dichloromethane/methanol 97:3). 
Yield: 63%.  
Yellow solid, mp 174 °C (HCl salt). 
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  EXPERIMENTAL SECTION  
1H NMR (CDCl3): δ 2.05 (s, 3H, CH3), 2.57 (td, 2H, 3J = 8.2 Hz, 4J = 1.6 Hz, H-3), 2.92 (t, 
2H, 3J = 8.2 Hz, H-4), 7.19-7.23 (m, 2H, Ar H), 7.27 (t, 1H, 3J = 7.6 Hz, Ar H), 7.38 (d, 1H, 
3J = 7.6 Hz, Ar H), 7.41-7.45 (m, 1H, Pyr. H-5), 7.72 (td, 1H, 3J = 7.92 Hz, 4J = 1.6 Hz, Pyr. 
H-4), 8.54 (dd, 1H, 3J = 5.0 Hz, 4J = 1.6 Hz, Pyr. H-6), 8.57 (s, 1H, Pyr. H-2).  
 
IR: νmax = 3024, 2937, 2831, 1602, 1487, 1408, 1250 cm-1.  
MS: m/z = 222 (MH+). 
 
C16H15N (221.30)·HCl·0.19H2O 
 
 C H N 
Calc. 73.59 6.32 5.36 
Obs. 73.58 6.40 5.05 
 
3-(1-Ethyl-3,4-dihydronaphthalen-2-yl)-pyridine (57)  
 
Synthesized from 1-ethyl-2-pyridin-3-yl-1,2,3,4-tetrahydronaphthalen-1-ol 57a. 
 
Purification: CC (dichloromethane/methanol 99:1).  
Yield 60%.  
White solid, mp 141 °C (HCl salt). 
 
1H NMR (CDCl3): δ 1.05 (t, 3H, 3J = 7.6 Hz, CH3), 2.47-2.54 (m, 4H, CH2, H-3), 2.87 (t, 2H, 
3J = 7.6 Hz, H-4), 7.18-7.20 (m, 2H, Ar H), 7.24-7.27 (m, 1H, Ar H), 7.30-7.33 (m, 1H, Pyr. 
H-5), 7.38 (d, 1H, 3J = 7.6 Hz, Ar H), 7.56 (dt, 1H, 3J = 7.6 Hz, 4J = 1.8 Hz, Pyr. H-4), 8.51-
8.53 (m, 2H, Pyr. H-6, Pyr. H-2).  
 
IR: νmax = cm-1. 
MS: m/z = 236 (MH+). 
 
C17H17N (235.33)·HCl·0.53H2O 
 
 C H N 
Calc. 72.57 6.83 4.98 
Obs. 72.48 6.79 4.86 
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Method 35 
 
2-(1H-imidazol-1-yl)indan-1-one (61b) 
 
A solution of 2-bromoindan-1-one 50c (1.01 g, 4.79 mmol) and imidazole (1.63 g, 23.94 
mmol) in DMF (20 mL) was stirred overnight at room temperature. The mixture was poured 
into ice water and extracted with dichloromethane. After washing exhaustively with water, the 
organic layer was dried (MgSO4), filtered and evaporated in vacuo.  
 
Purification: CC (dichloromethane/methanol 98:2). 
Yield: 39%. 
Yellow oil. 
 
1H NMR (CDCl3): δ 3.32 (dd, 1H, 2J = 17.2 Hz, 3J = 5.4 Hz, H-3), 3.87 (dd, 1H, 2J = 17.2 Hz, 
3J = 8.6 Hz, H-3), 5.06 (dd, 1H, 3J = 8.6 Hz, 3J = 5.4 Hz, H-2), 6.91 (s, 1H, Im. H-4), 7.12 (s, 
1H, Im. H-5), 7.49 (t, 1H, 3J = 7.6 Hz, Ar H), 7.54 (d, 1H, 3J = 7.6 Hz, Ar H), 7.70 (s, 1H, Im. 
H-2), 7.73 (t, 1H, 3J = 7.6 Hz, Ar H), 7.84 (d, 1H, 3J = 7.6 Hz, Ar H).  
 
IR: νmax = 3009, 1722, 1603, 1262 cm-1. 
 
C12H10N2O (198.23) 
 
2-(1H-imidazol-1-yl)-3,4-dihydronaphthalen-1(2H)-one (62b)  
 
Synthesized from 2-bromo-3,4-dihydro-2H-naphthalen-1-one 51c. 
 
Purification: CC (dichloromethane/methanol 98:2). 
Yield. 65%. 
Yellow solid. 
 
1H NMR (CDCl3): δ 2.62-2.69 (m, 2H, H-3), 3.22 (dt, 1H, 2J = 17.0 Hz, 3J = 3.8 Hz, H-4), 
3.34-3.41 (m, 1H, H-4), 5.21 (dd, 1H, 3J = 7.2 Hz, 3J = 5.4 Hz, H-2), 7.22 (s, 1H, Im. H-4), 
7.28 (s, 1H, Im. H-5), 7.34 (d, 1H, 3J = 7.6 Hz, Ar H), 7.40 (t, 1H, 3J = 7.9 Hz, Ar H), 7.59 (tt, 
1H, 3J = 7.6 Hz, 4J = 1.6 Hz, Ar H), 8.04 (s, 1H, Im. H-2), 8.09 (d, 1H, 3J = 7.9 Hz, Ar H).  
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IR cm-1: νmax 3061, 2959, 1700. 
 
C13H12N2O (212.25) 
 
2-(1H-imidazol-1-yl)-6-methoxy-3,4-dihydronaphthalen-1(2H)-one (63b)  
 
Synthesized from 2-bromo-6-methoxy-3,4-dihydro-2H-naphthalen-1-one 53c. 
 
Purification: CC (dichloromethane/methanol 98:2). 
Yield: 50%. 
Yellow oil. 
 
1H NMR (CDCl3): δ 2.59-2.63 (m, 2H, H-3), 3.14 (dt, 1H, 2J = 16.7 Hz, 3J = 3.8 Hz, H-4), 
3.26-3.31 (m, 1H, H-4), 3.91 (s, 3H, OCH3), 5.01 (m, 1H, H-2), 6.77 (s, 1H, Ar H), 6.91 (dd, 
1H, 3J = 8.8 Hz, 4J = 2.2 Hz, Ar H), 6.98 (s, 1H, Im. H-4), 7.18 (s, 1H, Im. H-5), 7.78 (s, 1H, 
Im. H-2), 8.06 (d, 1H, 3J = 8.5 Hz, Ar H).  
 
IR cm-1: νmax = 3006, 2963, 2835, 1710. 
 
C14H14N2O2 (242.28) 
 
 
Method 36 
 
Benzyl phosphonium salt (64a) 
 
A mixture of benzylalcohol 64b (0.50 g, 4.62 mmol) and triphenylphosphonium bromide 
(1.59 g, 4.62 mmol) in toluene (40 mL) was refluxed for 12 h under a nitrogen atmosphere. 
After cooling, the phosphonium salt 64a was filtered off, washed with diethyl ether and air-
dried. The salt was used for further reaction without purification. 
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Method 37 
 
(E)/(Z)-3-Styrylpyridine (64-65) 
 
A suspension of the phosphonium salt 64a (0.76 g, 1.75 mmol), K2CO3 (2.42 g, 17.50 mmol), 
pyridine-3-carbaldehyde 67 (0.19 g, 1.75 mmol) and a few milligrams of 18-crown-6 in 
anhydrous dichloromethane (50 mL) was refluxed for 12 h. After washing with water, the 
organic layer was dried (MgSO4), filtered and evaporated in vacuo. The two resulting isomers 
64 and 65 were separated by column chromatography. 
 
3-[(E)-2-phenylvinyl]pyridine (64)  
 
Purification: CC (hexane/ethyl acetate 1:1). 
Yield: 38%. 
White solid, mp 81 °C.  
 
1H NMR (CDCl3): δ 7.08 (d, 1H, 3J = 16.4 Hz, CH-Ph), 7.20 (d, 1H, 3J = 16.4 Hz, CH-Pyr), 
7.31 (tt, 1H, 3J = 7.6 Hz, 4J = 1.3 Hz, Ar H), 7.35-7.40 (m, 3H, Pyr. H-5, Ar H), 7.54 (d, 2H, 
3J = 8.8 Hz, Ar H), 7,91 (dt, 1H, 3J = 7.9 Hz, 4J = 1.6 Hz, Pyr. H-4), 8.50 (dd, 1H, 3J = 4.7 Hz, 
4J = 1.6 Hz, Pyr. H-6), 8.75 (d, 1H, 4J = 1.9 Hz, Pyr. H-2).  
 
IR: νmax = 3022, 962 cm-1.  
MS: m/z = 182 (MH+), 167, 115, 77, 51. 
 
C13H11N (181.24) 
 
 C H N 
Calc. 86.15 6.12 7.73 
Obs. 86.26 6.03 7.10 
 
3-[(Z)-2-phenylvinyl]pyridine (65)  
 
Purification: CC (hexane/ethyl acetate 1:1). 
Yield: 52%. 
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Colorless oil.  
 
1H NMR (CDCl3): δ 6.48 (d, 1H, 3J = 12.3 Hz, CH-Ph), 6.72 (d, 1H, 3J = 12.3 Hz, CH-Pyr), 
7.10-7.20 (m, 6H, Pyr. H-5, Ar H), 7.51 (dt, 1H, 3J = 8.2 Hz, 4J = 1.6 Hz, Pyr. H-4), 8.35 (dd, 
1H, 3J = 5.0 Hz, 4J = 1.3 Hz, Pyr. H-6), 8.41 (d, 1H, 4J = 1.6 Hz, Pyr. H-2).  
 
IR: νmax = 3079, 3026, 704 cm-1.  
MS: m/z = 182 (MH+), 167, 115, 77, 51. 
 
C13H11N (181.24)·HCl 
 
 C H N 
Calc. 71.72 5.56 6.43 
Obs. 71.69 5.75 6.08 
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B. Biological section 
 
B.I. Materials and reagents 
 
B.I.1. Apparatus 
 
Cell counter CASY Model TT, from Schärfe System, Reutlingen 
Phosphoimager system Fuji FLA-3000, from Raytest, Straubenhardt 
Shaking incubator Unitron 25, from Infors, Stuttgart 
ell culture incubator Biosafe, from Revco, Ashville (USA) 
entrifuge universal 30 RF, from Hettich GmbH, Tuttlingen 
rom Hettich GmbH, Tuttlingen 
ltracentrifuge 2330 Ultraspin 55 Hitachi, from Pharmacia LKB, Freiburg 
ansistor, from Bandelin, Berlin 
hemStation software, from Agilent, Waldbronn  
Nucleodur C18ec column (120-3,3 × 12.5 mm), from Macherey Nagel, Düren 
C
C
Table centrifuge Micro 24-48 R, f
U
Ultrasonic bath Sonsorex RK 106 Tr
Mixer Krups Promix 200, from Electro Meyer, Saarbrücken 
Sonicator Sonopuls HD60, from Bandelin, Berlin 
Ultra-turrax T25, from IKA-Labortechnik, Staufen 
HPLC system Agilent 1100: 
Agilent 1100 autosampler 
PDA detector 
C
LC-MS/MS: 
 Surveyor autosampler 
 Surveyor MS pump 
 TSQ quantum triple quadrupole mass spectrometer, from ThermoFinnigan,  
San Jose, (USA) 
 Gravity C18 column (3 µm, 125×3.0 mm) 
Gravity C18 column (3 µm, 10×3.0 mm), from Macherey-Nagel, Düren 
β-counter type 1209 Rackbeta Wallac, from Pharmacia LKB, Freiburg 
γ-counter Wallac CliniGamma 1272, from Wallac, Turku (Finnland) 
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B.I.2. Materials 
 
24-Well cell culture plates, from Nunc International, Roskilde (Denmark) 
HPTLC plates 20 cm×10 cm, Silicagel 60F254, from Merck, Darmstadt 
[14C]-imaging plate BAS-MS2340, from Raytest, Straubenhardt 
arburg 
ndrostenedione and DHEA ELISA, from ibl-hamburg, Hamburg 
rlan Winkelmann, Borchen 
ale Wistar rats, from Harlan Winkelmann, Borchen 
Corticosterone and aldosterone RIA, from DRG Instruments GmbH, M
A
Cortisol EIA, from Cayman Chemical, Ann Arbor (USA) 
 
B.I.3. Chemicals and reagents 
 
ACTH1-24, from Synacthen Depot®, Novartis, Basel (Switzerland) 
[14C]11-deoxycorticosterone, from NEN, Boston (USA) 
Progesterone, from Sigma, Deisenhofen 
NADPH, NADP+, from Sigma, Deisenhofen 
Glucose-6-phosphate, from Sigma, Deisenhofen 
Glucose-6-phosphate dehydrogenase, from Serva, Heidelberg 
[1β-3H]androstenedione, from Perkin Elmer Life & Analytical Sciences, Boston (USA) 
Fadrozole, from Ciba-Geigy, Basel (Switzerland) 
DMEM:Ham’s F12 medium, from c.c. pro, Neustadt 
Streptomycin, from c.c. pro, Neustadt 
ITS+Premix, from BD Biosciences, Bedford (USA) 
Ultroser SF, from Ciphergen, Cergy-Saint-Christophe (France) 
 
B.I.4. Biological material 
 
Male Sprague-Dawley rats, from Ha
M
Rat microsomes (male pool), from Gentest, Woburn, (USA) 
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B.II. In vitro methods 
 
B.II.1. CYP11B2 inhibition assay in fission yeast (Ehmer et al., 2002) 
 
Screening Assay in Fission Yeast.  
To test the inhibitory activity of compounds towards human CYP11B2, fission yeast 
Schizosaccheromyces pombe PE1, recombinantly expressing the target enzyme, was used. A 
fission yeast suspension (diluted to cellular density 3 x 107 cells/ml) was prepared from a 
ontained 1% ethanol. The enzymatic reaction was started by addition of 
he redissolved steroids were transferred onto an HPTLC plate (20 cm x 10 cm, silica gel 
o times using the solvent 
hloroform/methanol/water (300:20:1). For the CYP11B2 reaction, 11-deoxycorticosterone, 
corticosterone, 18-hydroxycorticosterone and aldosterone were used as reference. 
Subsequently, imaging plates (BAS MS2340) were exposed to the HPTLC plates for 48 h. 
The imaging plates were scanned using the phosphoimager system Fuji FLA 3000 and the 
steroids were quantified. 
 
B.II.2. CYP11B2 and CYP11B1 inhibition assay in V79 cells (Ehmer et al., 2002) 
 
V79 MZh 11B1 and V79 MZh 11B2 cells were grown on 24-well cell culture plates with 1.9 
cm2 culture area per well until confluence. Before testing, the DMEM culture medium was 
removed and 400 µl of fresh DMEM, containing the inhibitor in at least three different 
concentrations for determining the IC50 value, was added to each well. After a preincubation 
step of 60 min at 37°C, the reaction was started by the addition of 100 µl of DMEM 
freshly grown culture using a modified EMMG (EMM: Edinburgh Minimal Medium) 
medium at pH 7.4. A 500 µl-aliquot of the yeast suspension was preincubated with the 
potential inhibitor dissolved in ethanol, in a final concentration of 500 nM for 15 min at 32 
°C. Control samples c
[14C]-deoxycorticosterone (60 mCi/mmol) in a final concentration of 100 nM. Sample tubes 
were shaken horizontally at 32 °C for 6 h. The enzyme reaction was quenched by the addition 
of the same volume of ethyl acetate to extract the steroids. The organic layer was pipetted into 
a fresh cup and evaporated to dryness. The residue was dissolved in 10 µl chloroform and the 
conversion of the substrate into corticosterone was analyzed by HPTLC as described below. 
 
HPTLC Analysis and phosphoimaging of radiolabeled steroids.  
T
60F254) with concentrating zone and developed tw
c
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containing the substrate 11-deoxycorticosterone (20 µM, containing 6 nCi of [4-14C]11-
deoxycorticosterone, dissolved in ethanol). The V79 MZh 11B1 cells were incubated for 120 
min, whereas the V79 MZh 11B2 cells were incubated for 40 min. Controls were treated in 
the same way without inhibitor. Enzyme reactions were stopped by extracting the supernatant 
with ethyl acetate. Samples were centrifuged and the solvent was pipetted into fresh cups. The 
solvent was evaporated, and the steroids were redissolved in 10 µl of chloroform and 
analyzed by HPTLC as described above. 
 
B.II.3. Assay using the adrenocortical tumor cell line NCI-H295R 
 
NCI-H295R cells were obtained from the American Type Culture Collection (CRL-2128). 
The cells were maintained in 90 mm culture dishes in DMEM:Ham’s F12 medium 
supplemented with 2% Ultroser SF, 100 units/ml penicillin, 0.1 mg/ml streptomycin and 1% 
ITS+ Premix (containing 6.25 µg/ml insulin, 6.25 µg/ml transferrin, 6.25 ng/ml selenium, 1.25 
mg/ml BSA and 5.35 g/ml linoleic acid). Cells were grown at 37°C under an atmosphere of 
95% air/5% CO2. All cells used for the experiments were between passages 10 and 40. 
For testing compounds, cells were seeded at a cellular density of 1 x 106 cells per well in 24-
well plates. After 48 h, the monolayers were confluent. To determine the effect of the 
compounds, medium was removed and replaced by fresh DMEM:Ham’s F12. Aldosterone 
secretion was stimulated by the addition of 20 mM K+ in presence of the potential inhibitor in 
a final concentration of 1 µM. At the end of the 6 h incubation time, the medium was removed 
to fresh tubes and stored at - 20 °C until assayed. Aldosterone, cortisol, androstenedione and 
DHEA contents were quantified using commercially available ELISA kits according to the 
manufacturer’s instructions. Each experiment was performed in triplicate. 
 
B.II.4. CYP17 E. coli inhibition assay (Ehmer et al., 2000) 
 
Enzyme preparation 
Recombinant E. coli pJL17/OR coexpressing human CYP17 and rat NADPH-P450-reductase 
were grown and stored as described (Ehmer et al., 2000). For isolation of membrane fractions, 
5 mL of bacterial suspension with an OD578 of 50 were washed using phosphate buffer (0.05 
M, pH 7.4, 1 mM MgCl2, 0.1 mM EDTA and 0.1 mM dithiothreitol). Bacteria were harvested 
by centrifugation (2,000 × g) and the pellet was resuspended in 10 mL of ice cold TES buffer 
(0.1 M tris-acetate, pH 7.8, 0.5 mM EDTA, 0.5 M sucrose). Lysozyme was added with 10 mL 
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of ice cold water resulting in a concentration of 0.2 mg/mL followed by incubation for 30 min 
on ice with continuous shaking. Spheroplasts were harvested by centrifugation (12,000 × g for 
10 min), and resuspended in 4 mL of ice cold phosphate buffer (the same as described above 
plus 0.5 mM phenylmethylsulfonyl fluoride (PMSF)). 
After freezing and thawing, samples were sonicated on ice (pulse 20s on, 30s off, five times), 
using a sonicator Sonopuls HD60 at maximum power. Unbroken cells and debris were 
pelleted at 3,000 × g for 7 min, and the supernatant was centrifuged at 50,000 × g for 20 min 
at 4°C. The membrane pellet was resuspended in 2 mL of phosphate buffer (the same as 
described above) with 20% glycerol using and ultra-turrax T25. Protein content was 
determined by the method of Lowry. (Lowry et al., 1951) Aliquots of this preparation, which 
generally had a content of about 5 mg protein per mL, were stored at -70°C until used. 
 
Determination of the inhibitory activity towards CYP17 
The 17α-hydroxylase activity of CYP17 was determined by measuring the conversion of 
progesterone into 17α-hydroxyprogesterone and the byproduct 16α-hydroxyprogesterone. The 
assay was performed as follows: A solution of 6.25 nmol progesterone (in 5 µL methanol) in 
140 µL phosphate buffer (0.05 M, pH 7.4, 1 mM MgCl2, 0.1 mM EDTA and 0.1 mM 
dithiothreitol), 50 µL NADPH generating system (in phosphate buffer with 10 mM NADP+, 
100 mM glucose-6-phosphate and 2.5 units of glucose-6-phosphate dehydrogenase) and 
inhibitor (in 5 µL DMSO) was preincubated at 37°C for 5 min. Control cups were 
supplemented with 5 µL DMSO without inhibitor. The reaction was started by adding 50 µL 
of 1:5 diluted membrane suspension in phosphate buffer (0.8-1 mg protein per mL). After 
mixing, incubation was performed for 30 min at 37°C. Subsequently the reaction was stopped 
with 50 µL 1 N HCL. 
Extraction of steroids was performed by addition of 1 mL ethyl acetate and vigorous shaking 
for 1 min. After a centrifugation step (2,500 × g for 5 min) the organic phase (0.9 mL) was 
transferred into a cup containing 0.25 mL of incubation buffer and 50 µL 1 N HCl and mixed 
again. After centrifugation, 0.8 mL ethyl acetate solution was evaporated to dryness in a fresh 
cup. Samples were dissolved in 50 µL water and methanol (1:1) and analyzed by HPLC. 
HPLC was performed using an Agilent 1100 HPLC system with PDA detector and a 
Nucleodur C18ec column (120-3,3 × 12.5 mm), which was run at 40°C. The steroids were 
eluted under isocratic conditions using 10 mM sodium acetate buffer (adjusted to pH 4.0 with 
acetic acid):methanol (30:70; V/V) at a flow rate of 0.70 ml/min and pressure of about 25 
MPa. For each analysis 25 µL were injected by an Agilent 1100 autosampler, which was 
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thermostated at 4°C. UV absorbance was monitored at 240 and 254 nm. The products 17α-
hydroxyprogesterone and 16α-hydroxyprogesterone eluted with retention times of 1.8 and 2.8 
min, respectively. Elution time for the substrate progesterone was 4.7 min. Peak areas were 
determined by integration of the resulting chromatograms using ChemStations software. 
Substrate conversion was determined by product versus substrate peak areas. The inhibitory 
potencies were calculated using the diminished substrate conversion by the inhibitors. 
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B.II.5. CYP19 inhibition assay 
 
Preparation of aromatase CYP19 
The enzyme was obtained from the microsomal fraction of freshly delivered human term 
placental tissue according to the procedure of Thompson and Siiteri. (Thompson and Siiteri, 
1974) The isolated microsomes were suspended in a minimum volume of phosphate buffer 
(0.05 M, pH 7.4, 20% glycerol). Additionally, DTT (dithiothreitol, 10 mM) and EDTA (1 
mM) was added to protect the enzyme from degradation. Protein concentration was 
determined by the method of Lowry et al. (Lowry et al., 1951) and usually was about 35 
mg/mL. 
 
Determination of IC50 values for CYP19 
This assay was performed similar to the described methods (Graves et al., 1979; Foster et al., 
1983), monitoring enzyme activity by measuring the 3H2O formed from [1β-
3H]androstenedione during aromatization. Each incubation tube contained 15 nM [1β-
3H]androstenedione (0.08 µCi), 485 nM unlabeled androstenedione, 2 mM NADPH, 20 mM 
glucose-6-phosphate, 0.4 units of glucose-6-phosphate dehydrogenase and inhibitor (0-100 
µM) in phosphate buffer (0.05 M, pH 7.4). The test compounds were dissolved in DMSO and 
diluted with buffer. The final DMSO concentration in the control and inhibitor incubation was 
2%. Each tube was preincubated for 5 min at 30°C in a water bath. Microsomal protein was 
added to start the reaction (0.1 mg). The total volume for each incubation was 0.2 mL. The 
reaction was terminated by the addition of 200 µL of a cold aqueous dextran-coated charcoal 
(DCC) suspension (2%), the vials were shaken for 20 min and centrifuged at 1.500 × g for 5 
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min to separate the charcoal absorbed steroids. The supernatant was assayed for 3H2O by 
counting in a scintillation mixture using a LKB-Wallac β-counter. The calculation of the IC50 
values was performed by plotting the percent inhibition versus the concentration of inhibitor 
on a semi-log plot. From this the molar concentration causing 50% inhibition was calculated. 
 
B.II.6. Permeability screening in Caco-2 transport experiments.  
 
Caco-2 cell culture and transport experiments were performed according to Yee (Yee, 1997) 
with small modifications. Cell culture time was reduced to 10 days by increasing seeding 
density from 6.3·104 to 1.65·105 cells per well. Four reference compounds, atenolol, 
ketoprofene, testosterone and erythromycin, were used in each assay for validation of the 
transport properties of the Caco-2 cells. The compounds were applied to the cells as mixtures 
(cassette dosing) to increase the throughput of the permeability tests. The starting 
concentration of the compounds in the donor compartment was 50 µM in buffer containing 
either 1% ethanol or DMSO. After a preincubation step of 20 min at 37°C, the reaction was 
started. The 12-well Transwell plates (Corning Costar) were stirred (20 rpm) at 37°C. 
Samples were taken from the acceptor side after 60, 120 and 180 minutes and from the donor 
side after 0 and 180 minutes. Each experiment was run in triplicate. Monolayer integrity was 
checked by measuring the transepithelial electrical resistance (TEER) before the transport 
experiments and by measuring lucifer yellow permeability after each assay. All samples were 
analyzed by LS-MS/MS after 1:1 dilution with buffer of the opposite transwell chamber 
containing 2% acetic acid. The apparent permeability coefficients (Papp) were calculated using 
the equation Papp = dQ/dt·A·c0, where dQ/dt is the mass appearance rate in the acceptor 
compartment, A is the surface area of the transwell membrane, and c0 is the initial 
concentration in the donor compartment.  
 
B.II.7. Metabolic stability assay.  
 
The assay was performed with rat microsomes. The incubation solution contained a 
microsomal suspension of 0.15 mg of protein per ml in phosphate buffer 0.1 M, pH 7.4 and a 
NADPH-regenerating system (NADP 1 mM, glucose-6-phosphate 5 mM, glucose-6-
phosphate dehydrogenase 5U/ml, MgCl2 5 mM). After pre-incubation at 37°C, the reaction 
was initiated by the addition of the test compound (a stock solution of 10 mM in 100% 
DMSO, diluted in phosphate buffer 0.1 mM, pH7.4 to reach the final concentration of 5 µM 
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with 2% of final DMSO concentration). After 0, 30, 60, 120 and 180 minutes, 200 µl from the 
incubation was removed, added to ethyl acetate, containing the internal standard (I.S.) 
methoxyverapamil (5 µM), to stop the reaction and vortexed for 5 min. A negative control 
was run in addition, to which the microsomes were boiled and inactivated with ethyl acetate 
prior to addition of the test compound.  
For each test compound, appropriate dilutions of the stock solutions were prepared with 
phosphate-buffer (0.1 M, pH 7.4) containing rat microsomes to reach the working solutions of 
0.5, 2.5 and 5 µM. Ethyl acetate containing the I.S. was added.  
Subsequently, the water layer was frozen in a bath of acetone/dry ice for each sample and 
standard. The organic layer was removed and evaporated in under nitrogen stream. The 
residue was reconstituted in 200 µL mixture of acetonitrile and 10 mM ammonium acetate/2% 
methanol (1:1, v:v).  
Sample quantification was performed by LC-MS/MS: 20 µL of each sample was separated on 
a XterraTMMS C18 (5 µm, 50x2.1 mm, Waters) analytical column with a pre-column 
(XterraTMMS C18 5 µm, 50x2.1 mm, Waters) using a gradient elution with 10 mM ammonium 
acetate/2% methanol as aqueous phase (A) and acetonitrile as organic phase (B). The 
following gradient was applied: %B (t (min)), 20(0)-90(3)-20(3.5-6). The most intensive 
product ion of the [M+H]+ was used to quantify the compounds in the selected reaction 
monitoring mode (SRM). A second product ion was taken as a qualifier. 
 
Table 1. Overview of MS conditions used for quantification 
 
Compound 
Mw 
(g/mol) 
[M+H]+
(m/z) 
Monitoring 
ion (m/z) 
Qualifier ion 
(m/z) 
Collision 
energy (V) 
21 271.7 236.2 214.1 199.1 10/35 
53 273.7 238.2 216.1 201.1 10/35 
I.S. 484.6 485.2 311.1 143.0 25/25 
 
For the metabolite identification the gradient time was extended and the eluent mix gradient 
set as follows: %B (t (min)), 20(0)-85(6-7)-20(7.5-10). The data acquisition was performed in 
the auto scan mode switching between the full scan mode (80-500 Da) and MS2 dependent 
scan mode (collision energy 20V) by selection of the most intensive ion. In a second step, 
MS2 spectra (collision energy 35V) were taken from the parent compounds and the putative 
metabolite signals assigned in the first step. 
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Calibration curves, represented by the plot of the peak area ratios of the compound to I.S. (Y 
axis) versus the concentration of the calibration standards (0.5, 2.5 and 5 µM) were generated 
using quadratic regression. Sample concentrations were calculated from the resulting peak 
area of the compound to I.S. and the regression equation of the calibration curve. The 
percentage of the remaining test compound was plotted against the corresponding time points, 
and the half-life time derived by a standard fit of the data. 
 
B.III. In vivo methods 
 
B.III.1. Determination of aldosterone and corticosterone in rats (adapted from Häusler  
     et al., 1989). 
 
Male Sprague Dawley rats, weighting 200-300g, were housed in a temperature-controlled 
room (20-22°C) and maintained in a 12h light/12h dark cycle for 14 days in absolute 
quietness. The animals were divided into 4 groups, 2 control groups (unstimulated and 
ACTH-stimulated animals) and 2 test groups. On the first day of the experiment, the animals 
received at 16.00 h a subcutaneous injection of 1 mg/kg of a depot preparation of ACTH1-24; 
the unstimulated test group received a physiological NaCl solution. At 8.00 h on the second 
day of the experiment, the test groups received the test solution of fadrozole or the inhibitor 
intraperitoneally. The 2 control groups received only a NaCl solution. The test compounds 
were dissolved in physiological NaCl solution (maximum of 25% DMSO for solubility). Two 
hours later, all animals were killed through cervical dislocation and blood was collected by 
heart punction. The blood samples were left at room temperature for 60 min and plasma was 
obtained by centrifugation (5000 rpm for 30 min). The supernatans (serum) was then pipetted 
and aliquoted. For the analysis of the samples, an aldosterone RIA and corticosterone RIA 
were performed and subsequently, the samples were measured using the γ-counter. 
For the determination of the inhibitory effect of the inhibitor on the aldosterone and 
corticosterone level in rat, the following group divisions were made: 
 
Group Amount of rats ACTH application Inhibitor application 
Unstimulated control 7 NaCl sol., s.c. NaCl sol., i.p. 
ACTH stimulated control 8 ACTH, s.c. NaCl sol., i.p. 
Inhibitor (0.4 mg/kg/KG) 7 ACTH, s.c. Inhibitor, i.p. 
Inhibitor (4.0 mg/kg/KG) 7 ACTH, s.c. Inhibitor, i.p. 
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The doses of the selected compounds were calculated by comparing their IC50 values with the 
IC50 value of fadrozole. A dose of 4mg/kg of test compound pro 1 nM of its IC50 value was 
used in the animal test.  
 
B.III.2. In vivo pharmacokinetic evaluation in catheterized rats (peroral cassette dosing) 
 
Preparation and administration of cassette dosing solutions 
Male Wistar rats, weighting 260-305 g, were housed in a temperature-controlled room (20-
22°C) and maintained in a 12h light/12h dark cycle. Twelve hours prior to compound 
application food was removed, water was available ad libitum. The rats were anaesthetised 
with a ketamine (135mg/kg)/xylazine (10mg/kg) mixture, and cannulated with silicone tubing 
via the right jugular vein. Prior to the first blood sampling, animals were connected to a 
counterbalanced system and tubing to perform blood sampling in the freely moving rat. 
Immediately before application, the cassette dosing solution was prepared by adding equal 
volumes of stock solutions (5mg/ml in DMSO:NaCl (10:90)) of 5 test compounds to end up 
with a final concentration of 1mg/ml for each compound. This cassette dosing solution was 
perorally applied to 4 rats with an injection volume of 5ml/kg. Blood samples (0.2 ml) were 
taken at -1h, 1h, 2h, 4h, 6h, 8h, 10h and 24h after application. Blood samples collected in 
heparinised tubes were centrifuged at 3000 g for 10 min at 4°C and plasma was harvested and 
kept at -20°C until LC-MS analysis.  
 
Measurement of plasma drug levels 
The HPLC system consisted of a MS pump (Surveyor) and an autosampler (Surveyor). Mass 
spectrometry was performed on a TSQ quantum triple quadrupole mass spectrometer 
equipped with an electrospray (ESI) interface (Thermo-Finnigan) and connected to a PC 
running the standard software Xcalibur. Pump flow rate was set at 350µl/min and the 
compounds were separated on a Gravity C18 (3 µm, 125×3.0 mm, Macherey-Nagel) analytical 
column with a pre-column (Gravity C18, 3 µm, 10×3.0 mm) in gradient mode. A gradient 
elution with 10 mM ammonium acetate/0.1% formic acid as aqueous phase (A) and 
acetonitrile as organic phase (B) was used. The following gradient was applied: %B (t (min)), 
90(0)-97(3-4.4)-90(4.5-7). The most intensive product ion of the [M+H]+ was used to 
quantify the compounds in the selected reaction monitoring mode (SRM). Compound 57 was 
used as an internal standard.  
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100µl acetonitrile containing the internal standard (57, 150ng/ml) was added to 50µl of rat 
plasma sample to precipitate plasma proteins. Samples were then vigorously shaken and, after 
5 min at room temperature, centrifuged for 10 min at 6000g and 20°C. An aliquot of the 
particle-free supernatant was transferred to 200µl sampler vials and subsequently subjected to 
LC-MS/MS. 
The system was calibrated in the operating range of 4 to 3200 ng/ml using quadratic least 
squares regression as mathematical model. To improve the accuracy of determined plasma 
drug levels, the 1/X weighted regression equations were used. The regression was fitted on 
the group mean profiles and the pharmacokinetic parameters were calculated using a non 
compartment model software (PK solutions 2.0, Summit Research Services, Montrose, USA). 
 
C. Protein modelling and docking.  
 
Using the recently resolved human cytochrome CYP2C9 structure (PDB code: 1OG5) 
(Williams et al., 2003) as template, a homology model was build and refined for CYP11B2. 
Selected compounds were docked into the refined homology model using FlexX-Pharm 
(Hindle et al., 2002). Pharmacophore constraints were applied to ensure the right binding 
mode of the inhibitors (a Fe(heme)-N(inhibitor) interaction was required). Based on the 
docked protein-inhibitor complex structures, molecular dynamics simulations were performed 
using the GROMOS96 force field (Scott et al., 1999) and the GROMACS program (Lindahl 
et al., 2001). A cut-off of 14Ǻ was used for the non-bonded interactions and a time step of 1fs 
was applied. The temperature was maintained by weak coupling to an external bath with a 
temperature coupling relaxation time of 0.1ps. Throughout the simulations the bond lengths 
were constrained to ideal values using the LINCS procedure. No explicit solvent was 
included, because of the mainly hydrophobic character of the binding pocket. Potential 
solvent molecules were approximated through a dielectric constant of 4.0. Harmonic restraints 
were applied to all backbone atoms outside the binding pocket (all residues, except residues 
106-133, 212-221, 244-262, 305-332, 372-384, and 483-494). The systems were heated from 
0-300K over 200ps and afterwards 800ps of molecular dynamics were performed at 300K. 
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